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INTRODUCTION 
 
The science of medicine is of fundamental importance to man’s well 
being and his survival and so it must have originated with man and 
developed as civilization advanced. A system of medicine is not a discovery 
but a gradual evolution during successive periods of discovery. 
 The term ‘siddha’ comes from the word ‘siddhi’ which means an 
object to be attained (or) heavenly bliss. The siddha system of Medicine is 
the science of life. This system is taking care of prevention of diseases, 
comprehensive fitness of the body and mind (ie. Sthoola sareram and 
sookuma sareeram). 
  Panchapoothams are the basic fundamental elements in the universe 
and in man, the changes in the universe can change or affect the human 
body also as well as per chatamuni gnanam as. 
 அண்டத்திலுள்ளதத பிண்டம் 
 பிண்டத்திலுள்ளதத அண்டம் 
 அண்டமும் பிண்டமும் ஒன்தே 
 அறிந்து தான் பாரக்்கும் தபாதத. 
                                                                   (சட்டமுனி ஞானம்) 
 The changes in the Panchapoothas will result in various type of 
diseases. 
நாடியால் முன்தனார ்சசான்ன நே்குறி குணங்களாலும் 
நீடிய விழியினாலும் நின்ேநாக் குறிப்பினாலும் 
வாடிய தமனியாலு மலதமாடு நீரினாலும் 
சூடிய வியாதி தன்னனச ்சுகம்சபே வறிந்து சசால்தல 
                                                                                   (அகத்தியர ்நாடி) 
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Siddhars have their own way of diagnosing a disease by ‘Envagai 
thervugal’. The observation are made based on skin, colour, speech, eye, 
tongue, excreta (urine and motion) and all its variations from normal 
condition. 
 The siddha system of medicine is based on thrivital humours (Life 
forces- Vadham, Pitham, and kabam). Governing biological function of the 
body under the influences of Panchapootham. 
  மிகினும் குனேயினும் தநாய்சசய்யும் நூதலார ்
 வளிமுதலா சவண்ணிய மூன்று. 
                                                                           (திருகுேள்) 
 When natural harmony of the three vital humours is affected by 
altered Panchapoothams, it results in diseases. 
 Saint Yougi classified the diseases into 4448. Among them Siruneer 
noikal (urinary disorders) are further classified into, 
                            » Neerinai arukkal noi 
                            » Neerinai perukkal noi 
Azhal neerchurukku comes under the classification of neerinai arukkal noi 
and it is commonly prevalent in our country. Azhal neerchurukku incidence 
and its clinical signs and symptoms are mostly correlated with lower urinary 
tract infection in Modern scientific system of medicine because of its 
similarities.  
 Urinary tract infection is the second most common type of infection. 
These infection are much more common in girls than boys and men younger 
than 50 years of age. Recurrent infection cause considerable morbidity. If 
complicated it can cause severe renal disease including end stage renal 
failure. So there is a need for early screening & treatment for this easily 
curable infectious disease. 
 
  
11 
 
 
In the text Chikicha Rathina Deepam, Mallikai choornam (Internal medicine) a 
Siddha formulation have been indicated for Azhal neerchurukku. The method of 
preparation seems to be simple and cost effective. Siddha formulation are not only treat the 
disease but also strengthens the urinary tract. 
 So I selected Azhal neerchurukku as my dissertation subject for the 
present study, in order to give new innovation of treatment to help the 
suffering society.  
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AIM AND OBJECTIVE 
AIM: 
 Clinical evaluation of siddha drug “MALLIKAI CHOORNAM” 
(Internal) in the treatment of Azhal Neerchurukku (Urinary Tract Infection). 
PRIMARY OBJECTIVE: 
 To evaluate the therapeutic efficacy of Mallikai choornam in the 
treatment of Azhal Neerchurukku (Urinary Tract Infection) patient through 
urine culture. 
SECONDARY OBJECTIVE: 
 To study Azhal neerchurukku, on the basis of Envagai thervu, 
Mukkutram, Kalam, Naadi, Neerkuri, etc. in order to evaluate the 
pathology. 
 To study cofactors related to the disease such as age, sex, life style 
such as food, occupation etc. 
 To prepare the drug as per SOP . 
 To evaluate the physico chemical and phytochemical analysis. 
 To evaluate the antimicrobial activity of study drug. 
 To evaluate the lithotriptic activity of study drug. 
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LITERATURE REVIEW-SIDDHA ASPECT 
                                         AZHAL NEER CHURUKKU 
 
Urinary disorder are classified into two major categories. They are, 
 1.Neerinai Arukkal Noi 
 2.Neerianai Perukkal Noi 
 These disorders produce decreased amount of urine and increased 
amount of urine respectively. 
“நீரிருவினன குணத்னத நீயறிவிரித்துச ்சசால்வாம் 
நீரினன சபருக்க சலான்று நீரினனயருக்கசலான்று” 
                                                                                        -ததரன் கரிசல் 
Neerchurukku was described under the category of Neerinai Arukkal Noi.                                                   
                                        NEERCHURUKKU 
Synonyms-தவறுசபயரக்ள்: 
 Neer arugal 
 Neerkaduppu 
 Moothira kiricharam 
 Moothira kadharogam 
 Salasthamba vatham 
Definition-இயல்:  
 
 “நீரினனயருக்க சலன்னும் நீரக்ட்டின் குணத்னத தகட்டி 
 நீதமில்லாமே் தகாச நீரப்ுனை சநருப்பு தபாலாம்” 
                                                                                         -ததரன் கரிசல் 
 
It is a disease of the Urinary Tract Infection causing burning and scanty 
micturition. 
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Aetiology – ந ோய் வரும் வழி: 
I .According to yougi vaithiya chinthamani. 
 
 நவிலதவ நாரியனரத் துதராகம் பண்ணி 
       நடுவிதல னகவிடட்ு நழுவி தனாரக்்கு 
 குவிலதவ குைந்னதகள்தான் பசித்திடுக்கக்  
    கூடதவனவத் துண்ணாக்சகா டுனமதயாரக்்கு 
 தவிலதவ மூத்திரமாங் கிரிசச்ம் வந்து 
    கலக்கு சமன்றுமாமுனி வரக்ரு தினாதர” 
                                                                  -யூகி னவத்திய சிந்தாமணி-736 
 
1. Cheating damsels 
2. Least bothered about the pangs of hunger of a child and satisfying only 
themselves callously 
3. Not providing water to thirsty people. 
 
 
“கருதிதய மாப்பண்டங் கதித்து உண்ணல் 
    காலங்கள் மாறிதயமி கப்சபாசித்தல் 
 பருதிதய பகல் தனிதலஸ் திரிசங் கிதத்ல் 
    பகல்த னிதலபால்சகாள்ளல் பகலுேங்கல் 
 நிருதிதய நிசிதன்னிே் சயனஞ் சசய்தல் 
    நித்னதயாம் லாகிரிகள் நிரம்ப வுண்ணல் 
 வருதிதய அக்கினியில் சஞ்ச ரித்தல் 
    மகத்தான கிரிசச்ரத்தின் மருவு வாதர.” 
                                                                  -யூகி னவத்திய சிந்தாமணி-737 
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1. Taking excessive carbohydrates. 
2. Taking excessive food at irregular times. 
3. Having sex at day time. 
4. Taking milk in the day time. 
5. Sleeping in the day time and late time. 
6. Excessive chewing tobacco like products. 
7. Working in a hot place. 
II.According to Siddha Maruthuvanga Churukkam. 
“நீரினைத் தடுத்தல் செய்யிை் 
நீரக்டட்ுத் துவாரம் புண்ணாம்” 
                                             -சித்த மருத்துவாங்க சுருக்கம். 
 “சுக்கிலம் தனையடக்கிை் 
சுரமுடைீரக்் கட்டாகும்” 
-சித்த மருத்துவாங்க சுருக்கம் 
 
1. Avoiding normal micturition 
2. Avoiding natural semen ejaculation. 
 
III. According to Agathiyar guna vagadam, 
 
 “பாரடா மூத்திரக் குண்டிக்காயின் 
     பதிவான மூத்திரப்னப நீரத்்தானர தானும் 
  ஏரடா எதே்தகனும் வியாதி காணில் 
     இதமான கருப்பிணியில் மூத்திரப்னப தானும் 
  வாரடா கருப்னபனய அழுத்தலாலும் 
     வளமான மூத்திரப்னப சகடுதலாலும் 
  கூேடா மூலத்தின் அைனலயாலும் 
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     சகாே்ேவதன இந்தநாய் வருகும் பாதர.” 
                                                                        -பாடல்-265, பக்கம்-67 
“வருகுமடா சீரணத்தின் சதாழில்தான் சகடட்ு 
     வளமாக அதிகஉஷ்ணத்தினாதல யப்பா 
  மருவிதய இன்தனாய்தான் வருகும் தவனள 
     மானிடரக்்கு அடிக்கடி தான் சிறுநீர ்காணும் 
  திருகிதய அனதயடக்க முடியா தப்பா 
     திதரகத்தில் பிரயானச மிகதவ காடட்ும் 
  குறுகிதய மூத்திரந்தான் இேங்கும் பாரு” 
                                                                          - பாடல்-266, பக்கம்-67 
1. Renal disorder 
2. Bladder & urethral disorders 
3. In pregnancy (bladder is compressed by gravid uterus) 
4. During digestive disorders. 
5. All the above causes’ frequency of micturition and scanty micturition. 
“உண்டாகும் காரணத்னதச ்சசால்லக் தகளு  
   உத்தமதன மூத்திரத்தின் னபயிதல தான் 
நண்டான கல்லுகள்தான் இருக்கலாலும் 
   நலமான மூத்திரப்னப குண்டிக்காய் தராகம் 
திண்டான மலக்குடல் கருப்பாசய மான 
    தீங்கான தராகதத்ால் இந்தநாய் காணும் 
பண்டான அதிதபாகம் சூதகசன்னி 
பாைான ஆசனக்கிருமி தநாயால் இந்தநாய்    
ததான்றுங்காதன” 
                                                 -அகத்தியர ்குணவாகடம்(270) பக்கம்-68 
1. Renal calculi 
2. Disorders in kidney, bladder 
3. Rectal disorders 
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4. Excessive sex desire 
5. Anal canal infection (worm infestations) 
IV.According to Dhanvanthiri vaithiyam, 
 
 “அதிக உட்டின பதாரத்்த மசீரண பதாரத்்த்தாலும் 
 அதிக சம்தபாகத்தாலு மதுபான மடுக்கலாலும் 
 அதிகன மானவஸ்து உண்டியி ருக்கலாலும் 
 அதிகமூத ்திரமதன்னிே் கிரிசச்ன மடுக்கசமன்தன” 
                                        -தன்வந்திரி னவத்தியம் பாகம்-2,பக்கம்-209 
 
1. Taking hot and hard digestive food 
2. Excessive coitus, Excessive intake of food 
3. Taking liquors. 
 
Premonitory Symptoms- முற்குறி குணங்கள் 
1.நீர ்சரியாக இேங்காமல் மிக்க தநரங்கழிதத்ு 
நீரக்ழினகயில், அந்நீர ்அளவில் குனேந்தும் எனடயில் 
சுருங்கியும் காணப்படும். 
2.நிேத்தில் சிவந்தும், சிலதவனள புலால் மணத்துடனும் 
சவளிப்படும். 
3.நீரப்ுனையில் தாங்க முடியாத வலி, எரிசச்ல் என்னும் 
குறிக்னள உண்டாக்கி, நீரச்சாடட்ு சசாட்டாய் இேங்கும். 
4.இடுப்பில் வலியும் ஏே்படும். 
 
1. Scanty urination 
2. Sometimes reddish colour, foul odour urine 
3. Painful and burning micturition 
4. Suprapubic pain 
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Classification 
 
I.According to yougi vaithiya chinthamani: 
“சதரியதவ கிரிசச்ரத்தின் சசயனலத் தானுஞ் 
 சசப்பதவ நாலுவனகச ்சீரு மாகும் 
உரியதவ வாதமூதத்ி ரக்கி ரிசச்ம் 
 உகப்பான பித்தமூத்தி ரக்கி ரிசச்ம் 
பரியதவ சிதலத்தும மூத்தி ரக்கி ரசச்ம் 
 பாங்கான தமகமூத்தி ரக்கி ரிசச்ம் 
நரியதவ கிரீசச்ரந் தானால தாகும் 
 நாட்டமாய் உே்பத்திந விலக் தகளு” 
 
Four types of Neerchurukku. They are 
1. Vadha neerchurukku 
2. Pitha neerchurukku 
3. Kabha neerchurukku 
4. Mega neerchurukku 
 
II. According to Dhanvanthiri vaithiyam, 
 
“அடுத்திடும் வாதபித்த மருங்கபஞ் சந்நிவாதந் 
சதாடுத்த மூத ்திரக்கிரந்தி சுக்கிலக் கிரிசச்ங் காதம் 
அடுத்த சரக்்கரதம வாத குண்டலி வாதவத்தி 
எடுத்திடுங் கிரிசச்ன த்தின் சபயரினவ 
                                                               யீனரந்தாதம” 
                                                                               -பாகம் 2,பக்கம்-209 
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Dhanvanthiri classified Neerchurukku into ten types. 
1. Vadha neerchurukku 
2. Pitha neerchurukku 
3. Kabha neerchurukku 
4. Sannivadha neerchurukku 
5. Moothira sukila neerchukku 
6. Moothira katha neerchurukku 
7. Moothira kiranthi neerchurukku 
8. Chakkara neerchurukku 
9. Vadha kundala neerchurukku 
10. Vadhavathi neerchurukku 
 
III. According to pararasa shekaram, 
 
 “உே்தே ததான்றும் கிரிசச்ிந்தா  
                       நுனரத்தார ்நாலு வனகயாகச ்
 சசாே்ே வாத பித்த கபந் சதாந்த 
                     சமன்பரனவ நாலும்” 
                                                -பரராசதசகரம்,பக்கம்-69,பாகம்-5. 
 
In Pararasa sekaram neerchurukku is classified into 4 types 
1. Vadha neerchurukku 
2. Pitha neerchurukku 
3. Kabha neerchurukku 
4. Thontha neerchurukku 
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IV. According to Madhava Nidhanam.  
 
 An Ayurvedic text described the disease into 8 types. They are 
1. Vadha neerchurukku  2.Pitha neerchurukku 
3. Kabha neerchurukku  4.Sannipatha neerchurukku 
5. Koothaja neerchurukku   6.Pureeshaja neerchurukku 
7. Acharisha neerchurukku  8.Sukkaraja neerchurukku 
 
V. In Anuboga vaithiya deva ragasiyam- 
 
 Neerchurukku is classified in to following types. 
1. Vadha neerchurukku  2.pitha neerchurukku 
3. kabha neerchurukku  4.Thirithoda neerchurukku 
 
VI. According to sirappu payeram- (Pachayappa Mudaliar) 
 
 Neerchurukku was classified into 4 types 
1. Vadha neerchurukku  2.Pitha neerchurukku 
3. Kabha neerchurukku  4.Sannipatha neerchurukku 
 
Then the book classified into Moothira thosarogam into 12 types. They are 
 
1. Vadha vasthi   2.Vadhastilam 
3. Vadha kundaligam   4.Moothira sadaram 
5. Moothira theetham   6.Moothira sangam 
7. Moothira kiranthi   8.Moothira sukram 
9. Vitvikatham   10.Ushnavadham 
11. Moothira shyam   12.Moothira saatham 
                                                                                           பக்கம்-125 
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Mukkutra verupadugal: 
                “வாத பித்த னமய மூன்றும் 
     வன்பலத்துடதன தத்தம் 
       தபதசமான்றில்லா வண்ணம் 
                  தபசிய தானந் தன்னில் 
        நீதியாய் நினலத்து நிே்கில் 
      சநடும்பிணி சிக்கவில்னல 
          தாதுசமான்தோசடான்று 
        தாவிடிே் பிணிகள் தாதன” 
                                          -சித்த மருத்துவ தநாய்நாடல்  
                                      தநாய்   முதனாடல் திரடட்ு-பக்கம்-
155 
2. “வைங்கிய வாதம்மாத்தினர சயான்ோகில் 
      தைங்கிய பித்தந்தன்னிலனர வாசி 
      அைங்கு கபந்தானடங்கிதய காதலாடில் 
      பிேங்கிய சீவரக்்குப்பிச சகான்றுமில்னலதய”            
 [குணவாகடம்] 
Disharmony of the Uyirthathus leads to disease.Certain extrinsic, intrinsic, 
food and habits can change the hormony of the uyirthathus into thirithodam. 
  That is “தன்வினன புேவினன தாழினும்மிகினும் 
     உடனலப்பிணிக்கு முண்னமயிது தாதம-manuscript 
In neerchurukku vadham is altered, this inturn affects abanan and 
viyanan. Abanan possess property of theyu bootham. So it increase pitham 
which has following symptoms. 
“ஏலவார ்குைலாய் பித்தஞ்சசய்குணம் விளம்பக் 
தகளாய் 
தகாலதவல் விழிசிவந்து குளிரந்்திருக்கு மல்லால் 
சீலதவ நீரக்டுத்து சநாந்து சுறுக்சகன வந்துவீழும் 
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ஞாலதம கிறுகிசேன்று நாவுலரந்்திருக்குங் காதண” 
      -ரத்தினச ்சுருக்கநாடி 
It describes that aggravation of pitham produces symptoms of 
neerchurukku 
1. Burning micturition 
2. Burning pain in the external genitalia 
3. Dryness of the tongue 
Affected viyanan altered Akayapootham. This produces the following 
symptoms. 
1. Pain all over the body 
2. Fatigue 
CLINICAL FEATURES-குறிகுணங்கள் 
I.According to Yougi vaidhiya chinthamani. 
i.Azhal neerchurukku-அைல் நீரச்ுருக்கு 
 “தான் மூத்திர மஞ்சளிதத்ு மிகச ்சிவக்கும் 
  தளரந்்துதம னககாலு மசதியாகும் 
 பானருக்கிச ்சிறுகலா யருவி பாயும் 
  பாரமாங் குதமண்டமி லிங்கந் தானும் 
கான்வாயுதான் மீறிவயிறு உப்பும் 
  களக்சளன்று இனரசச்லாய்க் கசங்கி தயறும் 
 தவங்காயு வாயுலரந்்து மிரட்சியாகும் 
  விடும்பித்த மூத்திரத்தின் விவரந் தாதன” 
1. Yellowish (or) Reddish discoloured urine 
2. Malise (Pain in the upper & lower limbs) 
3. Scanty urination 
4. Supra pubic pain (lower abdominal pain) 
5. Heaviness of external genitalia 
6. Dryness of mouth 
7. Flatulence-Abdominal distension. 
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Clinical features of other types: 
ii.Vali neerchurukku-வளி ீ ரச்ுருக்கு 
 “மருவதவ தமகம்வந் துே்ப வித்தல் 
  வளரந்ாபி தன்னிே்றுள் மாம்சஞ் சிக்கித் 
 துருவதவ சுக்கிலத்தால் மாமிச முே்றிச ்
  சுைன்றுதம தம்பித்து வாயு தன்னால் 
 சிறுகதவ சிறுநீரவ்ீை் குதே்ோன் சிக்குந் 
  ததகசமங்குந் துனளத்துதம கடுப்பு மாகும் 
 அருவதவ துன்மாமிசங் கறுப்பாய் வீழும் 
  அருக்கதம வாதத்தின் கிரிசச்ந் தாதன” 
1. Due to venereal disease, inflammation of bladder wall. 
2. Excessive coitus 
3. Scanty urination 
4. Pain all over the body 
5. Excretion of desquamated blacky renal (or) urinary tract cells. 
iii.Iya neerchurukku-ஐய நீரச் ்சுருக்கு 
“விபரமாய் வே்றியண்டங் குதம்வ லிக்கு 
 தமனியிதம சவளுப்பாகி மிக்க்கண் பசன்ச 
திபரமாய்க் கிறுகிறுத்து தியக்க மாகும் 
 ததகசமல்லாம் மிகக்கடுப்புசச்சாறிசச்லாகும் 
அபரமாய ரிக்கிநீர ்எரிசச் லாகும் 
 அடிக்கடிக்கு நீரக்சிந்து அனலசச்லாகும் 
நிபரமாய் லிங்கத்திே் கூசச் லுண்டாம் 
 நீசச்ான தசடட்ுமதத்ின் கிரிசச்ந் தாதன” 
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1. Pain in the external genitalia & anus 
2. Pallor 
3. Fainting 
4. Pain & itching all over the body. 
5. Burning micturition 
6. Frequency of micturition. 
iv.Mega neerchurukku-நமக ீ ரச் ்சுருக்கு 
 “கிரிசச்மாய டிக்கடிக்கு சவள்னள காணும் 
  கிடட்ுதம நீரத்்தானர யடியிே் ோனும் 
 புரிசச்மாய் புோசவசச்ம் தபால விழும் 
  புடுங்குதம அடிவயிே்றிே் புழுக்க ளூரந்்து 
 விரிசச்மாய் சவள்னளதான் கவிசச் டிக்கும் 
  விம்மும்தபாது உடலுசச்ிம யினரத ்தூக்கும் 
 குரிசச்மாங் குதமிலிங்கம் தவக்கா டுண்டாம் 
  குமுறுதம தமகத்தின் கிரிசச்ந்தாதன” 
1. White discharge like dove’s faeces 
2. Worm like sensation in the lower abdomen 
3. White discharge with foul smelling 
4. Horripilation  
5. Burning sensation of the external genitalia & anus. 
II.In Pararasa sekaram. 
 “சிறுநீ சரரிந்து துளிதுளியாய்ச ்
  தசரு நிேமுமஞ்சளாய் 
 உறுதம சிவப்பாய் சவள்னளயு 
  மாயுவாதி மிகுந்து கடுதத்ு சநாந்து 
சபறுதம யன்றிப் கடுத்துனளயும் 
  பின்னு மபானங் கடுத்துனளயும் 
 சசறுதம சபாருமுங் கீை்வயிறு 
                          ததக சமலியுங் கிரிசச்ிரதம”. 
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1. Burning & painful micturition 
2. Passing urine drop by drop 
3. Yellow, white (or) red discolouration of urine 
4. Painful rectum 
5. Lower abdominal discomfort 
6. Loss of weight 
III.In theriyar vagadam 
 “மூத்திரக் கிரிசச்ிக் குணங்தகளீர ் 
                          முடுகுந்துளியாய் விழுஞ்சே்தே 
 ஆே்றித் தூரம் நடக்கசவாட்டா  
                           தறுனவ மருந்தாலாே்று விடும் 
 தூே்றி வினளவாய் வினளந்திருந்தால்  
                           துனடயால் கடுகி விழுசமன்று 
 மாே்றி மறுக்க வனககாண  
                            மனுதவரக்் சகல்லா முனரப்பீதர”  
   -168, ததனரயர ்வாகடம், பக்கம்-59 
கருப்பஞ்சாறு கண்டுகள்ளுக்கூடிய  
              தமாருங் காண்பிக்கும் 
        சுருக்குச ்சுண்ணஞ் சுக்கிலமுந் 
                துவரம்ண் ணதுதபால் ததான்றிவரும் 
        வருக்கமுடதன காமியந்தான்  
                   மருத்துவிழும தபால் மருகிடுங் காண் 
        சநருக்கு மூத்திரக்கிரிசச்ிசயன்று 
                   சநறிதயார ்குரியாய் நிகை்த்தியதத 
    -169, ததனரயர ்வாகடம், பக்கம்-59. 
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1. Passing urine drop by drop. 
2. Difficulty in walking for long distance 
3. It relived by surgery 
4. Butter milk, semen, liquor, lime-like urination 
5. Painful micturition. 
IV.In yougi vaithiya chinthamni 
 Symptoms of Salathamba vatham (Neerkatha vadham is mostly 
identical symptoms as Azhal neerchurukku. 
    “தாசனன்ே மலத்துவா  ரத்தி தனாடு 
            தாக்கிதய சசலத்துவா ரந்சதா டங்கி 
     தவசனன்ே நீரிேங்கும் தபாது தானும் 
             சவடிவுண்ணில் தநாவுதபாே்கிதலசம் பண்ணும் 
வாசனன்ே மலங்கடுத்துச ்சிறுகி வீழும் 
       மயிரக்்கூச ்சுண்டாகிதய வருத்தம் பண்ணும் 
ததசனன்ே தித்திப்புப் தபால்நீ ராகும் 
        சிறுகிவிழுஞ் சலத்தம்பச ்சசய்னக யாதம” 
     -யூகி னவத்திய சிந்தாமணி  
1. Primarily anus is affected and then the disease spread to urinary orifice. 
2. Sever pain during micturition & burning sensation 
3. Constipation 
4. Glycosuria 
5. Scanty urination. 
பித்த ீ ரச் ்சுருக்கு இயல்பு 
V.According to pararasa sekaram 
“பித்தத்திே் கிரிசச்ி ரந்தான் தபசரு மைே்சி யாகி 
உே்ேநீர ்மஞ்சள்தபாலு முறுசசம்னம நிேமுங் 
சகாள்ளும் 
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மே்றுட லசதியாகும் வாய்மிக வுலரந்்து காடட்ும் 
சசாே்றிடு மபான்ந் தானுந் துயரம்ிகக் கடுக்கு 
சமன்பதத” 
       பக்கம்-69-70 
1. Yellowish (or) reddish discoloured urine 
2. Malaise 
3. Dryness of tongue 
4. Pain in the anus. 
VI.Dhanvanthiri vaidhiyam 
                   Symptoms of Pitha neerchurukku 
“நீரவ்ிடட்ுங் காலந்தன்னில் சநலிவுே சமலிவு சசய்யுஞ் 
தசாருநீர ்மஞ்சள் தபாலத் ததான்றிடுஞ் சிவந்து வீழும் 
தயே் சபே சவரிந்து சநாந்து கடுத்திடு மிக்குணங்கள் 
கூரவ்ிழி மாதன பித்த கிரிசச்ன சமன்று கூதே”-பக்கம்209 
1. Loss of weight 
2. Yellow & reddish discoloured urine 
3. Painful & burning micturition. 
VII. In Athma Ratchamirtham vaidhiya sara sangiragam 
      பித்த நீரச்ுருக்கின் இயல்பு 
1.நீரத்ானரப் புண்ணாகி, சநாந்து வீங்கிக் கடுத்து எரியும் 
2.நீரவ்ருவது தபாலிருக்கும். இேங்காது. 
3.இேங்கினால் ஒவ்சவாரு துளியாய் வீழும்.அப்தபாழுது 
சகிக்க முடியாத தவதனனயும், மயக்கமும் காணும். 
4.உணவு சசல்லாது. உடல் சமலியும். 
1. Urethral passage will be ulcerated, Pain, swelling and burning sensation 
will also present 
2. Desire of urination, but no output 
3. Passing urine drop by drop. During micturition more pain will be present. 
4. Yellow,red,white discoloured urine 
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5. Anorexia, weight loss 
 
 
VIII. In Anubava Vaithiya Deva Ragasiyam 
 பித்த நீரச்ுருக்கு இயல்பு 
நீரத்ுவாரத்தில் தநானயயும், எரிசச்னலயும் உண்டாக்கி 
மஞ்சள் சிவப்பு நிேங்களாக நீனர இேங்கச ்சசய்யும். 
1. Pain, burning sensation in the urethral orifice 
2. Yellowish & reddish discolouration of urine.  Page-130 
General clinical features: (All types of Neerchurukku) 
1. Burning micturition 
2. Frequency of micturition 
3. Difficulty in micturition 
4. Scanty micturition 
5. Pain in the external genital organs 
6. Pain all over the body 
7. Lower abdominal discomfort 
8. White discharge 
In Azhal Neerchurukku 
According to Yougi Vaithiya Chinthamani 
1. Yellowish (or) Reddish discoloured urine 
2. Vague pain in the upper & lower limbs 
3. Scanty urination 
4. Frequency of urine 
5. Pain in the external genital & anus 
6. Flatulence – lower abdominal pain 
7. Dryness of mouth. 
In additional to above the other symptoms are 
8. Burning micturition 
9. Painful micturition 
10. Anorexia 
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Diagnosis (Piniyari muraimai) 
 Diagnosis is the very important thing for a physician by which he 
deals the disease by finding its cause and is helpful to undertake a correct 
line of treatment and also prognosis. 
The diagnosis is based on 
 1. Poriyalarithal (Inspection) 
 2. Pulanalarithal (Palpation) 
 3. Vinathal (Interrogation) 
 4. Envagai thervugal 
(1) poriyal arithal (Inspection) 
Porikal are the five organs of perception. They are nose, tongue, eyes, 
skin and ears.Poriyalarithal is examining the pori of the patient by pori of 
the physician. 
(2) Pulanal arithal (Palpation) 
Pulangal are theobject of sense namely smell, taste,vision, sensation and 
sound In Azhal neerchurukku most of the patients have supra pubic 
tenderness (or) Lower abdominal pain 
   (3)Vinathal (Interrogation) 
By Vinathal, the physician knows about the patient’s name, age, 
occupation, native place (thinai), family history, socio economic status, 
dietary habits, his (or) her complaints, history of past illness, relevant 
history of treatment and habits etc. 
(4)Envagai thervukal 
It is the basic diagnostic principle and the unique speciality of the 
siddha system of medicine. The following verses reveals this as follows. 
 “நாடிப் பரிசம் நா நிேம் சமாழி விழி 
 மலம் மூத்திரமினவ மருத்துவராயுதம்” -ததரன் 
Envagai thervugal are 
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1. Naadi(pulse) 
2. Sparisam (Palpation) 
3. Naa (Tongue) 
4. Niram (Colour of skin) 
5. Mozhi (Speech) 
6. Vizhi (eyes) 
7. Malam (Motion) 
8. Moothiram (Urine)  
i)Naadi 
 Naadi is defined as 
உடலில் உயிர ்தரித்திருப்பதே்குக் காரணமானசிவசக்தி 
எதுதவா அதுதவ தாது அல்லது நாடி எனப்படும். 
   -தநாய் நாடல் தநாய்முதனாடல் திரடட்ு 
Formation of Naadi 
 The Three thathukkal are formed by the combination of three 
naadies with three vayus 
 Idakali + Abanan   –Vadham 
 Pinkali + Pranan     - Pitham 
 Suzhumunai + Samanan – Kabham 
 “வந்த கனல மூன்றில் வாய்வாம்பான்னுடன் 
 தந்த பிராணன் சமானனும் சந்தனமுேக் 
 கூடட்ுேவில் தரசித்தல் கூறும் வாதம் பித்தம் 
 நாட்டுங் கபதம யாம் நாடு” -கண்ணுசாமியம் 
 Naadi is the main diagnostic scale of Siddha System. It can be felt 
at one inch below.The wrist on the radial lateral side by means of palpation 
with the tip of index, middle and ring finger correspondent to vadham, 
pitham and kabham. Normally these 3 vital forces exists in the ratio of 
1:1/2:1/4. Derangement of this ratio leads to various diseases entities.  
In Azhal Neer Churukku the following naadi nadai are seen 
commonly 
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1. Vadham  
2. Pitham 
3. Vadhapitham 
4. Vadha Miguthiudan ushnam (Increased vadha naadi with combination of 
heat) 
Vadham  
“வாத சமனும் நாடியது ததான்றிே்……. 
          நினலயும் நீரக்் கிரிசச்ரங்கள் தந்து தமகம்”-
சதகநாடி 
“தமவிய வாதஞ் சசய்யும்………… 
            ……………சிேத்துடன் சிறுநீர ்விழும்” 
                                                                 -இரத்தினச ்சுருக்க நாடி 
Pitham  
 “ஏவலார ்குைலாய் பித்தஞ் சசய்குணம்…… 
    ……………நீரக்டுதத்ு சநாந்து”  
                                                                 -இரத்தினச ்சுருக்க நாடி 
Vadhapitham  
 “சபாருளான வாத்ததில் பித்தஞ்தசரந்்து…… 
 …………….நீரிே் சிவப்பு”   -சதக நாடி 
Vadhathil ushnam 
 “சிேப்பான வாத்தத்ிலுடண்ந்தாதன………. 
 …….. உண்டாகும் நீரச்ச்ிறுப்புப் பிரதமகங்கள்” 
                                                                                              -சதக நாடி 
Sparisam: 
 Sparisam means touch. By touching the skin and various part of the 
body we can rule out any abnormalities. 
 Temperature of the skin, any abnormal growth, hypersensitivity, 
thickening of skin, swelling, ulcer etc. 
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 In Azhal neerchurukku some patients have increased temperature & 
per rectal examination shows enlarged prostate. 
Naa: 
 Inspecting the tongue for its colour, coating, pallor, dryness, 
ulceration etc. 
 In Azhal neerchukku the tongue may be dry or pallor. 
Niram: 
 By examining the niram, the type of udal whether vadham (black), 
pitham (red (or) yellow) or kabham (white) or mixed,pallor and cyanosis of 
the body can be noted. 
Mozhi (Speech) 
 It constitutes high (or) low pitched voice, Slurring and incoherent 
speech, nasal speech, hoarseness of voice. 
Vizhi  
 Both motor and sensory disturbances of eye are noted. Burning of 
eyes, lacrimation, irritation, colour are also noted, 
Malam  
 Quality, colour, odour, constipation, diarrhoea, presence of blood, 
undiagested matter etc. in the stools can be find out. In azhal neerchurukku 
some patients have constipation and stools examination may show ova and 
cyst. 
Moothiram 
 “வந்தநீரக்் கரிஎனட மணம் நுனர எஞ்சசலன் 
 னேந்தியலுளவனவ யனேகுது முனேதய” 
     -ததரரநீ்ரக்ுறி சநய்குறிநூல் 
Neerkuri  
 Niram   -It indicates colour of urine. 
 Manam -It indicates the smell of urine 
 Edai   -It indicates specific gravity of urine 
 Nurai   -It indicates frothy of urine. 
 Enjal   -It indicates quantity of urine. 
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In addition Azhal neerchurukku patients have frequency and burning 
micturition and some deposits are present. 
 Enjal   -Some Azhal neerchurukkr patient have scanty 
urination 
 Niram   -Azhal neerchurukku – yellowish (or) reddish 
discolouration of urine 
Manam       -Azhal neerchurukku – sometimes unpleasant (or) 
Ammonia odour.                            
இயே்னக நீர ்இலக்கணம் 
 “மிகத ்தடிப்பும் மிகத ்ததேலும் இன்சேனில் 
 சுகத்னதத்தரும் சமய்சச்ுபாவ நீர ்நன்தே” 
    -ததரர ்நீரக்்குறி சநய்க்குறி நூல் 
The normal urine must be in medium weight and moderate clarity. 
In Azhal neerchurukku patient’s urine show sometimes cloudy appearance. 
               சிறுநீரப்்னப நாளப் புண்ணீர ்மணம்: 
“சவய்ய துரக்ந்தம் வீசுநீர ்மூத்திரப் 
னபநாளமிவே்னேப் பே்றுபுண் குறிதய 
அம்சமாழியின் சேனின்னிலதம முதலிய 
மும்மலச ்சுததம மூலசமன் றுணதர.” 
    -ததரர ்நீரக்ுறி சநய்குறி நூல்  
Bladder & urethral ulceration causes unpleasant odourous urine. 
         குண்டிக்காய் துரப்்பலம் நீர ்
In neerchurukku the urine may be like flesh washed water. (Renal disorders) 
“தீப்புலால் கழுநீரச் ்சசய்சலனிே் குண்டிக் 
காய்தத்ுரப்் பலத்தால் கதித்த நீராமத் 
துரப்்பலக் கபமும் தசாரியும் சகாத்ப்புேப் 
பே்பகலாகப் னபனயப் பதிந்தத” 
                                      -ததரர ்நீரக்ுறி சநய்குறி நூல் 
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Neikuri   
 “அருந்து மாறிரதம் அவிதரா தமதாய் 
 அக்கல் அலரத்ல் அகாலவூண் தவிரத்்தைே் 
 குே்ேள வருந்தி உேங்கி னவகனே 
 ஆடிக் கலசத் தாவிதய காதுசபய் 
 சதாரு முகூரத்்தக் கனலக்குட்படு நீரின் 
 நிேக்குறி சநய்குறி நிருமித்தல் கடதன” 
    -ததரர ்நீரக்ுறி சநய்குறி நூல் 
 
Method 
 Prior to the day of urine examination the patient is advised to take a 
balanced diet and the quantity of food must be proportionate to his appetite 
and he should have a good sleep. After waking up in the morning the 
first urine voided by the patient is collected in a glass container and is 
subjected to analysis within 1 ½ hours.A drop of gingerly oil dropped into 
container without shaking. The nature of the neikuri should be noticed in 
direct sunlight. 
Observation  
1. Vadhaneer 
 “அரசவன நீண்டின் வாதம்” 
When the drop of oil like a snake it indicates vadhaneer. 
2. Pithaneer 
 “ஆழிதபாே் பரவின் பித்தம்” 
When the drop of oil spread like a ring it indicates pitha neer. 
3. Kabha neer 
 “முதச்தாதத்ு நிே்கின் சமாழிவதன் கபதம” 
When the oil drop remains as that of a pearl it indicates kabha neer  
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4. Thontha neer 
 “அரவிலாழியும் ஆழியில் அரவும் 
 அரவின் முதத்ும் ஆழியில் முத்தும் 
 ததாே்றில் சதாந்த ததாடங் களாதம” 
When the drop of oil show two shapes enclosed within one another it 
indicates thontha neer.In Azhal neerchurukku neikuri spread like a ring and 
sometimes snake. 
 
Thinai (Land and place) 
 The geographical distribution of the land is classified into five 
regions. 
 1. Kurinchi  - Mountain and its surroundings 
 2. Mullai  - Forest and its surroundings 
 3. Marutham  - Field and its surroundings 
 4. Neithal  - Sea and its surroundings 
 5. Palai  - Desert and its surroundings 
 Each region has its own characters which influence the habitants, 
physical, mental, economic, occupational and cultural activities. In each 
region some aliments are endemic based on the climatic features. 
Prevention and curative measure for these ailments are stated in the medical 
literature. 
Kaalm (season) 
 With reference to the position of sun, the year is divided into six 
seasons as follows. 
 1. Kaarkaalam  - Avani and puratasi 
 2. Koothir kaalam - Aypasi and karthigai 
 3. Munpani kaalam - Margali and thai 
 4. Pinpani kaalam - Massi and panuguni 
 5. Elavenil kaalam - Chithirai and vaikasi 
 6. Muthuvenil kaalam - Aadi and avani 
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 According to climatic conditions in every season, normally changes will occur in 
the land water, plants, animals, and human beings which will modify the physiology and 
make them susceptible to certain specific diseases on account of these changes, siddhars 
have Advised to follow certain measures in the form of diet, purgation, exercise etc, .to 
avoid the onset of disease. 
Udal vanmai 
 Smartness, strength and vitally constitute udal vanmai. It is 
classified into three types. 
 1. Iyarkai vanmai  - Inherited immunity by birth. 
 2. Kala vanmai - Vitality that is generally found in   different 
age. 
3. Cheyarkai vanmai  - Improvement of vitality obtained by 
good habits, Physical exercise, proper diet and medicines. 
Mukkutrangal 
 These are anatomical and physiological units of the body that is 
Vadham, Pitham, and Kabham. Vadham classified into 10 forms. Pitham 
and Kabham each are classified into five forms. 
Vadham 
 The word vayu not only implied wind but also comprehense the 
phenomenon, which comes under the functions of the motor and sensory 
nerves system. 
Ten types of vadham are, 
1. Pranan   2.Abanan 
3. Samanan   4.Viyanan 
5. Uthanan   6.Nagan 
7. Koorman   8.Kirukaran 
9. Thevadhathan  10.Dhananjeyan 
In Azhal neerchurukku abanan, samanan, uthanan, viyanan & thevathathan are 
affected. 
Functions of Abanan. 
 “இருக்கதவ யபானத்திம னியக்கங் தகளாய் 
 ஏே்ேசுவா திட்டானத் துே்பத்தி யாகும் 
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 மருக்கதவ கீை்தநாக்கி மலசலந் தள்ளும் 
 வாகாக நிேந்தானும் பசன்சயாகும் 
 அருக்கதவ யாசனத்னதச ்சுருக்கி னவக்கும் 
 அன்னசா ரத்னதசயலாச ்தசர னவக்கும்” 
 “சநளிந்திட்ட வாதமபானத்னதப் பே்றி 
 மணமான விந்துவிை மலநீர ்சபே்ே வழிகாட்டி” 
    -சித்த மருத்துவாங்கச ்சுருக்கம் 
 It originates in the swadhistana & expels faecal matter & urine. It 
constricts the anal sphincter. It distribute the ingested food extracts to their 
respective places. It is also responsible for the expulsion of spermo & 
menstrual flow. Its derangement leads to disease of the bladder, 
rectum & reproductive system.Affected abanan produces burning 
micturition, pain in the external genitalia, painful micturition, flatulence and 
constipation in Azhal neerchurukku. 
Functions of Viyanan. 
 Viyanan spreads all over the body in a nerve endings and cause 
constriction & relaxations of both voluntary and involuntary 
muscles.Affected viyanan produces urgency of urination, pain all over the 
body, (upper & lower limbs) in Azhal neerchurukku. 
Uthanan. 
 It lies stomach and in the throat. 
 Azhal neerchurukku patient have dryness of tongue & nausea. 
Samanan 
 It lies in the abdominal region especially around the umbilicus and 
acts as a neutralizing air for the upward & downward air. 
 In Azhal neerchurukku, flatulence, suprapubic pain may present. 
Thevadhathan 
 It lies in the anus & external genitalia. 
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Pitham 
“பிரிந்திடும் பித்தம் தபராஞ்சலத்தினில்” -திருமூலர.் 
 Pitham was excreted by urine. 
Sites of pitham 
 Between the heart & naval, sweat, lymph, blood, urinary bladder, 
saliva, eye & skin. 
Functions 
 Body temperature, digestion of food, colouring of skin and blood. 
Yellowish discolouration of urine, motion, skin etc. (excretions) 
Types 
1. Anal pitham 
2. Ranjaga pitham 
3. Sathaga pitham 
4. Alosaga pitham 
5. Prasaga pitham. 
 In some of the Azhal neerchurukku patients have pallor (Rnajaga 
pitham affected), Anorexia (Anal pitham affected) and Malaise (Sathaga 
pitham affected) 
Kabham. 
1. Avalampagam Helps in the functions of other kabhams 
2. Kilethagam  -Helps in digestion by moistening the food. 
3. Podhagam  -Helps in knowing different tastes 
4. Tharpagam  -gives cooling sensation to the eye 
5. Santhigam  -Helps in movement of the joints by providing 
lubrication. 
Seven udal thathukkal: 
 They are basic principles, which constitute the entire body. 
1. Saram    2.Senneer 
3. Oon     4.Kozhupu 
5. Enbu    6.Moolai 
7. Sukkilam/suronitham 
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In Azhal neerchurukku saram, senner are affected 
 Saram affected - Tiredness, Malaise 
 Senneer affected - pallor (Anaemia) 
Prognosis 
 According to yougi vaithiya chinnthamani 
தமகத்தின் கிரிசச்ந்தான் பித்த கிரிசச்ம் 
 மிகவிரண்டு குணமாகி வினரந்து தபாகும் 
ததகத்தில் இதுசரண்டு சாத்தி யமாகிச ் 
 சசயமான மருந்தினாே் றிரும்ப லாகும் 
வாத்த்தின் வாதமு மூத ்திர கிரிசச்ம் 
 மருவுகின்ே தசத்தும்மூத ்திரக் கிரிசச்ம் 
பாத்தி  னிதிரண்டு மசாத்ய மாகும் 
 பாடுபடட்ுந் தீராது பரிந்து பாதர”  
                                                             -யூகி னவத்திய சிந்தாமணி  
 Azhal and Mega neerchurukku can be cured easily 
 Vadham and Kabham neerchurukku cannot be cured easily 
Treatment:  
 Siddha system classifies treatment as follows. 
  Kappu (Prevention) 
  Neekam (Treatment) 
  Niraivu (Restoration of well beings) 
Neekam:  
 A good physician should know about the derangement of kuttram 
and should treat the patient on the basis of altered kuttram. 
 Treatment is based on  
1. To bring the tridosham to normal. 
2. To treat the disease according to its symptoms through medicines. 
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To normalise tridhosam 
 “விதரசனத்தால் வாதம் தாழும் 
 வமனத்தால் பித்தம் தாழும் 
 நசிய அஞ்சனத்தால் கபம் தாழும்” 
Vadha diseases can be brought down by viraesanam, by giving laxative and 
purgatives according to the patient condition 
 Pitha diseases  - Giving vamanam(Emetic) 
 Kabha diseases -Anjanam and Nasiyam (Nasal drops) 
 In Azhal neerchurukku first vadham is affected then if coupled with 
pitham.So laxative is administered on the previous day before starting the 
neerchurukku medicines. 
Pathiyam: 
 During the course of treatment, patient is advised to take following 
items regarding diet and physical activities. This form of medical advice in 
Siddha system of medicine is termed as PATHIYAM which is very 
important in siddha system of medicine.  
Pathiyam for neerchurukku 
அதிமதுரஞ் சிறுநாணலுந் சதே்னபயு 
 மரிய சநரிஞ்சில் துரா 
யானன சநருஞ்சில் கரும்சபாடு சந்தன 
 மாவதின் சநய் பாலும் 
மதியுறு சூரியகாந்தியும் பூசணி 
 வங் கமதின் பே்பம் 
மகிை்பூ சிறுகீனரயு சநல்லியு 
 மணலியுங் கவு தும்னப 
விதியுறு ததே்ோன் வித்ததாடு முந்திரி 
 சவள்ளரி யிளநீரும் 
சவள்ளறுகுட நீரம்ுள்ளி சபான்னாங்காணி 
 தமவிய மரமஞ்சள் 
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முதிருறு சீந்திலுதமல் முடன்னீர ்
 முத்தமு நிம்பஞ் சரக்்கனரயாவும் 
முட்டான்  பிரமியது 
 மூத்திரக் கிரிசச்ர ஹரதம”  
                                                       -தநாய்களுக்கு சித்த பரிகாரம் 
II.According to Agathiyar Gunavagadam 
“தகளடா தபாசனதன்தக் கிரமமாய்ச ்சசய்து 
 சகாடிதான உஷ்ணத்தின் பதாரத்்தம் தள்ளு 
நாளடா சாராயம் முதலாயுள்ள் 
 நலங்சகட்ட வஸ்து சவல்லாந் த்ள்ளிப்தபாடு 
ததளடா அயமுதல் குளிரக் கரியான் 
 சதளிவான ததத்தான் சநய் முதலாயுள்ள 
வாளடா வளனமகண்டு ரிய்ந்தாயானால் 
 வலுவே்று தராகந்தான் நீங்கிப் தபாதம”   -பக்கம்-69 
1. Timely meals 
2. Avoid hot food substances 
3. Avoid liquor, smoking etc. 
4. To give iron preparation. 
III.According to Anupava Vaithiya Deva Ragasiyam 
பனைய சிகப்பு அரிசி   பசுதமார ்
பசுசநய்     பசும்பால் 
பசன்சப்பயிறு    சரக்்கனர 
கல்யாண பூசணிக்காய்  புடலங்காய் 
சுக்கு      சநருஞ்சில் 
கே்ோனை     முள்ளுசவள்ளரிகாய் 
கரச்ூரம்     ததங்காய் 
நுங்கு     தரப்ூசணிப்பைம் 
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ஏலக்காய்               சீதளமானஅன்னபானங்கள் 
ஆே்று ஜலம்   பசன்சகே்பூரம் -பக்கம்-531. 
Apathiyam 
 During treatment. The patients are advised not to take following 
items regarding diet and physical activities. 
கள் குடித்தல்     அதிக உனைப்பு 
மாதரின் புணரச்ச்ி    குதினர சவாரி 
விருத்தமான விஷம்மான அன்னம்  தாம்பூலம் 
மீன்       உப்பு 
இஞ்சி      எள்ளு 
கடுகு      உளுந்து 
மூத்திரத்னத அடக்குதல்   அதிதீஷணம் 
அதிபுளிப்பு 
Kappu (Prevention) 
“முக்கால் மலமது சபால்லாத வாயுவு மூன்று தும்மல் 
சிக்கா மலாறு சலதானர விடட்ுச ் சிறுநனடயும் 
னமக்காடு சகாண்ட விழியாய் மனிதரக்்கு 
                                                        வாய்ப்பசதனில் 
எக்கால மும்பிணி வாராத காயமிரும் சபாக்குதம” 
    -சித்த மருந்துவாங்கச ்சுருக்கம் 
Evacuate stools 3 times/day and excrete urine 6 times/ day. 
 If anyone holds urine and semen for a long times it will end in 
Neerchurukku 
 “நீரினனத் தடுத்தல் சசய்யின் 
 நீரக்்கடட்ுத ்துவாரம் புண்ணாம்” 
 “சுக்கிலந் தனனயடக்கின் 
 சுரமுட னீரக்்கட ்டாகும்” 
    -சித்த மருத்துவாங்கச ்சுருக்கம் 
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Niraivu 
 
 Reassurance is given to all patients for speedy recovery 
 All of them are advised to live in a good morality 
தநாய்கள் அசாத்தியமாயினும் குணமாக தவண்டின் 
இவ்விதிகனள அனுசரிக்க தவண்டும்: 
பே்றுதநாய் தீரசவன்ோல் தருமம் தவண்டும் 
 பாங்கான குணம் தவண்டும் வணக்கம் தவண்டும் 
சித்திரமாய் அவுடத்ங்கள் சசய்ய தவண்டும் 
 சசய்மருந்து சுத்தி தவண்டும், பத்தியம் தவண்டும் 
முத்திசபறும் னவத்தியன்தமல் கிருனப தவண்டும் 
 முன்தனாரக்ள் நூல்முனேதபால் நடக்க தவண்டும் 
புத்தியுடனிப்படிதய நடந்ததபரக்்குப் 
 பிணி தீருசமன்று மனம் சபாருந்திச ்சசால்தல”  
                                                                                              -சதகநாடி 
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MODERN ASPECT 
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URINARY SYSTEM 
                    
MODERN ASPECT 
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    ANATOMY OF THE URINARY TRACT 
Urinary tract is divided into  
  Upper urinary tract 
  Lower urinary tract 
Upper urinary tract consist of  1. Kidney 
     2. Abdominal part of ureter 
Lower urinary tract consist of  1.Pelvic part of ureter 
     2. Bladder 
     3. Urethra 
                                                    KIDNEY 
 The kidneys are a pair of excretory organs. They have exocrine and 
endocrine functions. The endocrine function is done by the secretion of a 
hormone called renin. They remove waste products of metabolism and 
excess of water and salts from the blood and maintain its PH. 
SHAPE AND SIZE: 
 Each kidney is bean shaped and has two poles (upper and lower) two 
borders (medial and lateral) and two surfaces (anterior and posterior). Each 
kidney is 7.5cm in length, 5cm in breadth and 2.5cm in thickness. Each 
kidney weight about 120 to 150 gms. 
SITUATION: 
 They are situated on the posterior abdominal wall, on either sides of the lumbar 
vertebral column. They are situated below the liver but above the umbilicus. It occupies 
epigastric, hypochondrium, 
Lumbar and umblical regions. It extend from the upper border of vertebra T12 to 
the centre of the body of vertebra L3. Right kidney is slightly lower than the left, and the 
left kidney is a little longer and narrower than the right kidney. 
CAPSULES OF THE KIDNEY: 
 1. False capsule (renal fascia): It is the continuation of the 
tranversalis fascia. It splits at the lateral border of the kidney into an anterior 
and posterior layers. Between these two layers the perirenal space is present. 
This space is filled with the fat. 
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 2. Fatty capsule: Fatty capsule is found within the renal fascia. 
Fatty capsule is thickest at the periphery and formed by the perinephric pad 
of fat. 
 3. True capsule (Tunica albugenia): this capsule is made up of 
connective tissue. During diseases of the kidney it cannot be stripped off 
from the organ. 
LONGITUDINAL SECTION OF THE KIDNEY: 
When cut longitudinally, kidney shows an outer cortex and inner medulla 
with an ill-defined boundary line between the two. Medulla is divided into 
12 -14 conical portion called the pyramids of malphigi, the bases of which 
are in contact with cortex, and the apex projects in the form of papilla in to 
calyces ( minor and major), which opens in to the dilated commencement 
of the ureter at the pelvis of the kidney. Between the bases of the pyramids, 
the cortex dips down to form the renal columns of bertini. The structural 
and functional unit of the kidney is the nephron. Each kidney has over a 
million of nephrons. The length of the nephron varies from about 4- 6.5 
cms. Nephron has, 
 Renal corpuscle 
 Proximal convoluted tubule 
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 Loop of Henle 
 Distal convoluted tubule 
             Collecting duct. 
 
JUXTA GLOMERULAR APPARATUS: 
 
It is formed by 3 different structures. 
1. Macula densa: The end portion of thick ascending segment in each 
nephron runs in between afferent & efferent arterioles of the some nephron. 
2. Extra glomerular mesangial cells or Lacis cells: These cells are 
situated in the triangular region bound by different arteriole, efferent 
arteriole and macula densa. These cells are phagocytic and secrete 
prostaglandins and cytokines. 
3. Juxtaglomerular cells: The wall of the afferent arteriole, before entering 
the glomerulus is thickened like a cuff. The cells forming this are called 
juxtaglomerular cells. Juxtaglomerular apparatus secrete a hormone called 
Renin. 
RENAL VASCULATURE AND LYMPHATICS: 
 A single large renal artery, a lateral branch of the abdominal aorta, 
supplies each kidney. 
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 As each renal artery approaches the renal hilum, it divides into 
anterior and posterior branches, which supply the renal parenchyma. 
Accessory renal arteries are common. They originate from the lateral aspect 
of the abdominal aorta, either above or below primary renal arteries, enter 
this hilum with the primary arteries or pass directly into the kidney at some 
other level, and are commonly called extra hilar arteries. 
 Multiple renal veins contribute to the formation of the left and right 
renal veins, both of which are anterior to the renal arteries.The lymphatic 
drainage of each kidney is to the lateral aortic (lumbar) nodes around the 
orgin of the renal artery. 
NERVE SUPPLY: 
 Renal Plexus and branch of the coeliac plexus. It contains 
sympathetic (T10- L1) fibers which are chiely vasomotor. The afferent 
nerves of the kidney belong to segments T10 – T12. 
    URETERS 
 The ureters are a pair of narrow, thick walled muscular tubes which 
convey urine from the kidney to the urinary bladder. They lie deep to the 
peritoneum, closely applied to the posterior abdominal wall in the upper 
part, and to the pelvic wall in the lower part. 
Dimension: 
 Each ureter is about 25cm (10 inch) long of which the upper half lies 
in the abdomen and the lower half lies in the pelvis. It measures about 3mm 
in diameter hut it is slightly constituted at three places.They are continuous 
superiorly with the renal pelvis, which is a funnel shaped structure in the 
renal sinus. The renal pelvis is formed from a condensation of two or three 
major calices, which in turn are formed by the condensation of several 
minor calices. The minor calices surround a renal papilla. 
Parts of ureter: 
1. Abdominal Part: 
 It begins from the pelvis of kidney, run downwards, terminates with 
the pelvic part of the ureter. Its length about 12.5cm 
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2. Pelvic Part: 
 In female it forms the posterior boundary of the ovarian fossa. About 
2cm lateral to the cervix, it possess between the uterine and vaginal arteries. 
The ureter crosses anterior to the vagina before opening into the bladder. 
The left ureter is found within the intersigmoid recess while entering the 
pelvis. In male, the ureter is crossed by the vasdeferens 
3. Intra mural Part: 
 Within the bladder wall it is about 2cm long. It runs obliquely. It 
opens as the superolateral angle of the trigone of the bladder. In an empty 
bladder, the distance between the 2 ureteric openings will be 2.5cm. When 
the bladder is full the interaureteric distance is 5cm. 
Constrictions of the ureter: 
 There are three main constrictions in the ureter, 
  1. At Pelvi ureteral junction 
  2. at the brim of the lesser pelvis 
  3. Where ureter pierces the bladder wall. 
URETERIC VASCULATURE AND LYMPHATICS: 
 The ureters receive arterial branches from adjacent vessels as they 
pass towards the bladder. 
 Renal arteries- supply the upper end 
 The middle part may receive branches from the abdominal aorta, the 
testicular or ovarian arteries, and the common iliac arteries. 
 Lymphatic drainage of the ureters follows a pattern similar to that 
of the arterial supply, 
 Upper part- each ureter drains to the lateral aortic nodes. 
 Middle part- each ureter drains to lymph nodes associated with the 
common iliac vessels. 
 Inferior part- each ureter drains to lymph nodes associated with the 
external and internal iliac vessels. 
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Nerve supply: 
  The ureter is supplied by sympathetic (T10- L1) and 
parasympathetic (S2- S4) nerves. They reach the ureter through the renal. 
Aorta and hypogastric plexuses. All the nerves appear to be sensory in 
function. 
     THE URINARY BLADDER 
 The urinary bladder is a muscular reservoir of urine, which lies in 
the anterior part of the pelvic cavity. It is developed from the upper part of 
the urogenital sinus. It is the temporary store house of urine which gets 
emptied through the urethra. 
 It is varies in size, shape and position according to the amount of 
urine it contains, and the age of the person. When empty it lies within the 
pelvis. But as it fills it extends upwards into the abdominal cavity reaching 
upto the umbilicus or even higher. 
External features: 
 An empty bladder is tetrahedral in shape and has  
An apex-directed forwards 
Base or fundus- directed backward 
A neck- which is the lowest and most fixed part of the bladder 
Three surfaces- superior and right and left inferolateral 
Four borders- two lateral and anterior and one posterior. 
Interior of the bladder: 
 In a small triangular area over the lower part of the base of the bladder, the mucosa 
is smooth due to its firm attachment to theMuscular coat. This area is known as trigone of 
the bladder. The ureter open at the posterolateral angels of the trigone. The base of the 
trigone is formed by the interaureteric ridge produced by the continuation of the inner 
longitudinal muscle coats of the 2 ureters the ridge extends beyond the ureteric opening as 
the ureteric folds over the interstitial parts of the ureters. 
Capacity of the bladder: 
 Mean capacity is an adult male – 220 ml (varying from 120-320ml) 
 Filling beyond 220ml causes a desire to micturate. 
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 Filling upto 500ml – may be tolerated. But it becomes painful 
referred pain is felt the lower part of the anterior abdominal wall, perineum 
and penis. 
Ligaments of the bladder: 
I.True ligaments:  1.Lateral true ligament 
    2. Lateral puboprostatic ligament 
    3. Medial puboprostatic ligament 
    4. Medial umbilical ligament 
    5. Posterior ligament 
II.False ligaments:  1.Median umbilical fold 
  (Peritoneal folds)  2. Medial umbilical fold 
    3. Lateral false ligament 
    4. Posterior false ligament. 
 Arterial supply: 
 1. Superior and Inferior vesical arteries 
 2. Obturator and Inferior gluteal arteries. 
Venous drainage: 
 Internal iliac vein 
Lymphatic drainage: 
 Internal and external iliac nodes 
Nerve supply; 
 1. Parasympathetic efferent fibres or nervi erigentes (S2, S3, S4,) 
 2. Sympathetic efferent fibers (T11 to L2)  
 3. The somatic Pudendal nerve (S2, S3, S4)  
 4. Sensory nerve 
Relations: 
Female  Superior- Uterus 
  Inferior- Urethra 
Male  Posterior- Seminal Vesicles 
        Vasdeferns 
       Rectum 
56 
 
   
      URETHRA 
   
 
 
 
                    FEMALE URETHRA 
 The female urethra is only 4cm long and 6mm in diameter.it begins 
at the urethral orifice, at the neck of the urinary bladder roughly 5cm behind 
the middle of the pubic symphysis. It runs downwards and forwards 
embedded in the anterior wall of the vagina, transverse the urogenital 
diaphragm, and ends at the external urethral orifice in the vestibule. The 
female urethra is easily dilatable, and catheters or cystoscopies can be easily 
passed through it. 
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Cross section of female urethra: 
 Most of its lining consists of stratified squamous epithelium through 
further up it is transitional. Deeper to the mucosal layer are veins, 
connective tissue and smooth muscle. In cross section it is cresentic in the 
upper part, stellate in middle part and transverse in the lower part. The 
external urethral orifice is a sagittal slit with 2 lips. 
 The mucosa of the urethra is much folded and contains numerous 
mucous glands and lacunae which open into the urethra. The collections of 
mucous glands one on each side of the upper part of the urethra are called 
the Para urethral glands (skene). These glands are homologous with the 
male prostate. These glands are the sites for harbouring and occasional 
development of benign adenoma or malignant changes. 
 
Blood supply:  
 Proximal part of urethra is supplied by Inferior vesical branch and 
distal part is supplied by internal pudendal artery. The veins drain into the 
vesical plexus and into internal pudendal veins. 
 
Lymphatic drainage: 
 Superficial inguinal glands drain into internal and external iliac 
group of glands. 
 
Nerve supply: 
 Pudendal nerve. 
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                                 THE MALE URETHRA 
 Male urethra is a membranous canal for the external discharge of 
urine and seminal fluid. It is extends from the internal orifices at the neck 
of the urinary bladder to the external urethral orifice at the tip of the penis. 
 The male urethra is 18 – 20 cm long. 
Parts of urethra: 
 The Prostatic part passes through the prostate.  (Length- 3cm). 
 The Membranous part is surrounded by the sphincter urethrae   
(Length- 1.5 to 2cm) 
 The Spongy or Penile part passes through the bulb and corpus 
spongiosum of the penis. (Length – 15cm). 
Prostatic urethra: 
 Dilatable and widest part of male urethra. In cross section it is 
semilunar in outline. The prostate gland is divided in to lobes by urethra and 
is widest in the centre. 
Features: 
1. Colliculus seminalis; 
 It is situated on the posterior wall of prostatic urethra on the summit 
of the colliculus seminalis, there is an opening for the prostatic utricle. The 
prostatic utricle represents the uterus. Hence it may be called uterus 
musculinus. The ejaculatory ducts open on either sides of the prostatic 
utricle. 
2. Urethral crest: 
 The mucous membrane is elevated into ridges above and below the 
colliculus seminalis. This is called urethral crest. 
3. Urethral sinus: 
 On either sides of the urethral crest a depression called urethral sinus 
is situated. The duct of the glands of prostate are opening into this sinus. 
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Membranous Urethra: 
 It is situated in deep perineal pouch. It extended from the apex of 
prostate to the bulb of the penis. It pierces the perineal membrane about 2cm 
posterior to the pubic symphysis. It is surrounded by the sphincter urethra. 
Spongy urethra (Penile part of the Urethra) 
 It has a fixed part, narrow, with a uniform diameter of about 6mm. 
it runs forwards and upwards on the bulb of the penis. Free part which lies 
in the corpus spongiosum. It terminates at the external urethral orifice 
situated at tip of the glans penis. 
 The penile urethra is provided with numerous mucous glands. The 
secretions of these glands may help as a lubricant for the urine. The 
secretions also protect the lining mucous membrane of the urethra. There 
are pits or lacuna found within the spongy part. The largest depression is 
called “Lacuna Magna”. This lacuna is situated along the dorsal wall of the 
terminal part of the urethra 
Sphincters of Urethra: 
 1. The internal urethral sphincter or sphincter vesicae is involuntary 
in nature. It is supplied by sympathetic nerves, from lower thoracic and 
upper lumbar segments of spinal cord. 
 2. The external urethral sphincter or sphincter urethrae is voluntary 
in nature. It is made up of striated muscle fibres and is supplied by the 
perineal branch of the pudendal nerve. (S2 to S4). 
 Blood supply: 
 Internal pudendal artery 
 Urethral artery to the bulb of penis 
 Middle rectal artery 
 Inferior vesicle artery 
 Vein accompany the arteries. 
Lymphatic drainage: 
 Prostatic part, Membranous part – Internal and External iliac nodes. 
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 Penile part – Deep inguinal nodes.  
 
                                                  PHYSIOLOGY 
Functions of the Kidney: 
 The kidneys form urine which passes through the ureters to the 
bladder for excretion. The composition of urine reflects the activities of the 
nephrons in the maintenance of homeostasis. Waste products of protein 
metabolism are excreted. Electrolyte balance is maintained. Acid base 
balance is influenced by the excretion of hydrogen ion. 
Urine formation: 
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Kidney excrete the unwanted substances including metabolic end products 
and those substances, which are present in excess quantity in the body, 
through urine. Normally about 1 to 1.5 litres of urine is formed every day. 
The mechanism of urine formation includes various processes. 
 When blood passes through glomerular capillaries, the plasma is 
filtered into the Bowman’s capsule. When this filtrate passes through the 
tubular portion of the nephron, it undergoes various changes both in quality 
and quantity. Many wanted substances like glucose, amino acids, water and 
electrolytes are reabsorbed from the tubules. This process is called tubular 
reabsorption. 
 Some unwanted substances are secreted into the tubule from 
peritubular blood vessels. This process is called tubular secretion or 
excretion. 
 There are three phases in the formation of urine, 
I.Glomerular filtration 
II.Tubular reabsorption 
III.Tubular secretion 
I.Glomerular Filtration: 
 Filtration takes place through the semipermeable walls of the 
glomerulus and glomerular capsule. Water and large number of small 
molecules pass through, some of which are reabsorbed later. Large 
molecules are unable to filter through and remain in the capillaries. About 
180 litres of dilute filtrate are formed each day by the two kidneys. Of these 
1- 1.5 litre are excreted as urine. 
Glomerular Filtration Rate (GFR): 
 Glomerular Filtration Rate (GFR) is the total quantity of filtrate 
formed in all the nephrons of both the kidneys in the given unit of time. The 
normal GFR is 125 ml per minute or about 180 litres per day. 
Pressures determining filtration: 
1. Glomerular capillary pressure: 
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 It is the pressure exerted by the blood in the glomerular capillaries. 
It is about 60 mmHg and varies between 45 and 70 mmHg. Glomerular 
capillary pressure is the highest capillary pressure in the body. This pressure 
favours glomerular filtration. 
 
2. Colloidal osmatic pressure: 
 It is exerted by plasma protein in the glomeruli. The plasma protein 
are not filtered through the glomerular capillaries and remain in the 
glomerular capillaries. These proteins develop in colloidal osmatic pressure 
which is about 25 mmHg. It opposes glomerular filtration. 
3. Hydrostatic Pressure in Bowman’s capsule: 
 It is the pressure exerted by the filtrate in Bowman’s capsule during 
filtration. It is also called capsular pressure. It is about 15 mmHg. It also 
opposes glomerular filtration. 
II.Tubular Reabsorption: 
 It occurs in the convoluted tubules, the loop of henle and the 
collecting tubule. The general purpose of this process is to reabsorb those 
filtrate constituents needed by the body to maintain fluid and electrolyte 
balance and blood alkalinity.  
Some constituents of glomerular filtrate do not normally appear in urine 
 because they are completely reabsorb  unles  they  are  present  in  blood      in  
excessive   quantity.   The Kidney’s  maximum  capacity  for  reabsorption of a  
substance is the transport maximum                           
eg. Normal blood glucose level is 45 – 95 mg/100ml. if the level rise 
above the transport maximum of about 160 mg/100ml, glucose appears in 
the urine because the mechanism for active transfer out of the tubules is 
over loaded. 
 
In some cases reabsorption is regulated by hormones. Paratharmone 
from the parathyroid glands and calcitonin from the thyroid gland together 
regulate reabsorption of calcium and phosphate.  
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Antidiuretic hormone (ADH) from the posterior lobe of the pituitary 
gland regulating water reabsorption. Aldosterone secreted by the cortex of 
the adrenal gland, influences the reabsorption of sodium and excretion of 
potassium. Waste products, such as urea and uric acid are reabsorbed only 
to slight extent. 
 
Routes of reabsorption: 
 There are two routes for the substances to be reabsorbed from 
tubular lumen into the peritubular capillary called transcellular and 
paracellular routes 
» Trans cellular Route includes; 
1. Transport from tubular lumen into tubular cell through apical (luminal) 
surface of the cell membrane. 
2. Transport from tubular cell into interstitial fluid. 
3. Transport from interstitial fluid into capillary 
» Paracellular Route includes; 
1. Transport from tubular lumen into interstitial fluid present in lateral 
intercellular space through the tight junction between the cells. 
2. Transport from interstitial fluid into capillary. 
Site of reabsorption: 
 The reabsorption of the substances occurs in almost all the segments 
of tubular portion of nephron. 
1. Substances Reabsorbed from Proximal Convoluted Tubule: 
 Glucose, amino acid, sodium, potassium, calcium, bicarbonates, 
chlorides, phosphates, uric acid and water are reabsorbed from proximal 
convoluted tubule. 
2. Substances Reabsorbed from Loop Of Henle: 
 The substances reabsorbed from loop oh henle are sodium and 
chloride. 
3. Substances Reabsorbed from Distal Convoluted Tubule: 
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 Sodium, bicarbonate, and water are reabsorbed from distal 
convoluted tubule. 
III.Tubular secretion: 
 Substances not required and foreign materials eg drugs, may not be 
cleared from the blood by filtration because of the short time it remains in 
the glomerulus. Such substances are cleared by secretion into the 
convoluted tubules and passed from the body in the urine. 
 
Substances secreted in different segments of renal tubules: 
1. Potassium is secreted actively by sodium-potassium pump in proximal 
and distal convoluted tubules and collecting ducts. 
2. Ammonia is secreted in proximal convoluted tubules. 
3. Hydrogen ions are secreted in the proximal and distal convoluted tubules. 
Maximum hydrogen ion secretion occurs in proximal tubules. 
Thus urine is formed in the nephron by the process of glomerular filtration, 
selective reabsorption and tubular secretion.  
Normal constituents of urine: 
 Urine is the product of activities of kidneys. Through the urine waste 
products are excreted. 
Volume – 1 -1.5 litres per day. The quantity of urine is variable according 
to the quantity of fluid and food intake. Exercise reduces the volume of 
urine. 
Reaction – Usually acidic in nature. An average PH is 0.6 but PH range of 
from 4.8 – 7.5. It may be variable according to the type of diet. 
Specific gravity – 1.008 – 1.030. But usually it is within the limits of 1.015 
– 1.025. 
Colour – Fresh urine is slightly yellow or straw coloured or amber yellow. 
This is due to the presence of urochrome. 
Odour – Aromatic in odour. A putrid or strongly ammonical odour points 
to decomposition by bacteria, probably occurring in the urinary bladder. 
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Turbidity – Clear and transparent when voided. On standing faintly cloudy 
flocculence. 
Principle constituents of urine of normal adult (amount per 24 hours) 
  Water – 95% 
  Inorganic constituents 
Cations: 
  Sodium – 1 – 6 g 
  Potassium – 1.5 – 3g 
  Ammonium (NH4+) – 1.0 -1.8g 
Calcium – 0.2 – 0.5g 
  Magnesium – 0.1 – 0.2g 
Anions: 
  Chloride – 6.0 – 9.0g 
  Inorganic (SO4) – 0.6 – 1.8g 
  Phosphate – 0.7 – 1.6g 
  Bicarbonate - - 
Organic constituents: 
  Nitrogenous – 20 -40g 
  Urea – 18 – 35g 
  Creatinine – 1.0 – 1.8g 
  Creatinine – 0.06 – 0.15g 
  Ammonia – 1.0 -1.8g 
  Amino acids – 0.8 – 2.5g 
  Uric acid – 0.3 – 1.0g 
  Protein - < 0.1g 
Enzymes: 
 Trace of many enzymes are excreted in the urine. Eg pancreatic 
amylase, pepsin, trypsin and lipase. 
Hormones:  
 Hormones like sex hormones are found in the urine. The pregnancy 
test is depending on the hormonal excretion in the urine. 
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Abnormal constituents of urine: 
 Protein 
 Sugar 
 Acetone 
 Bile pigments 
 Bile 
 Blood 
 Porphyrin 
 Urobilin. 
          URINARY TRACT INFECTION 
INTRODUCTION: 
 Bacterial colonization of the urine within this tract (bacteriuria) is common and can 
at times result in microbial invasion of the tissues responsible for the manufacture, 
transport, and storage of urine. Infection of the upper urinary tract, consisting of the kidney 
and its pelvis, is known as pyelonephritis. Infection of the lower tract may involve the 
bladder (cystitis), urethra (urethritis), or prostate (prostitis), the genital organ that surrounds 
and communicates with the first segment of the male urethra. Because all portion of the 
urinary tract are joined by a fluid medium, infection at any site may spread to involve other 
areas of the system. 
EPIDEMIOLOGY: 
 Urinary Tract Infection is most common during the first year of life and is more 
common in young girls, except in neonates where UTIs in male predominate. Lowest rates 
are seen in 11 – 15 year olds. The incidence of infection increases in young adults women 
where sexual activity is an important contributory factor and increase again in old age. 
Indeed around 20% of women develop a urinary tract infection during their lifetime only 
after the age of 50 years is a similar incidence seen in males. Twenty three per cent of all 
health care associated or nosocomial infections are urinary tract infections. 
 UTI is among the most common of disease, particularly among women. Prevalence 
is age and sex dependent. Approximately 1% of children, many of whom demonstrate 
functional or anatomic abnormalities of urinary tract, develop infection during the neonatal 
period. It is estimated that 20% or more of the female population suffers some form of UTI 
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in their lifetime. Infection in the male population remains uncommon through the fifth 
decade of life, when enlargement of the prostate begins to interfere with emptying of the 
bladder. In the elderly of both sex, gynaecologic or prostatic surgery, incontinence, 
instrumentation, and chronic urethral catheterization push UTI rates to 30% to 40%. A 
single bladder catheterization carries an infectious risk of 1% and at least 10% of 
individuals with indwelling catheters become infected. 
PATHOGENESIS: 
 These organisms are create access are varied, but the most important is sexual 
intercourse, which has been shown to transiently displace bacteria into the bladder. This 
puts the female partner at risk because of short urethral distance.  In male infants, UTIs are 
common in the uncircumcised, and this is associated with colonization of the prepuce and 
urethra with faecal organisms.  
Main causes of obstruction to complete bladder emptying; 
  Pregnancy 
  Prostate hypertrophy 
  Renal calculi 
  Renal tumour 
  Strictures 
When there is a residual urine of more than 2 -3ml, infection is more likely. Infection, 
superimposed on urinary tract obstruction, may lead to ascent of infection to the kidney 
and rapid destruction of renal tissue. 
 Loss of neurological control of the bladder and sphincters (eg.  In spina bifida, 
paraplegia or multiple sclerosis), and the resultant large residual volume of urine in the 
bladder, causes a functional obstruction to urine flow, and such patients are particularly 
prone to recurrent infections. 
 Vesicoureteral reflux (reflux of urine from the bladder cavity up the ureters, 
sometimes into the renal pelvis or parenchyma) is common in children with anatomic 
abnormalities of urinary tract and many predispose to ascending infection and kidney 
damage. Reflux may also occur in association with infection in children without underlying 
abnormalities, but tends to disappear with age. 
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 People with diabetes mellitus may have more severe UTIs and if diabetic 
neuropathy interfere with normal bladder function, persistent UTIs are common. 
Catheterization is a major predisposing factor for UTI: 
 During insertion of the catheter, bacteria may be carried directly into the bladder 
and while in situ, the catheter facilitates bacterial access to the bladder either via the lumen 
of the catheter or by tracking up between the outside ot the catheter and the urethral wall. 
The catheter disrupts the normal bladder’s productive function action and allow bacteria to 
get a foothold. Thus duration of catheterization is directly associated with increased 
probability of infection i.e risk of UTI increases by about 3-5% each day of catheterization. 
 
 
ETIOLOGY: 
 Over 95% of UTIs are caused by Gram negative rods, and 90% of these are E coli. 
Other Enterobacteriaceae, Psudomonas, and Gram positive bacteria become increasingly 
common with chronic, complicated, and hospitalized patients. Of the Gram positive 
bacteria enterococci are the most important. Staphylococcus saprophyticus, a coagulase 
negative staphylococcus, is now recognized as the cause in a significant minority 
symptomatic infection in young, sexually active women. Yeast particularly species of 
Candida, may be isolated from catheterised patients receiving antibacterial therapy and 
from diabetic individuals, but they seldom produce symptomatic disease. 
COMMON MICROBIAL PATHOGEN CAUSING UTI 
E.coli        50 – 90 % 
Klebsiella / Enterobacter   10 – 40 % 
Proteus      5 – 10 % 
Pseudomonas aureginosa    2 – 10 % 
Staphylococcus saprophyticus  2 – 10 % 
Enterococcus     2 – 10 % 
Candida albicans    1 – 2 % 
Staphylococcus aureus    1 – 2 % 
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COMMON BACTERIAL CAUSES OF UTI IN HOSPITAL AND THE COMMUNITY: 
ORGANISM COMMUNITY (%) HOSPITAL (%) 
Escherichia coli 69.4 50.8 
Proteus mirabilis 4.3 5.1 
Klebsiella/Enterobacter spp 4.7 7.3 
Enterococcus spp 5.5 11.9 
Staphylococcus spp 4.0 8.4 
Pseudomonas aeruginosa 0 11.1 
Others 12.1 5.4 
 
 
 
 
(A)Escherichia coli: 
 
  
Gram negative bacilli 
70 
 
Escherichia coli is the commonest cause of UTI and in about 60 -90% of acute infections 
in the general population without urologic abnormalities or calculi and 50% of hospital 
acquired infections. 
 Certain strains of E. coli appear well adapted to invade the urinary tract (sero groups 
02, 04, 06, 07,018,075) 
Morphology; 
 Gram negative, non-sporing, non-capsulated bacillus measuring 1.3µm × 0.4-
0.7µm. most strains are motile by peritrichate flagella, some strains non motile. 
Resistance; 
 Higher resistance to heat then other coliforms. Excreted in faeces of man and 
animal in very large numbers and contaminate the soil very widely and survive in the 
environment without growth for several weeks or months. 
 
 
 
Antigenic structure; 
 Diagnostic scheme for E.coli based on the presence of o, H and K antigens detected 
by agglutination reactions. 
1. Somatic antigen (O antigen) 
 Early ‘O’ group – 1, 2, 3, 4, 5 etc 
 Later ‘O’ group – 26, 55, 86, 111, 112 etc 
2. Surface antigen (K antigen) 
 It is subdivided into 3 classes (L, B, A antigen ) 
 K antigen in now divided into 2 groups – group I & II 
3. Flagellar antigen (H antigen) 
 These are thermolabile. Now 50 ‘H’ antigen are described. 
4. Fimbrial antigen (F antigen) 
 Thermolabile proteins and heating the organisms at 1000C detaches its fimbriae. 
Pathogenesis; 
 E.coli ‘O’ serotypes forms the majority of isolates from urinary tract infection. 
These bacteria are also normally present in the colon of both infected and non-infected 
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individual. Most frequently encountered ‘O’ serotypes of E.coli UTI include 01, 02, 04, 
06, 07, 018 & 075 which are also called nephritogenic strains. These serogroups are 
believed to have a special nephron pathogenic potential due to following factors; 
* Polysaccharides of ‘O’ and ‘K’ antigens protects the bacteria from the bactericidal effects 
of complements and phagocytes in absence of specific antibodies. Strains possessing K1 
or K5 antigen appear to be more virulent. 
* Fimbriae specially mediates the adherence of the organism to the uroepithelial cells. The 
attachment may occur through the sugar residues that are present on the surface of the 
epithelial cells on the fimbriae. It is believed that the receptor is part of the ‘P’ Blood group 
antigen and hence the fimbriae are also termed as ‘P’ fimbriae. 
 The bacterial flora of colon is the reservoirs of infection and infection often occurs 
in an ascending manner via urethra from the perineum. Colonisation of peri-urethral area 
by potential pathogen may be a prerequisite for UTI. 
(B) Klebsiella Spp 
(C) Proteous Spp, especially P. mirablis 
(D) Occasionally Enterobacter, Pseudomonas, Serratia 
(E) Salmonella spp 
(F) Neisseria gonorrhoea 
Gram positive cocci: 
 The role of gram positive cocci in UTI is much less. 
(A) Staphylococcus SaprophyticusIt is a true primary pathogen of urinary tract accounts 
for 2-3% cases of urethritis and cystitis in sexually active otherwise healthy young 
females. 
Staphylococcus epidermidis constitute normal skin flora and found in urine as 
contaminants. 
(B) Enterococci – UTI, calculi or after instrumentation 
(C) Staphylococcus aureus – UTI calculi or after instrumentation 
(D) Mycobacterium tuberculosis. 
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(E) Acute uncomplicated urinary tract infection is usually caused by one organism 
which is E. coli more predominant. Chronic or complicated infection is often 
associated with more than one typo of organism and E coli is still the commonest, 
but other members such as klebsiella, Enterobacter, Proteus and Citrobacter are also 
frequent, especially in the abnormal or catheterised urinary tract particularly in 
hospital patients. 
(F) Citrobacter:  Motile, citrate positive bacilli are normal inhabitants of intestine. 
The genus contains two recognised species Citro. Freundi which gives typical 
reactions with production of H2S and citro. Diversus that does not form H2 S other 
species is c.amalonatics. citrobacter can cause UTI and sepsis. 
Klebsiella: 
 Morphologically Klebsiella species stimulate E coli except that they are non-motile 
and possess a polysaccharide capsule. They grow on ordinary media, produce pink colonies 
in Mac Conkey’s agar and mucoid colonies of varying stickness. They are widely 
distributed in nature, occurring both as commensals in human and animal intestine as well 
as saphrophytes is soil, water and vegetation. At present the name K. Pneumoniae is applied 
for the species as a whole. The most frequently encountered biochemically typical form of 
Klebsiella is referred as K.Pneumoniae sub spp aerogenes. 
Classification; 
 It contains 3 important sub species and into over 90 serotypes numbered as 1, 2, 3 
and so on. 
Pathogenicity; 
  k.pneumoniae is a second most popular member next to E coli of aerobic bacterial 
flora of intestine of man and more so in hospital patients. They are responsible for UTI, 
nosocomial infections, wound infection, septicaemia, meningitis and rarely diarrhoea. The 
hospital acquired intestinal strains are resistant to a wide range of antibiotics. 
Antigenic structure; 
 Klebsiella contains 5 different somatic or ‘O’ antigen in various combinations, four 
of which are identical or closely related to ‘O’ antigens of E coli. 
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Proteus: 
 Most strains of proteus are widely distributed in nature such as rotten meat, 
sewerage, soli frequently in the faeces of men and animals. These are gram negative, 
actively motile, non-capsulated aerobic bacilli.  
Classification; 
 The genus proteus was previously classified into 5 biotypes based on biochemical 
differences, P. vulgaris, P. mirablis, P. morganii, P. rettgeri and P.inconstans. 
Antigenic structure; 
 Motile srains of proteus possess thermostable ‘O’ and thermolabile ‘H’ antigens 
and all the strains have distinct ‘O’ antigens. 
Pathogenicity; 
 These are opportunistic pathogens and may cause; 
1. Urinary tract infection 
2. Pyogenic lesion, such as abscess, bed sores, infection of wound, ear and respiratory tract. 
3. P.morganii has been incriminated in summer diarrhoea of children. 
 Proteus infections tend to occur in patients in obstructive lesions of urinary tract 
following diagnostic instrumentation or during prolonged catheterisation. However the 
infections may occur by haematogenous dissemination of organisms. 
Source of infection 
 Infection via ascending route 
  E coli 
  Proteus spp 
  Klebsiella spp 
  Staphylococcus aureus 
  Pseudomonas app 
  Candida albicans. 
Infection via haematogenous route or desending route: 
  Salmonella spp 
  Mycobacterium tuberculosis 
  Cytomegalo virus 
  Adeno virus type II. 
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TYPES OF URINARY TRACT INFECTIONS: 
  It is classified into 2 types; 
 1. Upper Urinary Tract Infection 
 2. Lower Urinary Tract Infection 
UPPER URINARY TRACT INFECTION: 
 The hallmark symptoms of acute pyelonephritis are; 
  Flank pain  
  Fever 
  Nausea 
  Vomiting 
  Rigors 
In most cases infection from ascending lower urinary tract infection, resulting in 
bacteraemia in a third of cases the most common organism responsible is E coli. Chronic 
pyelonephritis is chronic inflammation of the kidney, often associated with chronic 
obstruction of the urinary tract in young children, from backflow of urine from the bladder 
into the ureter (vesicoureteric reflux) 
 Staphylococci are a common cause and renal abscesses are generally present. 
Recurrent episodes of pyelonephritis results in a loss of function of renal tissue, which may 
in turn, cause hypertension, itself a cause of renal damage. Infection associated with stone 
formation can result in obstruction of the renal tract and septicaemia. 
LOWER URINARY TRACT INFECTION: 
Cystitis:  
 95% of cases UTI are acute cystitis. It results from spread of organisms up the 
urethra and like other sites of infection, E coli is by far the most common cause. Symptoms 
of infection include; 
  Dysuria (painful urination) 
  Passing urine more frequently 
  Suprapubic pain 
Cystitis patients also experience pain and tenderness in the suprapubic area. Fever and 
systemic manifestation of illness are usually absent the infection spread to involve the 
kidney. 
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Urethral syndrome: 
 It is used to describe a patient who presents with the symptoms of dysuria; this may 
(particularly in women) result from a urinary tract infection (due to E coli or S. 
saprophyticus) sometimes with lower bacterial counts than anticipated with urinary tract 
infection in both men and women, it may be part an acute or chronic non- specific urethritis 
classically due to Neisseria gonorrhoeae or Chlamydia trachomatis but Mycoplasma spp 
may also implicated. 
Acute epididymitis: 
 It is inflammation of epididymis a tubing that connects the urethra to the testes. In 
older men this is usually due to typical UTI pathogens such as E. coli but in younger men 
it is more likely to be due to sexually transmitted bacteria. 
Prostatitis: 
 Infection of the prostate is typically manifested as pain in the lower back, perirectal 
area, and testicles. The same bacteria that cause cystitis and pyelonephritis are involved. In 
acute infection, the pain may be severe and accompanied by high fever, chills, and the signs 
and symptoms of cystitis. Inflammatory swelling can lead to obstruction of the 
neighbouring urethra and urinary retention. On rectal palpation, the prostate is boggy and 
exquisitely tender. 
 Patient with chronic prostatitis seldom give a history of an acute episode. Many are 
totally without symptoms others experience low grade pain and dysuria. Periodic spread of 
prostatic organisms to the urine in the bladder produces recurrent bouts of cystitis. In fact, 
chronic prostatitis is probably the major cause of recurrent bacteriuria in men.  
CLINICAL FEATURES AND COMPLICATIONS: 
Acute infections of the lower urinary tract are characterized by a rapid onset of; 
 Dysuria (burning pain on passing urine) 
 Urgency (the urgent need to pass urine) 
 Frequency of micturition. 
However UTIs in the elderly and those with indwelling catheters are usually asymptomatic. 
The urine is cloudy due to the presence of pus cells (pyuria) and bacteria (bacteriuria) and 
may contain blood (hematuria). Examination of urine specimens in the laboratory is 
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essential to confirm the diagnosis. Patients with genital tract infections such as vaginal 
thrush or chlamydial urethritis may present with similar symptoms. 
 Pyuria in the absence of positive urine cultures can be due to chlamydiae or 
tuberculosis and is also seen in patients receiving antibacterial therapy for UTI, as the 
bacteria are inhibited or killed by the antibacterial agent before the inflammatory response 
dies away. 
 Complication: Recurrent infections of the lower urinary tract occur in a significant 
proportion of patients. They may be; 
 Relapse, caused by the same strain of organism 
 Re-infections by different organisms. 
Recurrent infections can result in chronic inflammatory changes in the bladder, prostate 
and periurethral glands. 
 Acute bacterial prostatitis may arise from ascending or haematogenous infection 
and people lacking the antibacterial substances normally present in prostatic fluid are 
perhaps more susceptible. Chronic bacterial prostatitis usually caused by E. coli is difficult 
to cure and can be a source of relapsing infection within the urinary tract. 
MECHANISM DESIGNED TO PREVENT INFECTION: 
 The bladder has a number of mechanisms designed to resist infection. The most 
basic of these is the physical washing out effect in the production of urine that dilutes any 
bacterial load and removes infection organisms. This regular flushing helps prevent 
infection ascending either into the bladder into the ureter. One can imagine that the risk of 
infection would depend on the initial inoculum and multiplication rate of the organism in 
addition to any residual urine within the bladder, urine flow and frequency of voiding. 
 Obstruction to urine flow, for example through enlargement of the prostate gland 
in men, or if the bladder incompletely empties, for example through reflux of urine into the 
ureters (vesicoureteric reflux) due to inadequate development of the one way valve 
between ureter and bladder increase the risk of urinary tract infection developing. 
 Other physical property of urine such as extremes of pH, high osmolality, IgA and 
high urea concentration, tend to be protective. Historically urine has been used as an 
antiseptic. Furthermore the cells lining the urethra, bladder and ureter resist colonization 
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by bacteria. A type of antibody (IgA) secreted by immune cells within the bladder wall is 
also found in the urethra and stops bacteria binding. 
DIAGNOSIS: 
URINARY SAMPLES: 
SPECIMEN COLLECTION; 
 As is true many aspect of microbiology the quality of bacteriology results is only 
as good as the quality of the specimen. It is recognized that the distal urethra is colonized 
with bacteria although it should be noted that this often involves skin commensal organisms 
such as anaerobes or lactobacillus spp. This would rarely be considered significant in a 
urine culture. They may also have faecal organisms such as E.coli (which obviously could 
be deemed relevant) if the sample is not collected properly. There are a number of urine 
specimen types these are listed below; 
Midstream urine (MSU): 
 Patient should be given clear instructions on collection of urine. The first urine 
passed washes away organisms from the distal urethra and this should be discarded into 
toilet or other receptacle. The midstream urine sample can then be collected into a suitable 
sterile container.  
This process requires; 
 Good control of micturition 
 Appropriate hand eye co- ordination 
 Sufficient mobility to locate a sterile container in the urine stream 
It is obviously not suited to the very young the elderly or the infirm 
Some collection receptacles are associated with lower contamination rates. 
URINE CULTURE: 
 Based on studies done half a century ago demonstrating that the number of bacteria 
in infected urine is large quantitative bacteriology has been the gold diagnostic standard 
for UTI. Perhaps no number in medicine is better known or more slavishly adhered to than 
105 bacteria/ml of urine. Higher than it is UTI lower than it is contamination. We now 
know that it is possible to void more than 105   of contaminants and to have a genuine UTI 
with less than 105 bacteria. 
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 Virtually no woman with sterile bladder urine as determined by suprapubic 
aspiration can void a sterile specimen even with periurithral cleansing. Voided 
contaminants are most often mixtures of vaginal flora not associated with UTI such as 
lactobacilli, diptheroids and streptococci, but can include urinary pathogens. Conversely 
we now known that bacterial counts in UTI represent a spectrum from 102 to more than 106 
bacteria/ml. the lower counts are typical for simple cystitis and the high counts for 
pyelonephritis. Fully on third of women with UTI limited to the bladder demonstrate counts 
less than 105bacteria/ml.Given the overlap, application of these findings to clinical practice 
requires linking the epidemiologic probability to the clinical findings. If a women has 
symptoms of cystitis and a culture positive for urinary pathogen, the probability that she 
has a UTI is 90% even if the count is as low as 103 bacteria/ml. 
 If the women is asymptomatic, the probability drop to 80% even if the count is 
more than 105 ml. in the latter case the culture must be repeated before concluding that a 
UTI is present. Voiding more than 105 of the same contaminant twice in a row is unlikely. 
There is no repeat positive culture from symptomatic patients. Catheterized and suprapubic 
specimens may be accepted at face value, because they come directly from the bladder. 
DIFFERENTIAL DIAGNOSIS: 
 Pyelonephritis 
 Appendicitis 
 Salphingitis 
 Cholecystitis 
 Diverticulitis 
 Pancreatitis. 
PREVENTION; 
 Recurrent infection in otherwise healthy women can be prevented by regularly 
emptying the bladder. This washes bacteria out of the urinary tract and is 
particularly important following intercourse. 
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 The prophylactic use of antibiotics may also prevent recurrent infections, but in the 
presence of underlying abnormalities there is a tendency to select antibiotic-
resistant strains, which subsequently cause infections that are more difficult to treat. 
 Infection in catheterized patients is very common, but can be reduced by good 
catheter care procedures. Catheterization should be avoided if possible or kept to a 
minimum duration. 
 Infected children, men, and those who experience UTI relapse should be 
investigated with intravenous pyelography to allow detection and correction of any 
factor causing predisposition to infection. 
 Fluid intake of at least 3 litres/day. 
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PROTOCOL 
 
Title: 
 Clinical evaluation of siddha herbal formulation“MALLIKAI CHOORANAM” 
(Internal) in the treatment of “AZHAL NEERCHURUKKU” (Urinary Tract infection) 
 
Study design and conduct study: 
Study type    : open clinical trial 
Study place    : OPD of Ayothidoss Pandithar Hospital, 
       National Institute of Siddha,, Chennai-47. 
Study period    : 12 months 
Sample size    : 30 patients both Male and Female. 
Treatment: 
Drug     : MALLIKAI CHOORNAM 
Dosage    : ½ Thola (6 grams), twice a day, before food. 
Adjuvant    : Hot water 
Route of administration  : oral route 
Duration of the drug administration   : Initially 5 day’s trial drug will be administered to 
the patient. Followed by the urine culture report the extension of trail drug administration 
for another 5 days will be decided. 
Indication    : Azhal neerchurukku 
Ref.Book    : Chikicha Rathna Deepam 
Editor Name    : C.Kannusami pillai 
Edition    : 2007 
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PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION 
CRITERIA 
EXCLUSION 
CRITERIA 
EXCLUDED FROM 
TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
 
INFORMED CONSENT 
FORM 
ADVERSE REACTION 
ADVICED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
VALUES 
         REFERRED TO 
PHARMACOVIGILANCE            
DEPARTMENT,    NIS 
 ADVISED TO TAKE 
TREATMENT IN OPD 
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Subject selection: 
Patients reporting at OPD of Maruthuvam with the symptoms of inclusion criteria 
will be subjected to screening test and documented using screening proforma. 
Inclusion criteria: 
• Age: 19-59 years 
• Sex: Both, 
•  Patient having any of three symptoms such as burning micturition 
     , dysuria, abdominal pain, low backache 
• Patient who’s willing to go for urine culture&undergo routine blood investigation. 
• Patients with Urine culture significant for bacteria or fungus (eg.Escherichia coli, 
klebsiella, enterococci, proteusmirablis staphylococci etc.....) 
• Patient who is willing to participate in trial and signing in consent form 
 
Exclusion Criteria: 
• Pregnant 
• H/O Diabetes mellitus 
• H/O Sexually transmitted disease  
• H/O Malignancy 
 
Withdrawal Criteria: 
• Intolerance to the drug and development of adverse reactions during the drug trial. 
• Poor patient compliance & defaulters. 
• Patients turned unwilling to continue in the course of clinical trial. 
• Patient who will not take medication regularly. 
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TEST AND ASSESSMENTS: 
A. Clinical assessment 
B. Siddha assessment 
C. Investigations 
Clinical Assessment: 
• Frequency and urgency of micturation 
• Suprapubic pain and tenderness 
• Haematuria 
• Urine that may appear cloudy and have an unpleasant odour 
• Dysuria (Painful voiding) 
• Abdominal pain 
• Fever 
Siddha Assessment 
• Naadi (pulse perception) 
• Sparisam (palpable perception) 
• Naa (Tongue) 
• Niram (complexion) 
• Mozhi (voice) 
• Vizhi (eyes) 
• Malam (bowel habits) 
• Moothiram (urine) 
 Neerkuri: Niram- 
               Edai - 
               Manam- 
               Nurai - 
               Enjal – 
 Neikuri 
Routine Tests and Investigations 
Blood:  
• Hb (gms/dl)          
• Total RBC (million/cu.mm) 
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• Total WBC (cubic mm) 
• Differential count :(%) 
Polymorphs  
Lymphocytes   
Monocytes      
Esinophils 
Basophils 
•ESR (mm/hr) 
•Blood sugar level - Fasting (mg/dl) 
                                Post prandial (mg/dl) 
                           Random (mg/dl) 
•Lipid profile       - Total cholesterol (mg/dl) 
               HDL (mg/dl) 
              LDL (mg/dl) 
              VLDL (mg/dl) 
               TGL (mg/dl) 
• Renal function test    -     Blood Urea (mg/dl) 
SerumCreatinine (mg/dl) 
Uric acid (mg/dl) 
•Liver function test    -    Serum total bilirubin (mg/dl) 
Direct bilirubin (mg/dl) 
 Indirect bilirubin (mg/dl) 
SGOT (IU/L) 
SGPT (IU/L) 
Serum Alk.phosphotase (kingÅ units) 
Serum calcium (mg/dl)                
Serum phosphorus (mg/dl)  
Total protein (mg/dl)  
Serum albumin (mg/dl)  
 Serum globulin (mg/dl)  
 Serum fibrinogen (g/dl) 
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•Urine:                      
 Albumin 
Sugar (fasting and post prandial) 
Deposits 
Bile salts 
Bile pigments 
 Urobilinogen 
•Microbiology test:     VDRL 
Specific Investigations 
            URINE CULTURE – for Bacterial/fungal infection 
Study Enrolment: 
 Patient reporting at the NIS, OPD with clinical features of frequent micturation by 
day and night , dysuria, supra pubic pain and tenderness , haematuria , smelly urine, fever, 
abdominal pain, low backache are chosen for enrolment based on the inclusion criteria. 
The patients who are enrolled are informed about the study trial drug, possible outcomes 
and the objectives of the study in their own language and terms understandable to them and 
the informed consent would be obtained from them in the consent form. 
Conduct of the Study 
 From the first day , the trail drug MALLIKAI CHOORNAM –6gm  twice a day with hot 
water before food will be given continuously for 5 days by the investigator in the OP 
department of Maruthuvam, NIS,  Chennai. The patient’s urine will be screened for culture 
on the 6th day. Depending on the outcome of the urine culture report further extending of 
duration of trail drug administration for 5 more days will be decided. After deciding the 
duration of the drug further 30 patients will be included in the trail and the drug will be 
given. In every visit the clinical assessment will be recorded in the prescribed Proforma 
(form no: II A). The laboratory investigation will be done before and after treatment and 
recorded in the prescribed format (form no: III).  
                At the end of the trial the patients will be advised to come for follow up for 1 
month for observation.  
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Data Management: 
• After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filed in the file. Study No. and Patient No. will be entered on 
the top of file for easy identification.  Whenever the study patient visits OPD during the 
study period, the respective patient’s file will be taken and necessary recordings will be 
made at the assessment form or other suitable forms. 
• The screening forms will be filed separately. 
• The Data recordings will be monitored for completion by Guide (HOD, Dept. of 
Maruthuvam), SRO (Statistics) and the adverse event will be monitored by the members 
of the Pharmacovigilance department of NIS. All forms will be further scrutinized in 
presence of Investigator by Sr.Research Officer (Statistics) for logical errors and 
incompleteness of data to avoid any bias. No modification in the results is permitted for 
unbiased reports. 
OUTCOME 
O PRIMARY OUTCOME: 
 It is assessed by the Urine culture when the bacterial/fungal infection becomes 
negative after treatment & Absence of clinical signs and symptoms. 
O SECONDARY OUTCOME: 
• Invitro antimicrobial activity of trail drug will be studied                 
• Socio economic status, Age related to the disease will be assessed. 
Adverse effect and Serious effect Management: 
             If the trial patient develops any adverse reactions the patient will be referred to the 
Pharmacovigilance department of NIS and documented. For any adverse effect the 
investigator will give the proper management in the OPD. 
Ethical issues:  
1. Informed consent will be obtained from the patients after explaining about the 
clinical trial in an understandable language. 
2. After the consent of the patient (through consent form) they will be enrolled in the 
study. 
3. Treatment will be provided free of cost 
4. No other medicines will be used except the trial drug. 
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5. Urine culture is performed in NIS clinical laboratory. 
6. To prevent any infection, while collecting blood sample from the patient, only 
Disposable syringes, disposable gloves, with proper sterilization of lab equipments willbe 
used.  
7. The data collected from the patient will be kept confidentially. The patient will be 
informed about the diagnosis, treatment and follow up. 
8. The patients who are excluded (as per the exclusion criteria) are given proper 
treatment with full care at OPD. 
9. In conditions of treatment failure, adverse reactions patients will be given 
alternative treatment at the OPD with full care through the end. 
STATISTICAL ANALYSIS: 
All data will be entered into computer using MS Access software with macro for logical 
errors and manually cross checked for data entry error. Then the data will be exported to 
STATA/SPSS software for univariate/multivariate analysis. Student‘t’ test and Mantel-
Haenszel chi-square test will be performed for determining the significance of a particular 
effect variable.  
Data collection forms: 
Required information will be collected from each patient by using the following forms 
Forms: 
FORM l : Screening & Selection Proforma  
FORM ll : Case Record form 
FORM lll          : Laboratory Investigation form 
FORM IV         : Drug compliance form 
FORM V           : Patient Information Sheet 
FORM VI      : Informed Consent Form 
FORM VII     : Withdrawal Form/ Adverse reaction form (Pharmacovigilance form) 
FORM VIII      : Dietary advice Form 
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STANDARD OPERATING PROCEDURE FOR MALLIKAI CHOORNAM: 
 
Source of raw drug: 
         The required raw drugs will be purchased from a well reputed 
indigenous drug shop. The raw drug will be authenticated by the Assistant professor, 
Medicinal botany, National Institute of siddha, Chennai. The raw drug will be purified and 
the medicine will be prepared as per SOP in Gunapadam Laboratory of National Institute 
of Siddha.  
 
Purification of raw drugs: 
 
PARANKICHAKKAI (Tuber of Smilax china .Linn) 
        Powdered and steamed with cow’s milk and then dried. 
ATHIMATHURAM (Root of Glyciriza glabra. Linn) 
             Washed with clean water, skin is pealed and made in to small pieces. 
KARUNGJEERAGAM (Seeds of Nigella sativa. Linn) 
              Cleaned and kept in sunlight then fry it to golden colour. 
JEERAGAM (Seeds of Cuminum ciminum. Linn) 
               Sand and dust particles are cleaned and kept in sun light. 
KUKIL-Sajara (Gum of Shorea robusta. Gaertn) 
               Boil with tender coconut. 
EALAM (Fruits of Elettaria cardamomum. Marton) 
               Clean and kept in sunlight. 
SANNALAVANGA PATTAI (Stem bark of Cinnamomum zylanicum. Presl) 
               Clean and kept in sunlight. 
KIRAMBU (Buds of Syzygium aromaticum. Linn) 
               Clean and kept in sunlight. 
VITHAI ILLA THIRACHAI (Dry fruits of Vitis vinifera. Linn) 
                Clean and kept in sunlight. 
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THANIYA (Seeds of Coriandram sativam.Linn) 
                 Tie coriandram sativam seeds using a cloth and boil it by dipping in lemon juice, 
then dry in sun light. 
 
Method of preparation: 
 
Purified Ingredients:  
 
         Thaniya (Corriandram sativam.Linn)                                     -315grams (9palam) 
 
         Paranki chakkai (Smilax china.linn)                                       -35grams (1palam) 
 
         Athimathuram (Glyciriza glabra.Linn)                                  -35grams (1palam) 
 
          Karunjeeragam (Nigella sativa.Linn)                                    -35grams (1palam) 
 
         Jeeragam (Cumminum ciminum.Linn)                                   -35grams (1palam) 
 
         Sajara (Shorae robusta.Gaertn)                                            -35grams (1palam) 
 
         Ealam (Eletteria cardamomum.Marton)                              -35grams (1palam) 
 
         Sannalavanga pattai (Cinnamomum zylanicum.Presl)        -35grams (1palam) 
 
         Kirambu (Syzygium aromaticum.Linn)                                -35grams (1palam) 
 
          Vithai illa thirachai (Vitis vinifera.Linn)                              -35grams (1palam) 
Method of preparation: 
 Coriander seeds are dried in sunlight, the remaining raw drug are fried to till they 
reach golden color and powdered .Mix all the powder. The prepared drug will be stored in 
a clean and dry tight glass container. 
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Dose of drug: 
 6 grams (½ thola) twice a day, before food with palm sugar powder. 
 
Adjuvant: 
 Hot water. 
 
Duration: 
 15 days. 
 
Dispensing:                                                                                                                            
 The choornam will be given to the patient in premium quality of zip lock pack. 60 
gram pack for 5days. 
 
Pathiyam: 
 Itcha pathiyam. 
 
 Reference: Kannusamypillai, chikicharathnadeepam.2007, page no 122. 
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RAW DRUG REVIEW 
                                             தனியா 
 
BOTANICAL NAME: Coriandrum sataivum.Linn 
FAMILY         : Umbelliferae 
OTHER NAMES    : Urul arisi, Kothamalli 
VERNACULAR NAMES: 
English  - Coriander seeds 
 Telugu  - Kotimiri 
 Malayalam - Kotta malli, Kottam palari 
 Kanata  - Kottamari, Bija 
 Sanskrit - kustum bari, Dhanyaka 
 Arabic  - Kuzbarah 
 Pers  - Kashni z 
 Hindi  - Dhanya 
 
HABITATE:  
An annual plant, 40 – 50 cm high or sometimes somewhat more, glabrous, wild 
known from palatine, Syria, Mesopotamia and Greece. Cultivated throughout India. 
 
PARTS USED: 
            Leaf, seeds 
CHEMICAL CONSTITUENTS: 
Linaol (37.7%), geranyl acetate (17.6%), Y.terpiene (14.4%) 
 Essential oil, tannins, terpenoids, reducing sugar, fatty acids, sterols and glycosides. 
 
சுனவ  - காரப்்பு 
தன்னம - சீதசவப்பம் 
பிரிவு  - காரப்்பு 
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குணம்: 
“ சகாத்துமல்லி சவப்பம் குளிரக்ாய்சச்ல் பித்தமந்தஞ் 
 சரத்்திவிக்கல் தாகசமாடு தாதுநட்டம் – கத்திசயழும் 
 வாத விகாரம்டர ்வங்கரத்்த பிவிரணம் 
 பூதலத்தில் லாதகே்றும் தபாே்று.” 
 
ACTION: 
Stomachic 
 Carminative 
 Stimulant 
 Diuretic 
 Aphrodisiac 
 Laxative 
 Anthelmintic 
 
PHARMACOLOGICAL AND BIOLOGICAL STUDIES: 
Antibacterial, anxiolytic, antidepressant, sedative, hypnotic, anticonvulsant, 
neuroproductive, antifungal, anthelmintic, analgesic, anti-diabetic, hepatoproductive, 
anticancer. 
 
OTHER USES: 
 
 The seeds are chewed to correct foul breath. 
 The juice of fresh plant is used as an application to erythema caused by the 
application of marking nut. 
 Coriander seeds are used as a spice and flavoring agent in medicine throughout the 
east. 
 The roots and leaves powdered and mixed with alcohol are used to touch the 
eruption of measles in children. 
 The plant is prescribed for snake bite and scorpion bite. 
 
94 
 
 
   பேங்கிப் படன்ட 
 
BOTANICAL NAME: Smilax china.Linn 
FAMILY: Liliaceae 
OTHER NAMES: 
 Mathusmegam 
 Mathumeegi 
 Cheena pattai 
 Paranki chakkai 
 
VERNACULAR NAMES; 
 English  -China root 
 Telugu   -Piranki-chekka 
 Malayalam -Pavu 
 Sanskrit -Madusini 
 Hindi  -Chobchini 
 
HABITATE: 
 It is a climbing plant species. In china it is occur in forest, thickest hillsides, greasy 
slaps and shaded phases along vellum or streams. It is found from near sea level to 2000m. 
 
PARTS USED: 
 Rhizome 
 
CHEMICAL CONSTITUENTS: 
 Saponins – similax saponin 
 Ketone – 16-hentriacontanone 
 Carotenoids- β. Carotene, cytoxanthin, lutein 
 Amino acids- arginine, 4 methylene, 4 methyl glutamic acid. 
 Stilbenes and flavonoids –glycosides, piceid, oxyresveratrol, engeletin,  
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சுனவ  - இனிப்பு 
தன்னம - தட்பம் 
பிரிவு  - இனிப்பு 
 
குணம்: 
 “தாகம் பலவாதந் தாதுநட்டம் புண்பிளனவ 
 தமகங் கடிகிரந்தி வீை்மூலந் – ததகமுடன் 
 குடன்ட பகந்ததமே் சகாள்வமனம் தபாம்பேங்கிப் 
 படன்டயினன யுசச்ரித்துப் பார”் 
 
ACTIONS: 
 Alternative 
 Antisyphilitic 
 Aphrodiciac 
 Depurative 
 Diuretic  
 
PHARMACOLOGICAL AND BIOLOGICAL STUDIES: 
 Anti-inflammatory, anti-cancer, antioxidant, antidiabetic, antiobesity, hepato 
prodective, analgesic, antibacterial. 
 
USES: 
 A decoction of the roots of smilax china has been used to all stages of syphilis. 
 Roots has been employed to paralysis and sciatica. 
 It is used in urinary tract infection, stone and ulcer of bladder even chyluria by the 
physicians. 
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அதிமதுரம் 
 
BOTANICAL NAME: Glycyrrhiza glabra . Linn 
FAMILY: Fabaceae 
OTHER NAMES 
 Athingam 
 Atti 
 Mathoogam 
 Kuntri ver 
VERNACULAR NAMES: 
 English  - Jequility Indian or jamica liquorice 
 Telugu  - Ati-madhuramu 
 Sanskrit - Yasthi madhukam 
 Pers  - Bikhe mahak 
 Duke  - Mutti lak 
 Malayalam - ati Maduram 
 Arab   - Aslussus 
 Hindi  - Jathi madh 
 
HABITATE; 
 It is a hardy or undershrub attaining a height up to 2m. it is distributed in the sub-
tropical and warm temperature regions of the world, chiefly in mediterence countries, south 
Europe, Asia minor, Egypt. In India it is reported to be cultivated in Jammu, Srinagar, 
Delhi and south India. 
 
PARTS USED: 
 Roots 
CHEMICAL CONSTITUENTS: 
 Glycyrrhizine, Licoagnone, Glucoside, Kaempferol, Astergalin, Licuraside, 
Liquoric acid, Deoxoglycyrrhetic acid, Glycyhizic acid, Glabrone, Saponaretin, Glyzarzin, 
Glycyrin, Sugar and aspargin. 
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சுனவ  - இனிப்பு 
தன்னம - சீதம் 
பிரிவு  - இனிப்பு 
 
குணம்: 
 “தித்திக்கு மதிமதுரக் குணத்னதசயடுத்து னரக்கில் 
  சிரமயக்கஞ் சுரதாகங் திரிததாடங்கள் 
 பித்தஞ்சத் திக்குமிது குணமா மதுரதீபனமாந் 
  தாதுவுட்டிணமுந் தவிரக்்கும் விழிக்கிதமாம் 
 புத்திக்கு வித்தாகுந் சந்தாபந் தீரக்்கும் 
  புனகந்சதடுகுந் தசடட்ுமத்னதப் பித்ததராகத்னத 
 அத்திப்பே் றினதமகந் தன்னனவா தத்தினன 
  யறுத்திடும்வச ்சிரசமன்பா ரதிமதுரந்தனனதய” 
 
ACTION; 
 Emollient 
 Demullsant 
 Mild expectorant 
 Laxative 
 Tonic 
 Aphrodisiac 
 
PHARMOCOLOGICAL AND BIOLOGICAL STUDIES: 
 Antibacterial, antioxidant, expectorant, antiallergic, anti-inflammatory, antifungal, 
anti-carcinogenic, anti-malarial, hepato productive, anti-coagulant. 
 
USES: 
 It is useful in hyperdipsia, cough, bronchitis, ulceration of urinary tract. 
 Decoction of root in good wash for falling and graying of hair 
 It is externally applied for cuts and wound. 
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கருஞ்சீரகம் 
 
BOTANICAL NAME: Nigella sativa. Linn 
FAMILY: Ranunculaceae 
OTHER NAMES; 
 Aranam 
 Ubakunjikai 
 
VERNACULAR NAMES: 
 English  - Black cumin, smell fennal 
 Telugu  - Nalla jillakara 
 Malayalam  - Karincheakam 
 Kanata  - Kari jiriga 
 Sanskrit - ubakunjika, Krishna jiraka 
 Hindi  - Kulanji, Kala zira 
 
HABITATE: 
 It’s native south and southwest asia. It grows to 20 – 30 cm tall with finely divided, 
linear leaves. 
 
PARTS USED: 
 Seeds 
CHEMICAL CONSTITUENTS: 
 VOLOTILE OIL (0.4 – 0.45%), Saturated fatty acids, Nigelone (carbonyl fraction), 
Thymoquinone, Thymohydroquinone, Dithymoquione, Thymol, Carvacrol, d-limone, d-
citronellol, p-cymene. 
 
சுனவ  - னகப்பு 
தன்னம - சவப்பம் 
பிரிவு  - காரப்்பு 
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குணம்: 
 “கருஞ்சீ ரகந்தான் கரப்பசனாடு புண்ணும் 
 வருஞ்சிராய்ப் பீனிசமு மாே்றும் –அருந்தினால் 
 காய்சச்ல் தனலவலியுங் கண்வலியும் தபாகுலகில் 
 வாய்சச் மருந்சதனதய னவ” 
 
ACTION: 
 Carminative 
 Diuretic 
 Emmanogogue 
 Galactogogue 
 Anthelmintic 
 Stomachic 
 Parasiticide 
 Emollient. 
 
PHARMACOLOGICAL AND BIOLOGICAL STUDIES: 
 Antibacterial, antifungal, ant diabetic, anti-inflammatory, analgesic, immune 
modulator, gastro production, hepato production, testicular production, human neutrophil 
esterase activity. 
 
USES: 
 External application for head ache, osteoarthritis. 
 Powder of nigella sativa along with vinegar it is used for anthelmintic 
 Nigella sativa powder with gingili oil used external applicant for eczema and 
scabies. 
 Powder with honey it relieves dyspnea. 
 Powder with butter milk it relieves hiccup. 
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சீரகம் 
 
BOTANICAL NAME: Cuminum cyminum .Linn 
FAMILY: Apiaceae (umbelliferae) 
OTHER NAMES: 
 Asai 
 Seeri 
 Upakumbapeesam 
 Narcherri 
 Thuththasambalam 
 Praththivika 
 Pitha nasini 
 Posanakudari 
 Meththiyam 
VERNACULAR NAMES: 
 Sanskrit - Ajali, jeeraka, Ajmoda, Kunjika, Jira 
 English - Cumin seed, caraway seed 
 Hindi  - Safed Jeera, Zira, Jira 
 Telugu  - Jeelkara 
 Arbic  - Kamum, Kammon 
 Per  - Zeera, Zira 
 Malayalam - Cheerakam, jeerakam. 
HABITAT: 
 A small slender annual herb, cultivated in almost all the states in India except 
Bengal and Assam.  
PARTS USED: 
 Seed, fruit 
CHEMICAL CONSTITUENTS: 
 Lipid, phospholipids, flavonoid, glycoside, apigenin luteolin, chrysoeriol,thymine. 
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சுனவ  - காரப்்பு, இனிப்பு 
தன்னம - தட்பம் 
பிரிவு  - இனிப்பு 
 
குணம்: 
 “வாந்தி யருசி குன்மம் வாய்தநாய்பீ லிகபமினரப் 
 தபே்றிருமல் கல்லினடப்பி லாஞ்சனமும் – தசரந்்த கம்மல் 
 ஆனகு டாரிசயனும் அந்த கிரகணியும் 
 தபாசனகு டாரியுண்ணப் தபாம்” 
 
ACTION: 
 Carminative 
 Aromatic 
 Stomachic 
 Stimulant 
 Astringent 
 
PHARMACOLOGYICAL AND BIOLOGICAL STUDIES: 
 Anti-tumor, hypoglycemic, hepatoproductive, cholengic, antioxidant, galatogogue 
Nutrional, antibacterial, antifungal, insecticidal. 
USES: 
 Seeds are cooling in effect and used for gonorrhoeae, chronic diarrhea and 
dyspepsia 
 A quality of the seeds slightly smeared with ghee put into a pipe and smoked relives 
hiccup. 
 Cumin oil can be readily converted artificially into thymol, thymol is used as an 
anthelmintic against hookworm infestation and also as an antiseptic. 
 Cumin fruits are very useful in digestive disorders like biliousness, morning 
sickness, indigestion, diarrhea, flatulent colic. 
 Cumin fruits are also very useful in constipation.  
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சாஜரா -குக்கில் 
BOTANICAL NAME: Shorea robusta 
FAMILY: Dipterocarpaceae 
OTHER NAMES: 
 Gunguliyam 
 Gunguligam 
 Saruvarasam 
 Gukulu 
 Gukil 
 Gukkiliyam 
 
VERNACULAR NAMES: 
 English  - Sal tree 
 Telugu  - Guggilamu 
 Malayalam  - Kungiliyam 
 Arab  - Qanquaher 
 Pers  - Raal-maabbari 
 Hindi  - Dhuna, Damar 
 Sanskrit - Gugglium 
 
HABITATE: 
 A deciduous tree, seldom quite, leafless, bark brown in color, smooth brown with 
a few longitudinal cracks. It is distributed in kanga district of the Punjab, sub Himalayan 
tract, guar hill, Kashmir hill, jeypour, vizagapatinam. 
 
PARTS USED: 
 Gum 
 
CHEMICAL CONSTITUENTS: 
 Flavanoids, Saponins, Steroids, Tannins, Phenols, triterpenoids. 
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சுனவ  - னகப்பு 
 
தன்னம - சவப்பம் 
 
பிரிவு  - காரப்்பு 
 
குணம்: 
 “சபரும்பாடு தமகம்தபாம் தபரா துடலில் 
 அரும்பிய புண் ணாறுமினவ யல்லால் – குரும்பால் 
 எலும்புருக்கி புண்சீழும் ஏகும் உலகில் 
 சலிம்பருகுங் குங்கிலியத் தால்” 
 
ACTION: 
 Stimulant 
 Expectorant 
 Diuretic 
 
PHARMACOLOGY AND BIOLOGICAL STUDIES: 
 Antimicrobial, Analgesic, Anti-inflammatory, Hyperlipidemia, Anti diabetic, 
Immunomodulatory, Wound healing, Anti-ulcer, Antipyretic, 
 
USES: 
 The resin is cooling but difficulty to digest , bitter and acrid, astringent to the bowels 
 Purifies the blood. 
 The resin is tonic to the brain. 
 It is used to dysentery and for plaster and fumigation. 
 It is commonly used for weak digestion, gonorrhea and as an aphrodisiac. 
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ஏலம் 
 
BOTANICAL NAME: Elattaria cardamomum. Matron 
FAMILY: Zingiberaceae 
OTHER NAMES: 
 Aanji 
 Korangam 
 Thudi 
 
VERNACULAR NAMES: 
 English  - Cardamon seeds 
 Malayalam - Elattari 
 Hindi  - Elachi 
 Telugu  - Elakulu 
 Kandam  -Elakki 
 Sanskrit  - Ela 
 
HABITATE: 
 Cardamom is commonly native to India. It is widely found in Western Ghats of 
southern India. This area is known as cardamom hills. Tropical rain forest at the elevations 
of 2000 – 5000 fts. Are best for its growth. 
 
PARTS USED: 
 Seeds 
 
CHEMICAL CONSTITUENTS: 
 Mycrene, Terpinol, Geraneol, Trans nerodiol, Hepatone, Linalool, Camphor, Citral, 
Farsneol. 
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சுனவ  - காரப்்பு 
 
தன்னம - சவப்பம் 
 
பிரிவு  - காரப்்பு 
 
குணம்: 
 
 “சதாண்னட வாய்கவுள் தாலுகு தங்களில் 
  ததான்றும் தநாயதி சாரம்பன் தமகத்தால் 
 உண்னட தபாசலழுங் கட்டி கிரிசச்ரம் 
  உைனல வாந்தி சிலந்தி விஷஞ்சுரம் 
 பண்னட சவக்னக விதாகதநாய் காசமும் 
  பாழுஞ் தசாமப் பிணிவிந்து நட்டமும் 
 அண்னட யீனளவன் பித்தம் இனவக்சகல்லாம் 
  ஆல மாங்கமை் ஏல மருந்தத” 
 
ACTION: 
 Stimulant 
 Carminative 
 Stomachic 
 
PHARMACOLOGICAL AND BILOGICAL STUDIES: 
 Antimicrobial 
 
OTHER USES: 
 Cardamom with ginger juice to use loss of appetite 
 Cardamom cures sinusitis, head disorder. 
 Powder of cardamom cures cough, dryness of tongue, abdominal pain. 
 Eathi vadagam cures abdominal pain. 
 Cardamom decoction cures fever. 
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   சன்னலவங்க படன்ட 
 
BOTANICAL NAME: Cinnamomum zeylanicum. Breyn. 
FAMILY: Lauraceae 
OTHER NAMES: 
 Karuvapattai 
 
VERNACULAR NAMES: 
 English  - Bark of cinnamon 
 Telugu  - Lavanga patta, Sanna lavanga patta 
 Malayalam - Lavanga patta 
 Kandam  - Lavanga patta, Dala chinni. 
 Sanskrit - Turak 
 Arab  - Qifahe-sailiyiab, Darchini 
 Pers  - Salikhae- sailaniyah 
 Hindi  - Qulami dar chini 
 Duk  - Qalan dal chini 
 
HABITATE: 
 Cinnamon is an evergreen tree which grows from 20 -30 feet. It is found widely in 
srilanka but grows in Malabar, Cochin, china, Sumatra and in eastern islands. It is 
cultivated in Brazil, India, Jamica and in other countries also. 
 
PARTS USED: 
 Bark 
 
CHEMICAL CONSTITUENTS: 
 Cinnamaldehyde, Cinnamate, Cinnamic acid, essential oil, such as trans 
cinnamaldehyde, Cinnamyl acetate, euginol, L-borneol, α terpineol, Caryophyllene oxide. 
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சுனவ  -காரமும் இனிப்புமுனடயது 
 
தன்னம - தட்பம் 
 
பிரிவு  - இனிப்பு 
 
குணம்: 
 “தாதுநட்டம் தபதி சருவவிஷம் ஆகியதநாய் 
 பூதகிர கஞ்சிலந்திப் பூசச்ிவிடஞ் –சாதிவிடம் 
 ஆடட்ுமினரப் தபாடிருமல் ஆகியதநாய்க் கூட்டமே் 
 ஓடட்ுமில வங்கத் துரி” 
 
ACTION: 
 Stimulant 
 Carminative 
 Aphrodisiac 
 
PHARMACOLOGY AND BIOLOGICAL STUDIES: 
 Anti-oxidant, antimicrobial, anti-inflammatory, immunomodulatiory, anti-
amylase, anticholen esterase, antifungal. 
 
USES: 
 Cinnamon can also improve the health of the colon, thereby reducing the risk of 
colon cancer. 
 It is a coagulants and prevent bleeding. 
 It stops vomiting, relives flatulence and is useful in diarrhea and hemorrhage of the 
womb. 
 Recent study suggest that consuming a little as one half teaspoon of cinnamon each 
day may reduce blood sugar and cholesterol level. 
 
 
 
108 
 
கிராம்பு 
BOTANICAL NAME: Syzygium aromaticum (Linn) Merill& Perry 
FAMILY: Myrtaceae 
OTHER NAMES: 
 Anjugam 
 Urkadam 
 Karuvaikkirambu 
Sosam 
Thirali 
Varangam 
 
VERNACULAR NAMES: 
 English - cloves 
 Telugu  - Lavangalu, Lavanga pu 
 Malayalam - karambu 
 Kandam - Lavanga 
 Hindi  - Long 
 Sanskrit - Lavanga 
 Arab  - Aranful 
 Per  - Mekhak 
 Duk   - Lavan 
HBITATE: 
 A pyramidal or conical evergreen tree up to 12m height. Flower buds greenish to 
pink, aromatic, clustered at the ends of branches. It is a native of some islands of Malay 
archipelaya especially Moluccas. In India it is reported to be grown in Tamilnadu and 
Kerala. 
PARTS USED: 
 Flower buds 
CHEMICAL CONSTITUENTS: 
 Isobiflorin, eugenol, acetyleugenol, caryophyllene, furfural traces, naphthalene, 
caryopylline oxide, eugenol acetate, eugenon, eugenine, eugenitine, syzyginis. 
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சுனவ  - காரமும் விறுவிறுப்புமுள்ளது 
 
தன்னம - சவப்பம் 
 
பிரிவு  - காரப்்பு 
 
குணம்: 
 “பித்த மயக்கம் தபதிசயாடு வாந்தியும் தபாம் 
 சுத்தவிரத் தக்கடுப்புந் ததான்றுதமா – சமத்த 
 இலவங்கங் சகாண்டாவருக் தகே் சுகமாகும் 
 மலமங்தக கடட்ுசமன வாை்த்து.” 
 
ACTIONS: 
 Antispasmodic 
 Carminative 
 Stomachic 
 
PHARMACOLOGY AND BIOLOGICAL STUDIES: 
 Antifungal, antibacterial, antioxidant, analgesic, ant carcinogenic, anti-
inflammatory, anesthetic, anti-thrombotic. 
 
USES: 
 Externally the oil is used as an application in rheumatic pains, sciatica, lumbago, 
headache, neuralgia, tooth ache. 
 The oil is antiseptic, general debility. Tuberculosis, syphilitic affections. 
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திராடன்ச 
 
BOTANICAL NAMES: Vitis vinifera. Linn 
FAMILY: Vitaceae 
OTHER NAMES: 
 Aravanm 
 Kodimunthiri 
 Kodimunthirigai 
 Munthirikai 
 Thirakshathi 
 Madhurasam 
 Kothirigai 
 Thirakkam 
 Patoththamai 
 
VERNACULAR NAMES: 
 English - Grapes, common grape wine, wine grape, European grape 
 Telugu  - Draksha 
 Malayalam - Draksha 
 Sanskrit - Draksha 
 Hindi  - Munaka 
 Kan  - Draksha 
 
HABITATE: 
 A large delicious climber, tendrils long, bifid. It is native of west Asia, cultivated 
in many parts of India. 
PARTS USED: 
 Leaves, fruits 
CHEMICAL CONSTITUENTS: 
 Catechin, epicatechin, gallocatechin, epigallocatechin, afzelechin, epiafzelechin, 
proanthocyanidins. 
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சுனவ  - இனிப்பு 
 
தன்னம - தட்பம் 
 
பிரிவு  - இனிப்பு 
 
ACTION: 
 
Fruit; 
 Laxative 
 Refrigerant 
 Diuretic 
 Nutritive 
 
Leaf; 
 Astringent 
 
Dry fruit; 
 Demulcent 
 Laxative 
 
PHARMACOLOGY AND BIOLOGICAL STUDIES: 
 Antioxidant 
 Antibacterial 
 Antimicrobial 
 
USES: 
 The dried fruits are demulcent, laxative, sweet and useful in thirst. 
 The sap of the young branch is a popular remedy for skin disease. 
 The juice of unripe grapes is used as an astringent in affection of throat. 
 The leaves in all out of their astringency are sometimes used in diarrhea. 
 The leaves are useful in piles.  
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  PILOT STUDY – DURATION OF DRUG ADMINSTRATION 
AIM: 
 To evaluate the duration of drug administration 
OBJECTIVE: 
 Anti-microbial activity of Mallikai choornam before and after treatment. 
 DRUG:  MALLIKAI CHOORNAM (Internal) 
(Ref; Kannusamypillai, chikicharathnadeepam.2007, page no; 122), 
Dosage  : ½ thola (6 grams) twice a day. Before food 
Vehicle            : Hot water 
METHOD OF STUDY: 
10 patient were included based on inclusion and exclusion criteria. From the first 
day , the trail drug MALLIKAI CHOORNAM –6gm  twice a day with hot water before 
food will be given continuously for 5 days by the investigator in the OP department of 
Maruthuvam, NIS,  Chennai. The patient’s urine will be screened for culture on the 6th 
day. Depending on the outcome of the urine culture report further extending of duration of 
trail drug administration for 5 more days will be decided. 
Inclusion criteria: 
• Age: 19-59 years 
• Sex: Both, 
• Patient having any of three symptoms such as burning micturition 
     , dysuria, abdominal pain, low backache 
• Patient who’s willing to go for urine culture&undergo routine blood investigation. 
• Patients with Urine culture significant for bacteria or fungus                                  
(eg.Escherichia   coli, klebsiella, enterococci, proteusmirablis staphylococci etc.....) 
• Patient who is willing to participate in trial and signing in consent form 
Exclusion Criteria: 
• Pregnant 
• H/O Diabetes mellitus 
• H/O Sexually transmitted disease  
• H/O Malignancy 
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S.NO OPD 
NO 
AGE/ 
SEX 
0TH DAY 5TH DAY 10THDAY 15TH 
DAY 
>15TH 
DAY 
1. I 66998 30/F Escherichia 
coli- +ve 
No 
organism 
   
2. I64308 34/F Escherichia 
coli- +ve 
Escherichi
a coli- +ve 
Escherichi
a coli- +ve 
No 
organism 
 
3. I73212 45/F Escherichia 
coli- +ve 
Escherichi
a coli- +ve 
Escherichi
a coli- +ve 
No 
organism 
 
4. I51276 35/F Escherichia 
coli- +ve 
Escherichi
a coli- +ve 
No 
organism 
  
5. I41931 37/F Klebsiella - 
+ve 
Klebsiella- 
+ve 
No 
organism 
  
6. I74296 38/F Escherichia 
coli- +ve 
No 
organism 
   
7. I83754 32/M Escherichia 
coli- +ve 
Escherichi
a coli- +ve 
Escherichi
a coli- +ve 
No 
organism 
 
8. I94838 21/M Escherichia 
coli- +ve 
Escherichi
a coli- +ve 
klebsiella- 
+ve 
Klebsiell
a- +ve 
Klebsie
lla- +ve 
9. H61783 27/F Escherichia 
coli- +ve 
Escherichi
a coli- +ve 
No 
organism 
  
10. I92194 55/M Escherichia 
coli- +ve 
Escherichi
a coli- +ve 
Escherichia 
coli- +ve 
No 
organism 
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Table: 
DURATION NO OF CASES PERCENTAGE 
5th day 2 20 
10th day 3 30 
15th day 4 40 
>15th day 1 10 
 
 
CONCLUSION: 
 
  From this pilot study report shows out of 10 cases, 4 cases showed negative result 
in urine culture. For whom the trial drug given for a period of 15days. 
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                                         OBSERVATION AND RESULTS 
I.DISTRIBUTION OF CASES BY GENDER 
     TABLE: 1 
       
S.NO GENDER NO OF CASES PERCENTAGE 
1 Male           4          13.4 
2 Female          26          86.6 
 Total          30         100 
 
Fig-1 
 
 
Inference: 
 Among 30 cases 26 females and 4 males are affected. 
 
 
 
 
 
  
NO.OF CASES PERCENTAGE
4
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86.6
GENDER
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II. DISTRIBUTION OF CASES BY KAALAM (According to age) 
Table: 2 
S. NO KAALAM (age) NO OF CASES PERCENTAGE 
1 Vadha kaalam (1-33 years) 7 23.3 
2 Pitha kaalam (34-66 years) 23 76.7 
3 Kaba kaalam (67-100years) 0 0 
 
 
Fig-2 
 
Inference: 
 Among 30 cases 7cases were found to be in Vatha kaalam (1-33 years) and 23 cases 
were Pitha kaalam (34-66 years) 
 
 
 
 
 
 
1
2
3
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7
23
0
23.3
76.7
0
KAALAM (AGE)
KAALAM (age) NO OF CASES PERCENTAGE
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III.DISTRIBUTION OF CASES BY OCCUPATIONAL STATUS 
Table: 3 
S.NO NATURE OF  WORK NO OF CASES PERCENTAGE 
1 Home maker 20 66.6 
2 Field work 6 20 
3 Desk work 4 13.4 
 Total 30 100 
 
 
Fig-3 
 
Inference: 
 Home maker accounts for highest number of occurrence ie. 20 cases (66.6%) 
 
  
Home maker Field work Desk work
20
6 4
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IV.DISTRIBUTION OF CASES BY SOCIO ECONOMIC STATUS 
Table: 4 
S.NO SOCIO-ECONOMIC STATUS NO OF CASES PERCENTAGE 
1 Upper class 2 6.7 
2 Middle class 25 83.3 
3 Lower class 3 10 
 Total 30 100 
 
Fig-4 
 
Inference: 
 Among 30 cases, 25 cases (83.3%) were middle class, 3 cases (10%) were poor 
class and 2case (6.7%) were upper class. 
 
  
Upper class Middle class Lower class
2
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36.7
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V.DISTRIBUTION OF CASES BY DIETARY HABIT 
Table: 5 
S.NO DIETARY HABIT NO OF CASES PERCENTAGE 
1 Vegetarian 5 16.7 
2 Non vegetarian 25 83.3 
 Total 30 100 
 
Fig-5 
 
Inference: 
 Among 30 cases, 25 (83.3%) cases were non vegetarians, 5 (16.7%) were 
vegetarians. Most of the cases were found in non-vegetarian category. 
 
  
1 2
5
16.7
25
83.3
DIETARY HABIT
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VI.DISTRIBUTION OF CASES BY PARUVA KAALAM 
Table: 6 
SL.NO PARUVA KAALAM NO. OF CASES PERCENTAGE 
1 Kaar Kaalam (Aug 18-Oct 17) 0 0 
2 Koothir Kaalam (Oct 18-Dec 16) 0 0 
3 Munpani Kaalam (Dec 17-Feb 12) 5 16.7 
4  Pinpani Kaalam (Feb 13-Apr 13) 8 26.7 
5 Elavenil Kaalam (Apr 14-Jun 14) 4 13.3 
6 Muthuvenil Kaalam (Jun 15-Aug 17) 13 43.3 
 Total 30 100 
 
Fig-6 
 
Inference: 
 Among 30 cases 13 cases (43.3%) were affected in Muthuvenil Kaalam (June 15- 
Aug 17), 8 cases (26.7%) were affected in Pinpani Kalam (Feb13-April 13), 5cases (16.7%) 
were affected in Munpani kaalam (Dec 17- Feb12) and 4 cases (13.3%) were affected in 
elavenil Kalam (April 14-June14) 
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VII.DISTRIBUTION OF CASES BY THINAI (LAND) 
Table: 7 
S.NO THINAI (LAND) NO.OF CASES PERCENTAGE 
1 Kurinji (Hill) 0 0 
2 Mullai (Forest) 0 0 
3 Marutham (Fertile) 11 36.7 
4 Neithal (Coastal) 19 63.3 
5 Paalai (Desssert) 0 0 
 Total 30 100 
 
Fig-7 
 
Inference: 
 63.3% (19) of the cases were coming from Neithal thinai and 36.7% (11) cases were 
coming from Marutha thinai. 
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VIII.DISTRIBUTION OF CASES BY YAKKAI 
Table: 8 
S.NO YAKKAI NO OF CASES PERCENTAGE 
1 Vatham 11 36.7 
2 Pitham  11 36.7 
3 Kabam 8 26.7 
 Total 30 100 
 
Fig-8 
 
Inference: 
 Among 30 cases 11 cases (36.7%) were Vatha thegi 11 cases (36.7%) were Pitha 
thegi, 8cases (26.6%) were Kaba thegi. 
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IX.DISTRIBUTION OF CASES BY GUNAM (CHARACTER) 
Table: 9 
S.NO GUNAM NO OF CASES PERCENTAGE 
1 Saththuva Gunam 3 10 
2 Raso Gunam 20 66.7 
3 Thamo Gunam 7 23.3 
 Total 30 100 
 
Fig-9 
 
Inference: 
 Among 30cases 20 cases (66.7%) possessed Rasogunam. 7 cases (23.3%) 
possessed Thamo gunam, 3 cases (10%) possessed Sathuva gunam. 
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X.DISTRIBUTION OF CASES BY ENVAGAI THERVUGAL 
Table: 10 
S.NO EN VAGAI THERVUGAL NO OF CASES PERCENTAGE 
1 Naa 9 30 
2  Niram 3 10 
3 Mozhi 0 0 
4 Vizhi 1 3.3 
5 Sparisam 1 3.3 
6 Malam 5 16.7 
7 Moothiram 30 100 
8 Naadi 
a.Vatha Pitham 
b.Pitha Vatham 
 
22 
8 
 
73.3 
26.7 
 
Fig-10 
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Inference: 
  
 In Envagai thervugal, Naadi was affected in all the 30 cases (100%), Naa was 
affected ( coated,dryness) in 9 cases (30%), Niram was affected ( Hyperpigmentation, pale) 
in 3 cases (10%), Vizhi was affected ( pallor) in 1 case (3.3%), sparism was affected ( 
temperature) in 1 case (3.3%). 
 
 Moothiram was affected (Burning micturition, dysuria, hematuria) in 30 cases 
(100%), Malam was affected (Constipation) in 5 cases (16.7%). 
 
XI.DISTRIBUTION OF CASES BY UDAL KATTUGAL 
 
Table: 11 
 
S.NO UDAL KATTUGAL NO OF CASES PERCENTAGE 
1 Saaram 30 100 
2 Senneer 3 10 
3 Oon 0 0 
4 Kozhuppu 2 6.7 
5 Enbu 11 36.7 
6 Moolai 0 0 
7 Sukkilam / Suronitham 7 (2/5) 23.3 
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Fig-11 
 
 
 
Inference: 
 
 Among 30 patient Saaram was affected ( indigestion, general tiredness) in 30 
cases(100%), Seneer was affected ( reduced Hb level) in 3case (10%), Kozhupu affected 
(hyperlipidemia) in 2 cases (6.7%), Enbu was affected ( low back pain, knee joint pain) in 
11 cases (36.7%), Sukkilam and suronitham were affected ( male infertility, PCOS) in 7 
cases (23.3%) 
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XII.DISTRIBUTION OF CASES BY KOSANGAL 
Table: 12 
KOSAM NO OF CASES PERCENTAGE 
Annamaya Kosam 15 50 
Pranamaya Kosam 9 30 
Manomaya Kosam 1 3.3 
Vignanamaya Kosam 0 0 
Ananthamaya Kosam 11 36.7 
 
Fig-12 
 
Inference: 
 Among 30 cases Annamaya kosam was affected (abdominal pain, anorexia), in 15 
cases (50%), Pranamaya kosam was affected (dyspnea, cough) in 9 cases (30%),  
 
Manomaya kosam was affected (stress) in 1 case (3.3%), Ananthamaya kosam was affected 
(sleep disturbance) in 11 cases (36.7%), Vinyanamaya kosam normal in all. 
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XIII.DISTRIBUTION OF CASES BY UYIR THATHUKKAL 
 
A.VATHAM 
 
Table: 13a 
 
SL.NO CLASSIFICATION OF VATHAM NO OF CASES PERCENTAGE 
  BT AT BT AT 
1 Pranan 8 5 26.7 16.7 
2 Abanan 30 13 100 43.3 
3 Udhanan 0 0 0 0 
4 Samanan 30 20 100 66.7 
5 Viyanan 30 24 100 80 
6 Naagan 0 0 0 0 
7 Koorman 0 0 0 0 
8 Kirukaran 0 0 0 0 
9 Devathathan 30 2 100 6.7 
10 Dhananjayan 0 0 0 0 
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Fig-13a 
 
 
 
Inference: 
  
 Among 30 cases Pranan was affected (dyspnea, wheezing) in 8 cases (26.7%), 
Abanan was affected (burning miturition, dysuria) in 30 cases (100%), Samanan affected 
(derangement of other vayus), and Viyanan were affected (low back pain, abdominal pain) 
in all 30 cases (100%), devathathan was affected (general tiredness) in all 30 cases (100%) 
in before treatment. 
 
 In after treatment, 5 cases was affected (16.7%) in pranan (dyspnea, wheezing), 13 
cases was affected (43.3%) in Abanan (burning micturition, dysuria), 20 cases (66.7%) 
were affected in Samanan, 24 cases (80%) were affected in Viyanan, 2 cases (6.7%) 
affected in Devathathan. 
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B.PITHAM 
Table: 13b 
S.NO CLASSIFICATION OF PITHAM NO OF CASES PERCENTAGE 
  BT AT BT AT 
1 Anarpitham 7 5 23.3 16.7 
2 Ranjaga pitham 3 3 10 10 
3 Sathga pitham 28 25 93.3 83.3 
4 Alosaga pitham 0 0 0 0 
5 Prasaga pitham 2 2 6.7 6.7 
 
Fig-13b 
 
 
Inference: 
 Among 30 cases Analpitham was affected ( loss of appetite, abdominal pain ) in 7 
cases (23.3%),Ranjaga pitham ( low Hb ) was affected in 3 cases( 10%), Sathaga pitham ( 
inability to doing work) was affected in 28 cases ( 93.3%), Prasaka pitham ( 
hyperpigmentation) was affected in 2 cases ( 6.7%) at before treatment. 
 In after treatment, 5 cases (16.7%) were affected in Analpitham (loss of appetite, 
abdominal pain), 3 cases (10%) were affected in Ranjaga pitham (low Hb), 25 cases (83.3) 
were affected in Sathagapitham (inability to doing work), 2 cases (6.7%) were affected in 
Prasaga pitham. 
Anarpitham Ranjaga
pitham
Sathga
pitham
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pitham
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pitham
7 3 28 0 2
5 3 25 2
23.3 10 93.3 6.7
16.7 10 83.3 6.7
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C.KABAM 
Table: 13c 
S.NO CLASSIFICATION OF KABAM NO OF CASES PERCENTAGE 
  BT AT BT AT 
1 Avalambagam 15 14 50 46.7 
2 Kelethagam 8 6 26.7 20 
3 Pothagam 0 0 0 0 
4 Tharpagam 0 0 0 0 
5 Santhigam 12 12 40 40 
 
Fig-13c 
 
Inference: 
 Avalambagam was affected (derangement of other type of kabam), in 15 cases 
(50%), Kilethagam was affected (loss of appetite) in 5 cases (26.7%), Santhigam affected 
(knee joint pain) was affected in 12 cases (40%) at before treatment. 
 
In after treatment, 14 cases (46.7%) in Avalambagam (derangement of other type 
of kabam), 6 cases (20%) were affected in Kelethagam (loss of appetite), 12 cases (40%) 
were affected in Santhiga pitham. 
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XIV.DISTRIBUTION OF CASES BY NEERKURI 
Table: 14 
S.NO NEERKURI NO OF CASES PERCENTAGE 
  BT AT BT AT 
1 Niram  
a.Yellow 
b.Red 
c.colourless 
d.Straw Colour 
e.Crystal White 
 
26 
2 
0 
2 
0 
 
7 
0 
0 
23 
0 
 
86.7 
6.7 
0 
6.7 
0 
 
 
23.3 
0 
0 
76.7 
0 
2 Manam 7 3 23.3 10 
3 Nurai 2 0 6.7 0 
4 Edai 12 4 40 13.3 
5 Enjal 30 7 100 23.3 
6 Volume 22 7 73.3 23.3 
 
 
Fig-14 
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Inference: 
 
 In before treatment yellow color urine was observed in 26 cases (86.7%), red color 
urine was observed in 2 cases (6.7%), straw color urine was observed in 2 cases (6.7%). In 
after treatment yellow color urine was observed in 7 cases (23.3%), straw color urine was 
observed in 23 cases (76.7%).   
 
 Manam – Foul smell was observed in 7 cases (23.3%)    
   
 Nurai -   Froth was observed only in 2 cases (6.6%)  
   
Edai     - Affected in 12 cases (40%)  
 
 Enjal -    present in 30 cases (100%)    
 
 Volume - The volume of urine was decreased in 22 cases (73.3%). 
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XV.DISTRIBUTION OF CASES BY NEIKURI 
Table: 15 
 
S.NO TYPES NO OF CASES PERCENTAGE 
     
1 Serpentine 11  36.7 
2 Ring 9  30 
3 Pearl 7  23.3 
4 Mixed 1  3.3 
5 Irregular 2  6.7  
 
Fig-15 
 
 
 
Inference: 
 Among 30 cases the Neikuri in 11 cases (36.6%) was observed as serpentine shape   
( Vatha neer), In 9 cases ( 30%) was observed as a ring shaped ( Pitha neer), in 7 cases ( 
23.3%) it was observed as pearl shaped ( Kaba neer ), in 1 case ( 3.3%) it observed in mixed 
shape ( Vatha pitham), in 2 cases was ( 6.7%) observed as irregular shape. 
XVI.DISTRIBUTION OF CASES BY CLINICAL FEATURES 
0
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Table: 16 
 
S.NO CLINICAL FEATURES NO OF CASES PERCENTAGE 
  BT AT BT AT 
1 Frequency and urgency of micturition 
 
17 5 56.7 16.7 
2 Suprapubic pain and tenderness 
 
3 2 10 6.7 
3 Haematuria 
 
4 0 13.3 0 
4 Urine that may appear cloudy and have an 
unpleasant odour 
 
5 0 16.7 0 
5 Dysuria (Painful Voiding)  
 
11 5 36.7 16.7 
6 Burning Micturation 
 
27 6 90 20 
7 Oliguria 
 
5 1 16.7 3.3 
8 Low Back Ache 
 
28 18 93.3 60 
9 Abdominal Pain 
 
26 11 86.7 36.7 
10 Fever 
 
1 3.3 0 0 
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 Fig-16 
 
Inference: 
 In clinical features 17 cases ( 56.7%) had frequency and urgency of micturition, 3 
cases ( 10%) had supra pubic pain and tenderness, 4 cases ( 13. 3%) had hematuria, 5 cases 
( 16.7%) had cloudy and unpleasant odor urine, 11 cases ( 36.7%) had dysuria, 27 cases 
(90%) had burning micturition, 5 cases (16.7%) had oliguria, 28 cases ( 93.3%) had low 
back pain, 26 cases (86.7%) had abdominal pain, 1 case (3.3%) had fever at befpre 
treatment. 
 In after treatment, 5 cases (16.7%) had frequency and urgency of micturition, 2 
cases (6.7%) had supra pubic pain and tenderness, 5 cases (16.7%) had dysuria, 6 cases 
(20%) had burning micturition, 1 case (3.3%) had oliguria, 18 cases (60%) had low back 
ache, 11 cases (36.7%) had abdominal pain, hematuria and urine may be appear cloudy and 
have an unpleasant odor negative. 
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XVII.IMPROVEMENT OF CLINICAL FEATURES AFTER TREATMENT 
Table: 17 
S.NO IMPROVEMENT NO OF CASES PERCENTAGE 
1 Good  18 60% 
2 Moderate 7 23.3% 
3 Poor 5 16.7% 
 Total 30 100% 
 
Fig-17 
 
Inference: 
 Among 30 cases 18 cases (60%) has clinically good improvement (symptoms 
completely relieved after treatment with test drug), 7 cases (23.3%) had moderately 
improved (symptoms slightly reduced), 5 cases (16.6%) had poor improvement (symptoms 
persists) 
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XVIII.LABORATORY ASSESSMENT 
 
Table: 18 
 
S.NO ORGANISM NO OF CASES PERCENTAGE 
  BT (Positive)  AT(Negative) BT(Positive)  AT(Negative) 
1 Escherchia coli 
 
22 20 73.3 66.7 
2 Klebsiella 
 
3 0 10 0 
3 Enterococcus 
 
2 2 6.7 6.7 
4 Proteus 
vulgaris 
 
1 0 3.3 0 
5 Staphylococcus 
epidermis 
 
1 0 3.3 0 
6 Staphylococcus 
aureus 
 
1 0 3.3 0 
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Fig-18 
 
 
 
Inference: 
 
 Among 30 cases Escherichia coli positive for 22 cases (73.3%) in before treatment, 
this organism negative for 20 cases (96.6%) in after treatment, Klebsiella positive for 3 
cases (10%) in before treatment, no improvement in after treatment, Enterococcus positive 
for 2 cases (6.7%), this organism negative for both cases (6.7%), Proteus vulgaris positive 
for 1 case (3.3%), no improvement in after treatment, Staphylococcus epidermis positive 
for 1 case (3.3%), no improvement in after treatment, Staphylococcus aures positive for 1 
case (3.3%), no improvement in after treatment 
 
 
 
 
 
 
 
22 3 2 1 1 1
20 0 2 0 0 0
73.3
10
6.7
3.3 3.3 3.3
66.7
0
6.7
0 0 0
LABORATORY ASSESSMENT
NO OF CASES BT (Positive) NO OF CASES AT(Negative)
PERCENTAGE BT(Positive) PERCENTAGE AT(Negative)
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XIX.IMPROVEMENT OF LABORATORY ASSESSMENT AFTER TREATMENT 
Table: 19 
S.NO IMPROVEMENT NO OF CASES  PERCENTAGE 
1 Good  22 73.3% 
2 Moderate 5 16.7% 
3 Poor 3 10% 
 Total 30 100% 
 
Fig-19 
 
 
 
Inference: 
Out of 30 cases, Good improvement in 22 cases (73.3%), Moderate improvement in 5 cases 
(10.7%), Poor improvement in 3 cases (10%). 
 Good – Urine culture negative (no organism) 
 Moderate – colony count slightly reduced 
            Poor – additional organism found 
Good Moderate Poor
22
5
3
73.30% 16.70% 10%
IMPROVEMENT OF LABORATORY 
ASSESSMENT -AFTER TREATMENT
NO OF CASES PERCENTAGE
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STATISTICAL ANALYSIS 
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STATISTICAL ANALYSIS FOR CLINICAL STUDY 
 All collected data were entered into the MS excel software using different columns 
as variable and rows as patients. SPSS software was used to perform statistical analysis. 
Basic descriptive statistics include frequency distribution and cross-tabulations were 
performed. The quantity variables were expressed as Mean± Standard Deviation and 
qualitative data as percentage. A probability value of <0.05 was considered it indicate as 
statistical significance. Paired‘t’ test was performed for determining between before and 
after treatment. 
  PAIRED SAMPLE STATISTICS (CLINICAL SYMPTOMS BEFORE AND 
AFTER TREATMENT) 
Table: 1 
 
 
    
 
 
Inference: 
The Mean ± Standard Deviation score at before and after treatment were 4.23±1.07 
and 1.56±1.56 respectively which is extremely significant. (t value= 7.685, p = <0.0001) 
PAIRED SAMPLE STATISTICS (TOTAL WBC COUNT BEFORE AND AFTER 
TREATMENT) 
Table: 2 
    
 
 
 
Inference: 
The Mean ± Standard deviation of Total WBC at before and after treatment were 
7720±1325.45 and 6893±1559.31 respectively which is significant (‘t’value=2.213, p 
value=0.0308) 
Variable Sample Mean ± SD ‘t’ value P value 
Before treatment 30 4.23±1.07 7.685 <0.0001 
After treatment 30 1.56±1.56 
Variable Sample Mean±SD ‘t’ value P value 
Before treatment 30 7720±1325.45 2.213 0.0308 
After treatment 30 6893±1559.31 
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PAIRED SAMPLE STATISTICS (ESR BEFORE AND AFTER 
TREATMENT) 
Table: 3 
 
Variable Sample Mean ±SD ‘t’value P value 
Before treatment (1/2hr) 30 15.63±10.23 1.056 0.292 
After treatment (1/2hr) 30 12.83±10.27 
Before treatment (1hr) 30 30.83±20.73 1.740 0.0872 
After treatment (1hr 30 21.5±20.82 
 
Inference: 
 The Mean± Standard Deviation of ESR at before and after treatment were 
15.63±10.23 and 12.83±10.27 for ½ hour and 30.83±20.73 & 21.5±20.82 for 1 hour 
respectively which no significant ( ‘t’value=1.056,  p value=0.292 for ½ hr. ‘t’ 
value=1.740, p value= 0.0872) 
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DRUG ANALYSIS REPORT 
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            BIOCHEMICAL ANALYSIS OF MALLIKAI CHOORNAM 
Preparation of extract: 
 10g of mallikai choornam is measured accurately and placed in 250ml of clean 
beaker and added with 50ml of distilled water. Then it is boiled well for about 10 minutes. 
Then it is cooled and filtered in a 100ml volumetric flask and made up to 100ml with 
distilled water. 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1 Appearance of sample Dark brown in  color  
2.  Solubility: 
a. A little of the sample is 
shaken well with 
distilled water. 
Sparingly soluble Presence of silicate 
3. Action of heat: 
       A small amount of the 
sample is taken in a dry test tube 
and heated greatly at first and 
then strong. 
No brown fumes 
 
 
No white fumes 
evolved 
Absence of nitrate 
 
 
Absence of 
carbonate. 
4. Flame test: 
       A small amount of the 
sample is made into paste with 
con.HCL in a watch glass and 
introduced into non luminous 
part of the Bunsen flame. 
No bluish green 
flame appeared. 
Absence of copper 
5. Ash test: 
       A filter paper is soaked into 
a mixture of sample and cobalt 
nitrate solution and introduced 
into the Bunsen flame and 
ignited. 
Yellow color flame Presence of sodium. 
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I TEST FOR ACID RADICLES:   
1. Test for sulphate: 
     2ml of above prepared extract 
is taken in the test tube to this 
added 2ml of 4% ammonium 
oxalate solution. 
No cloudy 
appearance 
Absence of 
Sulphate 
2. Test for Chloride: 
      2ml of the above prepared 
extract is added with dil. HNO3 
till the effervescence ceases. 
Then 2ml of silver nitrate 
solution is added. 
No cloudy 
appearance 
Absence of chloride 
3. Test for Phosphate: 
      2ml of the extract is treated 
with 2ml of ammonium 
molybdate solution and 2ml of 
con.HNO3  
No cloudy yellow 
appearance 
Absence of 
phosphate 
4. Test for corbonate: 
        2ml of the extract is treated 
with 2ml magnesium sulphate 
solution 
 No Cloudy 
appearance  
Absence of 
carbonate 
5. Test for nitrate: 
       1 drop of the substance is 
heated with copper tunics and 
concentrated H2SO4 and viewed 
the test tube vertically down. 
No characteristic 
changes. 
Absence of nitrate. 
6. Test for sulphide: 
       1ml of the substance is 
treated with 2ml of con.HCL. 
 Rotten egg smelling 
gas evolved 
Presence of 
sulphide. 
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7. Test for Fluride & Oxalte: 
     2ml of the extract is added 
with 2ml of dil.Acetic acid and 
2ml calcium chloride solution 
and heated. 
No cloudy 
appearance 
Absence of Fluride 
and Oxalate. 
8. Test for Nitrite: 
      3 drops of the extract is 
placed on filter paper on that 2 
drops of acetic acid and 2 drops 
Benzidine solution is placed. 
No characteristic 
changes. 
Absence of Nitrite. 
 
9. Test for Borate: 
        2 pinches of the substance 
is made into paste by using 
sulphuric acid and alcohol (95%) 
and introducer into the blue 
flame. 
Bluish green color 
flame appeared. 
Presence of Borate. 
II. TEST FOR BASIC RADICLES:   
1. Test for Lead: 
        2ml of the extract is added 
with 2ml of potassium iodide 
solution. 
No yellow 
precipitate is 
obtained. 
Absence of Lead. 
2. Test for copper: 
       One pinch of substance is 
made into paste with con HCL in 
a watch glass and introduced into 
the non-luminous part of the 
flame. 
No blue color flame. Absence of copper 
3. Test for Aluminum: 
         To the 2ml of the extract 
sodium hydroxide is added in 
drops to excess. 
No characteristic 
changes 
Absence of 
aluminum. 
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4. Test for Iron: 
a. To the 2ml of extract add 
2ml of ammonium 
thiocynate solution. 
b. To the 2ml of extract add 
2ml ammonium 
thiocynate solution and 
2ml of con HNO3 is 
added. 
Mild red color not 
appeared 
 
 
 
 
 
 
Blood red color not 
appeared. 
Abscence of iron 
 
 
 
 
 
 
 
Absence of Iron 
 
5. Test for Zinc: 
    To 2ml of the extract sodium 
hydroxide solution is added in 
drops to excess. 
White precipitate 
appeared. 
Absence of Zinc 
6. Test for Calcium: 
       2ml of the extract is added 
with 2ml of 4% ammonium 
oxalate solution. 
No cloudy 
appearance. 
Absence of calcium. 
7. Test for Magnesium: 
       To 2ml of extract sodium 
hydroxide solution is added in 
drops to excess. 
White precipitate is 
not obtained 
Absence of 
magnesium. 
8. Test for Ammonium: 
       To 2ml of extract few ml of 
Nessler’s reagent and excess of 
sodium hydroxide solution are 
added. 
No brown color 
appeared. 
Absence of 
ammonium. 
9. Test for potassium: 
      1ml of substance is treated 
with 2ml of sodium and then 
 yellowish 
precipitate is 
obtained 
Presence of 
potassium. 
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treated with 2ml of cobalt nitrate 
in 30% glacial acetic acid. 
10. Test for Sodium: 
       2 pinches of the substance is 
made into paste by using HCL 
and introduced into the blue 
flame of Bunsen burner. 
No yellow color 
flame appeared. 
Absence of Sodium. 
11. Test for Mercury:  
       2ml of the extract is treated 
with 2ml of sodium hydroxide 
solution. 
No yellow 
precipitate is 
appeared. 
Absence of 
mercury. 
12. Test for Arsenic: 
       2ml of the extract is treated 
with 2ml of sodium hydroxide 
solution. 
No brownish red 
precipitate is 
obtained. 
Absence of Arsenic. 
III. MISCELLANIOUS   
1. Test for Starch: 
        2ml of the extract is treated 
with weak iodine solution. 
No blue color 
developed 
Absence of starch. 
2. Test for reducing sugar: 
         5ml of Benedict’s 
qualitative solution is taken in a 
test tube and allowed to boil for 
two minutes and added 8 to 10 
drops of the extract and again 
boil it for 2 minutes. The color 
are noted. 
No brick red color 
developed. 
Absence of 
reducing sugar. 
3. Test for alkaloids: 
        2ml of extract is treated 
with 2 ml of picric acid. 
Yellow color 
developed. 
Presence of 
alkaloid. 
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4. Test for Tannic acid: 
       2ml of extract is treated with 
2ml of ferric chloride solution. 
Black color 
precipitate is 
obtained. 
Presence of Tannic 
acid. 
5. Test for Unsaturated 
compounds: 
         To the 2ml of extract 2ml 
of potassium permanganate 
solution is added. 
Potassium 
permanganate is not 
decolorized. 
Absence of 
Unsaturated 
compound. 
6. Test for amino acids: 
     2 drops of the extract is 
placed on a filter paper and dried 
well. 
No violet color 
developed. 
Absence of amino 
acids. 
7. Test for type of Compound: 
     2ml of the extract is treated 
2ml of ferric chloride solution. 
 
No green developed. 
 
 
 
No red color 
developed. 
 
 
 
 
No violet color 
developed. 
 
No blue color 
developed. 
Absence of 
oxyquninole 
epinephrine and 
pyro catechol. 
Anti pyrine, 
Aliphatic amino 
acids and meconic 
acid are absent. 
Apo morphine 
salicylate and 
Resorcinol are 
absent. 
Morphine, phenol 
cresol and hydro 
quinine are absent. 
 
Result: 
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 The chemical study of trial drug reveals silicate, sodium, sulphide, borate, 
potassium, tannic acid 
 
 
 
THE PREMILINARY PHYTOCEMICAL SCREENING TEST 
 
Mallikai Chooranam 
 The preliminary phytochemical screening test was carried out for each extract of 
Mallikai chooranam as per the standard procedure. 
 
Decoction of Alkaloids 
Extract was dissolved individually in diluted hydrochloric acid and filtered. 
 
Mayer test 
2 ml of extract was treated with few drops of Mayer’s reagent. Formation of brown/reddish 
precipitate indicate the presence of alkaloids. 
 
Detection of Carbohydrate 
Extract was dissolved individually in 5 ml distilled water and filtered .The filter were used 
to test for Carbohydrates. 
 
Molisch’s test 
2ml of filtrate was treated with few drops of alcoholic Alpha Naphthol solution in a test 
tube. Formation of the violet ring at the junction indicates presence of carbohydrates. 
 
Benedict’s test 
Filtrate was treated with Benedict’s reagent and gently heated .Orange red precipitate 
indicate the presence of reducing sugars. 
 
Detection of Saponins 
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Froth test 
Extract was diluted with diluted water to 20 ml and this was shaken in a graduated cylinder 
for 15 minutes. Formation of 1 centimeter layer of foam indicates the presence of Saponins. 
Foam test 
0.5 Gram extract was shaken with 2ml of water .If foam produced persists for 10 minutes, 
it indicates the presence of Saponins. 
Detection of Phytosterols 
Salkowski’s test 
Extract was treated with chloroform and filtered; the filtrates were treated with few drops 
of concentrated Sulphuric acid, shaken and allowed to stand for few minutes. Golden 
yellow color indicates the presence of triterpense. 
Detection of Phenols 
Ferric chloride test 
2 ml of extract was treated with 3-4 drops of ferric chlorides solution .Formation of bluish 
black color indicate the Tannins. 
Detection of Tannins 
Gelatin test 
To the extract, 1% of gelatin solution containing sodium chloride was added; Formation of 
white precipitate indicates the presence of Tannins. 
Decoction of Flavonoids 
Alkaline reagent test 
Extract was treated with few drops of 10 % of sodium hydroxide ,formation of intense 
yellow color then on addition of diluted hydrochloric acid it become colourless,it indicate 
the presence of Flavonoids. 
Lead acetate test 
Extract was treated with few drops of lead acetate solution; yellow color precipitate 
indicate presence of Flavonoids. 
Detection of Diterpenes 
Copper acetate test 
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Extract was dissolved in water and treated with 2-3 drops of Copper Acetate solution. 
Formation of emerald green color indicates the presence of diterpenes. 
 
Test for gum and mucilage 
The extract was dissolved in 10 ml of distilled water and to this 2 ml of absolute alcohol 
with the constant stirring white cloudy precipitate indicate the presence of gum and 
mucilage. 
Detection of Glycosides 
Liebermannn’s test 
2 ml of extract was treated with 2 ml of chloroform and 2 ml of acetic acid, Violet color 
change into green indicates the presence of Glycosides. 
Test for Quinones 
Extract was treated with Sodium hydroxide blue and red precipitate indicates the presence 
of Quinones. 
Result  
The preliminary phytochemical studies of extract of Mallikai Choornam in various solvents 
were done using standard procedures. The result were presented in table. The present study 
reveals that the bioactive compound were present in all the extract of Mallikai chooranam 
. 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Phytochemicals Test name  H2O ext 
1. Alkaloids Mayer’s test +ve 
 Wagner’s test +ve 
2. Carbohydrates Molisch’s test -ve 
 Benedict’s test +ve 
3. Glycosides Libermann Burchard’s 
test 
-ve 
4. Saponins Froth test +ve 
  Foam test +ve 
5. Phytosterols Salkowski’s test -ve 
6. Phenols Ferric chloride test +ve  
7. Tannins Gelatin test -ve 
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8. Flavonoids  Alkaline Reagent Test +ve 
  Lead acetate test +ve 
9. Proteins and Amino 
acid 
Xanthoproteic test +ve 
10. Diterpenes Copper acetate test +ve 
11. Gum and Mucillage Extract+ Alcohol -ve 
12. Quinone NAOH+ Extract +ve 
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PHYSIOCHEMICAL ANALYSIS OF MALLIKAI CHOORNAM 
 
1. Moisture content 
An accurately weighted 1g of Mallikai choornam formulation was taken in a tarred glass 
bottle. The crude drug was heated at 1050C in an oven till a constant weight. Percentage 
moisture content of the sample was calculated with reference to the shade dried material.  
2. Determination of total ash 
Weighted accurately 1g of Mallikai chooranam formulation was added in crucible at a 
temperature 6000C in a muffle furnace till carbon free ash was obtained. It was calculated 
with reference to the air dried drug. 
3. Determination  of water insoluble ash 
Ash above obtained, was boiled for 5 min with 25 ml of 1m Hydrochloric acid and filtered 
using an ash less filter paper. Insoluble matter retained on filter paper was washed with hot 
water and filter paper was burnt to a constant weight in a muffler furnace. The percentage 
of acid insoluble as was calculated with reference to the air dried drug. 
4. Determination of water soluble ash 
Total ash 1g was boiled for 5 min with 25 ml water and insoluble matter collected on an 
ash filter paper was washed with hot water and ignited for 15 min at a temperature not 
exceeding 4500C in a muffle furnace. Difference in weight of ash and weight of water. 
5. Determination of water soluble extractive 
1 gm of air dried drug, coarsely powered Mallikai choornam was macerated with 100 ml 
distilled water in a closed flask for twenty-four shaking frequently. Solution was filtered 
and 25 ml of filtrated was evaporated in a tarred flat bottom shallow dish ,further dried at 
1000C and weighted .The percentage of water soluble extractive was calculated with 
reference to the air dried drug. 
6. Determination of alcohol soluble extractive 
1 gm of air dried drug, coarsely powdered Mallikai chooranam was macerated with 100 ml 
alcohol in alcohol in closed flask for 24 hours with frequent shaking. It was filtered rapidly 
taking precaution against loss of alcohol 25 ml of filtrate was then evaporated in a tarred 
flat bottom shallow dish, dried at 1000C and weighted. The percentage of alcohol soluble 
extractive was calculated with reference to air dried drug. 
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S.No     Parameters      Percentage 
1. Moisture content        8.26% 
2. Total Ash value        5.8% 
3. Acid insoluble ash        0.3% 
4. Water Soluble Ash        2.15% 
5. Water soluble extraction         17.6% 
6. Alcohol soluble extraction        25.4% 
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Anti- Microbial Profiling of Siddha Formulation Malligai Choornama 
Project Id: NRS/AS/0033/02/2017 
Sample ID: MC 
Institute: National Institute of Siddha, Chennai. 
Purpose: Struvite Crystal growth inhibition Assay 
Sample Description: Siddha Formulation 
Project Report 
Disc-diffusion method:  
The antibacterial activities of the sample MC were carried out by disc diffusion 
method.  The concentrations of the test compounds were used at the concentration of 100, 
200, 300 µg. The target microorganisms were cultured in Mueller–Hinton broth (MHB). 
After 24 h the suspensions were adjusted to standard sub culture dilution. The Petri dishes 
containing Muller Hinton Agar (MHA) medium were cultured with diluted bacterial strain. 
Disc made of Whatman No.1, diameter 6 mm was pre-sterilized and was maintained in 
aseptic chamber. Each concentration was injected to the sterile disc papers. Then the 
prepared discs were placed on the culture medium. Standard drug Ciprofloxacin (10µg) for 
anti-bacterial and Fluconazole (25µg) was used as a positive reference standard to 
determine the sensitivity of each microbial species tested. Then the inoculated plates were 
incubated at 37o C for 24 h (Bacterial) - 72 hr (Fungal). The diameter of the clear zone 
around the disc was measured and expressed in millimeters as its anti-microbial property. 
The results were depicted in Table. 
Organisms used for Anti-Bacterial Activity 
s.no organisms Type 
1.  Staphylococcus aureus Gram-positive 
2.  Proteus vulgaris  Gram-positive 
3.  Escherichia coli Gram-negative 
4.  Klebsiella pneumonia Gram-negative 
 
Organisms used for Anti-Fungal Activity 
s.no organisms 
1.  Candida albicans 
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Zone of Inhibition data of Anti-Microbial Activity  
Sample code Proteus 
vulgaris 
Staphylococcus 
aureus 
Escherichia 
coli 
Klebsiella 
pneumoniae 
Candida 
albicans 
Concentration 100 
µg 
200 
µg 
300 
µg 
100 
µg 
200 
µg 
300 
µg 
100 
µg 
200 
µg 
300 
µg 
100 
µg 
200 
µg 
300 
µg 
100 
µg 
200 
µg 
300 
µg 
MC - - - - - 14 - 9 15 - - - - - - 
Ciprofloxacin 
(10µg) 
18 22 23 16 - 
Fluconazole 
(25µg) 
NA NA NA NA 21 
 
-  =  Not active 
NA = Not Applicable 
Conclusion 
From the results of the present study it was concluded that the sample MC was effective 
against Escherichia coli, Staphylococcus aureus and not active against Klebsiella 
pneumonia, Proteus vulgaris and Candida albicans. 
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Anti-Bacterial Evaluation of MC 
Anti- Microbial Effect of MC against Escherichia coli 
 
Anti- Microbial Effect of MC against Staphylococcus aureus
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Anti- Microbial Effect of MC- A against Proteus vulgaris 
 
 
 
ANTI-FUNGAL EVALUATION 
Anti- Microbial Effect of MC against Candida albicans 
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Detection of  Anti-urolithiasis activity using Struvite Crystal growth inhibition Assay 
Project Id: NRS/AS/0033/02/2017 
Sample ID: MC 
Institute: National Institute of Siddha, Chennai. 
Purpose: Struvite Crystal growth inhibition Assay 
Sample Description: Siddha Formulation 
Project Report 
Objective 
The single diffusion gel growth technique was adopted to evaluate anti-urolithiatic 
potential of the study drug Malligai Choornam 
Test Drug concentration 
 Test drug was prepared at two different concentration of 0.5 and 1 % dispersed in 
1.0 M magnesium acetate solution 
Methodology 
An aqueous solution of 0.5M Ammonium dihydrogen phosphate was admixed with 
the sodium metasilicate solution of specific gravity 1.05 in appropriate amount using 
magnetic stirrer so that the pH value 7.0 .pH of the reaction was ensured by using pH probe 
meter. The gel solution of 10 mL was transferred into the test tubes of 140 mm length and 
25 mm diameter. After the gelation took place, 5 mL of supernatant solutions of 0.5 and 
1% conc of test drug in 1.0 M magnesium acetate were gently poured on the set gels in test 
tubes to enumerate the growth inhibition of Struvite crystals. About 5 ml of 1.0 M 
magnesium acetate without test drug were added as supernatant to control tubes which 
serves as crystal control group. All the procedures was done in the aseptic medium in 
laminar flow hood to avoid microbial contaminations. All test tubes and other glassware 
were autoclaved at 120°C for 15 min. After pouring supernatant solution, the test tubes 
were capped with airtight stopples. The experiment was con ducted at the room 
temperature. Study on growth of crystal were carried out for five consecutive days. 
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 Growth Pattern of crystal in control and drug added medium 
 
Growth of Struvite crystals in control Gel medium 
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Growth of Struvite crystals in Gel medium with 0.5 of Malligai Choornam 
 
 
 
Growth of Struvite crystals in Gel medium with 1% of Malligai Choornam 
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Size variation of  Struvite crystals 
 
A - Size variation of Struvite crystals in Control Gel medium 
B- Size variation of Struvite crystals in Gel medium with 0.5 % of Malligai Choornam         
 C- Size variation of Struvite crystals in Gel medium with 1 % of Malligai Choornam 
 
Microscopic view of Struvite crystals size after fragmentation. 
            
Control Gel medium 
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Gel medium with 0.5 % of Malligai Choornam 
 
      Gel medium with  1 % of Malligai Choornam 
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Report on Average Length of the Crystal in different medium 
S.No Medium 
Average Length 
of the Crystals in 
cm 
1 Control Gel medium   
  Mean 1.14 
  Std. Deviation 0.1517 
  Std. Error 0.06782 
2 
Gel medium + 0.5 % 
MC   
  Mean 0.66 
  Std. Deviation 0.1673 
  Std. Error 0.07483 
3 Gel medium +1% MC   
  Mean 0.46 
  Std. Deviation 0.1342 
  Std. Error 0.06 
 
Observation 
Control Medium  
Average size of the crystal was higher in the control medium with the Avg length 
of 1.14 cm 
Gel medium + 0.5 % MC 
Average size of the crystal was significantly decreased in medium contains 0.5% 
of test drug MC with the Avg length of 0.66 cm 
Gel medium +1% MC 
Average size of the crystal was much reduced in medium contains 1 % of test drug 
MC with the Avg length of 0.46 cm 
 
Conclusion 
From the result of the study it was concluded that the test drug MC has anti-
urolithiasis activity in the tested medium. 
Reference 
Chauhan, C.K., K.C. Joseph, B.B. Parekh and M.J. Joshi, 2008. Growth and 
characterization of Struvite crystals, Ind. J. Pure Appl. Phys., 46: 507-512. 
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INVESTIGATIONS 
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            BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT 
 
 
 
 
  
S.NO OPD NO. AGE /SEX Hb gm% T.RBC 
mill/µl 
TC cells / µl 
  
 
 
 
BT 
 
AT 
 
BT 
 
AT 
 
BT 
 
AT 
 
1 J04255 31/F 11.2 11.7 4.1 4.3 9600 9700 
2 H86207 37/F 11.3 11.5 3.8 4 8200 8100 
3 J01022 36/F 10.6 12.8 3.4 4.4 7000 5900 
4 I70491 45/M 6.8 7.3 4.4 4.8 8200 6900 
5 H02278 31/F 11.9 12 4.5 5.1 9500 8700 
6 J09324 43/F 8.6 10 4.2 5.1 6500 7000 
7 I63314 40/F 13.5 13.5 4.3 4.6 6900 5500 
8 J07352 47/F 10.4 10.4 4.8 4.3 8500 4400 
9 J11800 41/F 11.4 11.5 4.3 4.1 8000 9190 
10 J08673 22/F 11.9 12.4 4.5 4.6 8800 7500 
11 I87174 40/F 11.9 11.3 4.5 4.3 8100 7900 
12 J16842 31/M 16.9 15.7 5.3 5.1 7100 5100 
13 J22865 52/F 12.8 12 4.7 4.3 9000 7000 
14 J16540 34/F 8.9 9.1 4.5 4.7 6500 8400 
15 G87332 29/F 13 12.9 4.5 4.1 8000 7500 
16 J08665 52/F 14.2 13.1 4.9 4.7 8700 9200 
17 J39132 55/F 11.7 11.2 4.5 4 8500 7100 
18 H30798 43/F 10.4 11 4.4 4.5 7000 6800 
19 J55501 42/F 13.2 13 4.4 4.1 7500 7000 
20 J45744 55/F 11.1 12 4.2 4.4 4800 3900 
21 H99304 23/F 12.2 12.1 4.4 5.1 8600 6300 
22 J35640 54/M 13.4 14 4.8 5.5 8700 8000 
23 J78302 34/F 14.1 12.3 4.7 4.3 5800 4700 
24 J94334 40/F 12.7 12.5 3.9 3.8 8700 8900 
25 J09153 32/F 12.2 12.5 4.8 5 9200 7200 
26 K09235 42/F 12.6 12.4 4.5 4.1 5600 4500 
27 K05211 43/F 10.9 10.6 4.9 4.8 7000 6000 
28 K15624 42/M 14.3 14.4 4.8 4.9 5800 4700 
29 H06297 55/F 13 13.2 4.4 4.5 5300 6200 
30 H53004 36/F 11 11.3 4.8 5 9500 9200 
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BLOOD INVESTIGATION BEFORE TREATMENT 
 
 
  
S.NO OPDNO. AGE/SEX 
DC%-
P DC%L DC%M 
DC%-
E 
DC%-
B 
ESR 
½/1 Hr 
1 J04255 31/F 63 32 5 0 0 14/30 
2 H86207 37/F 59 37 4 0 0 10/20 
3 J01022 36/F 63 31 5 0 0 20/40 
4 I70491 45/M 60 32 8 0 0 20/42 
5 H02278 31/F 64 33 3 0 0 20/40 
6 J09324 43/F 63 31 6 0 0 30/60 
7 I63314 40/F 68 27 5 0 0 40/82 
8 J07352 47/F 68 32 5 0 0 30/60 
9 J11800 41/F 59.5 33.2 5.4 1.7 0 20/31 
10 J08673 22/F 52 45 5 0 0 34/70 
11 I87174 40/F 50 43 7 0 0 4/8 
12 J16842 31/M 63 34 3 0 0 2/6 
13 J22865 52/F 52 43 5 0 0 16/32 
14 J16540 34/F 57 40 3 0 0 24/50 
15 G87332 29/F 62 32 6 0 0 10/32 
16 J08665 52/F 65 33 2 0 0 18/20 
17 J39132 55/F 65 32 0 3 0 6/12 
18 H30798 43/F 64 34 0 2 0 10/22 
19 J55501 42/F 71 24 5 0 0 16/34 
20 J45744 55/F 53 43 4 0 0 10/20 
21 H99304 23/F 60.5 34.6 0 5.1 0 5/10 
22 J35640 54/M 63 41 5 0 0 20/40 
23 J78302 34/F 61 37 0 2 0 6/10 
24 J94334 40/F 59 38 1 2 0 4/8 
25 J09153 32/F 64 33 0 3 0 4/12 
26 K09235 42/F 65 32 0 3 0 30/60 
27 K05211 43/F 70 27 0 3 0 4/8 
28 K15624 42/M 57 37 1 5 0 4/6 
29 H06297 55/F 68 27 2 3 0 20/40 
30 H53004 36/F 62 37 0 1 0 18/20 
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 BLOOD INVESTIGATION AFTER TREATMENT 
 
 
S.NO OPDNO. AGE/SEX 
DC 
%-P 
DC%-
L 
DC%-
M 
DC%-
E 
DC%-
B 
ESR ½/1 
Hr 
1 J04255 31/F 59 33 3 0 0 12/18 
2 H86207 37/F 59 36 5 0 0 50/100 
3 J01022 36/F 65 31 4 0 0 6/12 
4 I70491 45/M 60 32 8 0 0 16/32 
5 H02278 31/F 66 31 5 0 0 12/18 
6 J09324 43/F 58 34 4 0 0 12/17 
7 I63314 40/F 69 32 4 0 0 20/18 
8 J07352 47/F 77 19 4 0 0 44/90 
9 J11800 41/F 61.3 22.2 3 1.7 0 14/16 
10 J08673 22/F 58 38 4 0 0 12/24 
11 I87174 40/F 62 51 5 0 0 4/8 
12 J16842 31/M 62 41 5 0 0 8/12 
13 J22865 52/F 62 41 4 0 0 12/14 
14 J16540 34/F 62 42 2 0 0 13/18 
15 G87332 29/F 60 35 5 0 0 16/32 
16 J08665 52/F 64 41 5 0 0 16/20 
17 J39132 55/F 66 32 0 2 0 7/14 
18 H30798 43/F 68 35 0 3 0 11/16 
19 J55501 42/F 68 31 4 0 0 12/16 
20 J45744 55/F 68 30 0 2 0 6/12 
21 H99304 23/F 61 35 0 1 0 6/12 
22 J35640 54/M 65 45 3 0 0 4/8 
23 J78302 34/F 65 41 0 1 0 4/8 
24 J94334 40/F 56 41 0 3 0 7/14 
25 J09153 32/F 55 42 0 3 0 6/12 
26 K09235 42/F 61 31 0 1 0 10/20 
27 K05211 43/F 65 31 0 4 0 7/14 
28 K15624 42/M 63 39 1 1 0 16/20 
29 H06297 55/F 66 28 2 4 0 16/18 
30 H53004 36/F 61 37 0 1 0 6/12 
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 BLOOD INVESTIGATION BEFORE TREATMENT 
 
 
 
S.NO OPDNO. AGE/SEX 
FBS 
mg/dl 
PPBS 
mg/dl 
UREA 
mg/dl 
S.Cr 
mg/dl 
S.UA 
mg/dl VDRL 
1 J04255 31/F 88 107 24 0.8 4.5 NR 
2 H86207 37/F 104 133 12 0.8 4.1 NR 
3 J01022 36/F 79 124 24 0.8 5.4 NR 
4 I70491 45/M 88 124 14 1 4.7 NR 
5 H02278 31/F 109 123 11 0.9 3.4 NR 
6 J09324 43/F 87 121 13 0.9 4.7 NR 
7 I63314 40/F 88 121 20 0.7 5.5 NR 
8 J07352 47/F 97 120 35 0.8 3.5 NR 
9 J11800 41/F 108 124 33 0.9 2.6 NR 
10 J08673 22/F 89 124 12 0.7 5.5 NR 
11 I87174 40/F 94 117 20 0.9 3.4 NR 
12 J16842 31/M 89 124 15 1.1 5.1 NR 
13 J22865 52/F 94 108 26 0.8 5.5 NR 
14 J16540 34/F 88 122 21 0.8 5.5 NR 
15 G87332 29/F 93 134 17 0.7 4.2 NR 
16 J08665 52/F 94 104 12 0.9 4.7 NR 
17 J39132 55/F 104 133 16 1.1 5.2 NR 
18 H30798 43/F 91 104 33 0.8 4.1 NR 
19 J55501 42/F 91 89 13 0.8 2.8 NR 
20 J45744 55/F 92 109 17 1 5.1 NR 
21 H99304 23/F 97 102 5 0.8 3 NR 
22 J35640 54/M 88 124 17.14 0.7 5.2 NR 
23 J78302 34/F 93 103 10 0.7 3.5 NR 
24 J94334 40/F 87 120 10 0.9 3.4 NR 
25 J09153 32/F 93 122 10 0.9 4.9 NR 
26 K09235 42/F 95 124 14 0.9 5.7 NR 
27 K05211 43/F 101 131 15 0.9 3.9 NR 
28 K15624 42/M 91 124 15 1.2 4.1 NR 
29 H06297 55/F 93 132 24 0.9 7.1 NR 
30 H53004 36/F 87.5 116.8 31 0.9 2.7 NR 
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 BLOOD INVESTIGATION AFTER TREATMENT 
 
 
S.NO OPDNO. AGE/SEX 
FBS 
mg/dl 
PPBS 
mg/dl 
UREA 
mg/dl 
S.Cr 
mg/dl 
S.UA 
mg/dl VDRL 
1 J04255 31/F 94 123 17 0.9 5.1 NR 
2 H86207 37/F 95 121 11 0.9 4.5 NR 
3 J01022 36/F 88 100 17 0.7 4.1 NR 
4 I70491 45/M 104 133 12 0.9 5.8 NR 
5 H02278 31/F 95 131 12 1.1 4.1 NR 
6 J09324 43/F 95 131 11 0.9 6.7 NR 
7 I63314 40/F 104 124 18 0.9 6.3 NR 
8 J07352 47/F 98 121 7 0.7 4.1 NR 
9 J11800 41/F 98 123 34 1 3.1 NR 
10 J08673 22/F 94 129 11 0.9 5.3 NR 
11 I87174 40/F 98 124 22 0.8 5.2 NR 
12 J16842 31/M 107 131 19 1.2 5.4 NR 
13 J22865 52/F 101 120 31 0.9 5.4 NR 
14 J16540 34/F 97 128 31 0.9 5.1 NR 
15 G87332 29/F 79 113 20 0.9 4.8 NR 
16 J08665 52/F 97 117 33 0.8 4.9 NR 
17 J39132 55/F 109 122 17 1 4.8 NR 
18 H30798 43/F 94 121 41 0.9 5.3 NR 
19 J55501 42/F 98 102 25 0.8 4.1 NR 
20 J45744 55/F 99 109 25 1.1 4.9 NR 
21 H99304 23/F 102 131 21 0.9 4.4 NR 
22 J35640 54/M 94 121 32 0.9 7.1 NR 
23 J78302 34/F 103 121 17 1.1 2.7 NR 
24 J94334 40/F 115 122 14 0.9 3.2 NR 
25 J09153 32/F 97 124 12 1 4.1 NR 
26 K09235 42/F 96 122 17 0.9 6.1 NR 
27 K05211 43/F 107 110 17 0.9 4.3 NR 
28 K15624 42/M 97 125 19 0.9 3.4 NR 
29 H06297 55/F 109 129 20 1.1 6.6 NR 
30 H53004 36/F 103 126 25 1 2.7 NR 
 
 
  
178 
 
 BLOOD INVESTIGATION BEFORE TREATMENT 
 
 
 
S.NO OPDNO. AGE/SEX 
T.CHL 
mg/dl 
HDL 
mg/dl 
LDL 
mg/dl 
VLDL 
mg/dl 
TGL 
mg/dl 
T.BIL 
mg/dl 
D.BIL 
mg/dl 
1 J04255 31/F 208 73 124 29 143 0.8 1.2 
2 H86207 37/F 177 48 107 59 295 0.8 1.1 
3 J01022 36/F 172 42 44 22 112 0.8 1.2 
4 I70491 45/M 109 47 59 9 45 1.1 0.8 
5 H02278 31/F 127 56 76 21 104 1.1 0.9 
6 J09324 43/F 146 51 94 22 110 1.1 0.8 
7 I63314 40/F 220 64 146 38 193 0.8 1.2 
8 J07352 47/F 213 166 132 34 154 1.1 1.2 
9 J11800 41/F 207 48 102 17 103 0.5 0.1 
10 J08673 22/F 135 44 84 15 74 0.8 1.2 
11 I87174 40/F 131 41 76 31 157 1.1 0.8 
12 J16842 31/M 137 31 90 16 32 0.9 0.8 
13 J22865 52/F 151 53 81 21 104 1.1 0.8 
14 J16540 34/F 121 42 101 32 152 0.5 0.7 
15 G87332 29/F 142 46 79 26 129 1.4 0.6 
16 J08665 52/F 178 54 103 27 134 0.9 1.1 
17 J39132 55/F 185 43 111 47 236 0.2 0.1 
18 H30798 43/F 213 63 126 16 79 0.9 1.1 
19 J55501 42/F 172 53 98 13 65 0.5 0.2 
20 J45744 55/F 199 59 114 21 104 0.3 0.4 
21 H99304 23/F 108 40 70 32 160 0.2 0.1 
22 J35640 54/M 186 56 96 17 86 0.6 0.3 
23 J78302 34/F 169 52 90 19 97 0.6 0.2 
24 J94334 40/F 198 56 129 37 186 0.9 0.4 
25 J09153 32/F 144 51 77 11 57 0.4 0.2 
26 K09235 42/F 215 47 123 34 173 0.5 0.2 
27 K05211 43/F 178 37 106 30 149 0.5 0.2 
28 K15624 42/M 218 51 131 34 169 0.7 0.3 
29 H06297 55/F 163 53 94 20 88 0.9 0.4 
30 H53004 36/F 171 51 92 24 101 0.7 0.4 
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 BLOOD INVESTIGATION BEFORE TREATMENT 
 
 
 
ID.BIL 
mg/dl 
T.PRO 
mg/dl 
S.ALB 
mg/dl 
S.GLB 
mg/dl 
S.Cal 
mg/dl 
S.PHO 
mg/dl 
SGOT 
IU/L 
SGPT 
IU/L ALK.PH 
0.3 6.7 4.1 2.5 9.2 3.4 12 14 119 
0.4 7.1 4.1 3.1 9.2 4.1 32 14 94 
0.4 7.1 4.1 2.4 10.1 4.1 14 18 123 
0.6 7.4 4.1 2.5 9.8 3.4 14 18 81 
0.4 6.1 4.1 2.4 9.2 4.4 14 18 94 
0.6 6.4 4.7 2.8 9.2 4.3 18 12 99 
0.6 7.4 4.7 3.4 9.3 4.1 18 14 144 
0.8 7.9 3.8 2.9 10.2 3.8 12 14 149 
0.4 8 3.9 2.4 8.6 3.8 43 40 147 
0.3 6.8 3.6 2.7 9.3 4.1 14 18 179 
0.3 6.4 4.4 2.8 9.3 4.4 14 18 184 
0.3 6.4 3.7 2.8 9.4 4 18 20 177 
0.4 8.1 4.8 2.4 9.2 4.4 14 18 182 
0.7 7.7 3.7 2.7 9.3 4.4 16 10 60 
0.9 7.7 4.8 2.8 7.7 4.3 20 19 79 
0.6 6.9 3.8 2.9 9.3 4.7 18 17 141 
0.1 7.5 4.5 3.1 10.2 4.1 15 15 177 
0.8 6.8 4.4 2.8 9.3 4.4 18 19 144 
0.3 6.8 3.9 2.8 9.3 3.9 17 10 67 
0.8 7.1 4.1 2.5 9.3 4.4 2 8 94 
0.1 6.9 3.9 3 8.2 4.4 10 18 92 
0.3 6.9 3.8 3 9.5 3.8 16 7 105 
0.4 6.3 3.2 3.1 8.2 4.4 21 27 72 
0.4 7.2 3.9 3.3 8.4 4.1 18 20 79 
0.3 7.5 3.9 3.6 10.8 3.8 18 15 94 
0.3 8.3 3.8 4.5 8.6 4.1 14 15 104 
0.3 7.4 3.7 3.7 8 4.1 16 18 132 
0.4 6.6 3.9 2.6 8 3.8 24 31 58 
0.6 7.8 4.4 3.8 8.4 4.2 20 18 177 
0.4 7.4 4.4 3.1 7.4 3.8 24 30 181 
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 BLOOD INVESTIGATION AFTER TREATMENT 
 
 
 
 
  
S. 
NO 
OPD 
NO. 
AGE/
SEX 
T.CHL 
mg/dl 
HDL 
mg/dl 
LDL 
mg/dl 
VLDL 
mg/dl 
TGL 
mg/dl 
T.BIL 
mg/dl 
D.BIL 
mg/dl 
1 J04255 31/F 211 69 98 33 121 0.9 1.4 
2 H86207 37/F 212 54 124 60 299 0.7 1.2 
3 J01022 36/F 163 62 90 18 90 0.9 1.1 
4 I70491 45/M 125 52 63 12 61 0.7 0.4 
5 H02278 31/F 144 61 81 32 130 0.9 1.1 
6 J09324 43/F 131 53 112 25 110 0.9 0.8 
7 I63314 40/F 167 42 122 36 151 0.9 1.2 
8 J07352 47/F 186 47 111 31 156 1.1 0.9 
9 J11800 41/F 188 51 92 22 132 0.9 0.3 
10 J08673 22/F 173 49 107 19 95 1.1 0.8 
11 I87174 40/F 122 48 93 31 130 1.1 0.8 
12 J16842 31/M 122 30 92 17 41 0.8 1.1 
13 J22865 52/F 164 42 92 23 150 0.9 0.8 
14 J16540 34/F 152 45 93 33 141 0.8 1.1 
15 G87332 29/F 141 43 82 33 167 1.1 0.5 
16 J08665 52/F 160 33 97 33 134 0.8 1.1 
17 J39132 55/F 178 34 107 49 243 0.3 0.1 
18 H30798 43/F 188 51 114 21 121 1.1 1.2 
19 J55501 42/F 201 55 101 21 71 0.9 1.1 
20 J45744 55/F 238 58 140 28 142 0.9 0.3 
21 H99304 23/F 141 53 74 28 141 1.1 1.1 
22 J35640 54/M 155 57 101 21 151 1.1 1.2 
23 J78302 34/F 180 61 102 21 107 1.2 0.8 
24 J94334 40/F 183 53 102 28 143 0.5 0.2 
25 J09153 32/F 149 53 78 11 54 0.5 0.2 
26 K09235 42/F 168 51 117 36 112 1.1 0.9 
27 K05211 43/F 196 42 115 24 123 0.6 0.2 
28 K15624 42/M 150 61 121 37 153 1.1 1.2 
29 H06297 55/F 158 50 87 14 69 0.8 0.3 
30 H53004 36/F 166 45 93 18 92 0.6 0.2 
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 BLOOD INVESTIGATION AFTER TREATMENT 
 
 
 
ID.BIL 
mg/dl 
T.PRO 
mg/dl 
S.ALB 
mg/dl 
S.GLB 
mg/dl 
S.Cal 
mg/dl 
S.PHO 
mg/dl 
SGOT 
IU/L 
SGPT 
IU/L ALK.PH 
0.2 7.1 3.2 3.1 10.1 3.5 17 14 233 
0.6 6.8 4.5 3.4 10.1 4.2 12 14 181 
0.4 7.2 4.5 2.5 9.8 4.2 22 14 181 
0.3 8 3.4 2.7 10.1 3.4 11 8 155 
0.6 5.8 4.8 3.1 10.4 3.9 18 14 98 
0.6 6.6 3.9 2.9 10.1 3.9 17 14 177 
0.6 6.4 4.8 2.4 10.2 4.4 20 18 178 
0.8 6.7 4.4 3.4 10.3 4.1 14 18 177 
0.6 6.4 4.1 2.7 9.3 4.3 18 21 178 
0.6 6.4 4.7 2.9 10.2 4.8 20 18 194 
0.3 7.9 4.4 2.9 10.1 4.1 14 17 222 
0.6 6.9 3.9 2.9 10.1 4.1 14 17 241 
0.4 7.4 3.4 3.4 10.4 4.1 12 10 244 
0.4 6.8 3.4 3.4 10.1 3.4 18 13 190 
0.6 7.9 4.9 2.7 8.7 3.9 18 20 78 
0.7 7.7 3.9 3.1 10.1 4.1 17 20 197 
0.2 7.6 3.8 3.8 7.5 4.1 14 13 66 
0.4 6.9 3.6 3.1 9.4 3.9 20 17 201 
0.5 7.1 4.1 3.1 9.3 4.1 20 18 104 
0.6 7.4 4.1 3.3 8.1 3.8 19 10 82 
0.6 6.2 4.1 2.7 9.3 4.1 14 17 101 
0.5 7.4 3.5 3.1 9.4 4.4 20 18 171 
0.6 7.1 3.9 3.4 9.4 4.1 17 21 171 
0.3 6.9 3.8 3.1 8.1 3.9 13 10 44 
0.3 7.5 4 3.5 8.3 4.1 18 15 100 
0.6 7.9 3.4 4.7 9.4 4.1 17 21 172 
0.4 8 3.8 4.2 10.1 4.2 13 11 128 
0.7 7.1 4.6 3.1 9.4 4.1 14 17 180 
0.5 7 4 3 8.3 4.1 19 19 104 
0.4 7.1 3.8 3.3 7.1 4.1 10 12 79 
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 URINE INVESTIGATION BEFORE TREATMENT 
 
 
  
S.
N
O 
OPD 
NO. 
AGE/
SEX ALB SUG 
DEP 
PUS 
CELLS 
DEP 
EPI 
CELLS 
CAST 
CELLS BS/BP URO 
1 J04255 31/F Nil Nil 4 to 6 2 to 3  Nil Nil 
2 H86207 37/F Nil Nil 1 to 2 1 to 2  Nil Nil 
3 J01022 36/F Nil Nil 6 to 8 2 to 4  Nil Nil 
4 I70491 45/M Nil Nil 1 to 3 1 to 2  Nil Nil 
5 H02278 31/F Trace Nil 2 to 4 2 to 4  Nil Nil 
6 J09324 43/F Nil Nil 3 to 6 3 to 4  Nil Nil 
7 I63314 40/F Nil Nil 3 to 5 1 to 2  Nil Nil 
8 J07352 47/F Nil Nil 2 to 3 3 to 4 
4 to 5 
RBC Nil Nil 
9 J11800 41/F Nil Nil 3 to 6 2 to 4 
1 to 4 
RBC Nil Nil 
10 J08673 22/F Nil Nil 2 to 3 4 to 6  Nil Nil 
11 I87174 40/F Nil Nil 8 to 9 4 to 6  Nil Nil 
12 J16842 31/M Nil Nil 2 to 3 1 to 2  Nil Nil 
13 J22865 52/F Nil Nil 3 to 5 2 to 4  Nil Nil 
14 J16540 34/F Nil Nil 3 to 5 1 to 2  Nil Nil 
15 G87332 29/F Trace Nil plenty 2 to 4  Nil Nil 
16 J08665 52/F Nil Nil 8 to 10 1 to 2  Nil Nil 
17 J39132 55/F Nil Nil 1 to 2 1 to 2  Nil Nil 
18 H30798 43/F Nil Nil 4 to 6 4 to 6  Nil Nil 
19 J55501 42/F Nil Nil 2 to 4 2 to 4  Nil Nil 
20 J45744 55/F Nil Nil 1 to 2 1 to 2  Nil Nil 
21 H99304 23/F Nil Nil 2 to 3 5 to 6  Nil Nil 
22 J35640 54/M Trace Nil --- --- 
RBC++
+, 
WBC++
+ Nil Nil 
23 J78302 34/F Nil Nil 3 to 5 2 to 4  Nil Nil 
24 J94334 40/F Nil Nil 3 to 5 1 to 2  Nil Nil 
25 J09153 32/F Nil Nil 6 to 8 1 to 4  Nil Nil 
26 K09235 42/F Nil Nil 8 to 10 1 to 4  Nil Nil 
27 K05211 43/F Nil Nil 3 to 5 1 to 2  Nil Nil 
28 K15624 42/M Nil Nil 1 to 2 3 to 4  Nil Nil 
29 H06297 55/F Nil Nil loaded 4 to 6  Nil Nil 
30 H53004 36/F Nil Nil 1 to 3 1 to 3  Nil Nil 
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 URINE INVESTIGATION AFTER TREATMENT 
 
 
S.NO OPDNO. AGE/SEX ALB SUG 
DEP 
PUS 
CELLS 
DEP 
EPI 
CELLS BS BP URO 
1 J04255 31/F Nil Nil 1 to 2 1 to 3 Nil Nil Nil 
2 H86207 37/F Nil Nil 2 to 4 2 to 4 Nil Nil Nil 
3 J01022 36/F Nil Nil 3 to 5 1 to 2 Nil Nil Nil 
4 I70491 45/M Nil Nil 2 to 3 1 to 2 Nil Nil Nil 
5 H02278 31/F Nil Nil 1 to 2 1 to 2 Nil Nil Nil 
6 J09324 43/F Nil Nil 1 to 2 1 to 2 Nil Nil Nil 
7 I63314 40/F Nil Nil 1 to 2 1 to 2 Nil Nil Nil 
8 J07352 47/F Nil Nil 2 to 4 2 to 4 Nil Nil Nil 
9 J11800 41/F Nil Nil 1 to 2 1 to 2 Nil Nil Nil 
10 J08673 22/F Nil Nil plenty 3 to 5 Nil Nil Nil 
11 I87174 40/F Nil Nil 1 to 2 2 to 4 Nil Nil Nil 
12 J16842 31/M Nil Nil 1 to 2 1 to 2 Nil Nil Nil 
13 J22865 52/F Nil Nil 1 to 2 4 to 5 Nil Nil Nil 
14 J16540 34/F Nil Nil 1 to 2 2 to 4 Nil Nil Nil 
15 G87332 29/F Nil Nil 1 to 2 1 to 2 Nil Nil Nil 
16 J08665 52/F Nil Nil 2 to 4 3 to 4 Nil Nil Nil 
17 J39132 55/F Nil Nil 4 to 5 1 to 2 Nil Nil Nil 
18 H30798 43/F Nil Nil 1 to 2 1 to 2 Nil Nil Nil 
19 J55501 42/F Nil Nil 2 to 3 1 to 2 Nil Nil Nil 
20 J45744 55/F Nil Nil 2 to 4 2 to 4 Nil Nil Nil 
21 H99304 23/F Nil Nil 1 to 2 1 to 3 Nil Nil Nil 
22 J35640 54/M Nil Nil 1 to 5 5 to 7 Nil Nil Nil 
23 J78302 34/F Nil Nil 1 to 2 1 to 2 Nil Nil Nil 
24 J94334 40/F Nil Nil 1 to 2 1 to 2 Nil Nil Nil 
25 J09153 32/F Nil Nil 1 to 3 1 to 3 Nil Nil Nil 
26 K09235 42/F Nil Nil 1 to 3 3 to 4 Nil Nil Nil 
27 K05211 43/F Nil Nil 1 to 3 1 to 2 Nil Nil Nil 
28 K15624 42/M Nil Nil 1 to 2 3 to 5 Nil Nil Nil 
29 H06297 55/F Nil Nil 4 to 6 1 to 2 Nil Nil Nil 
30 H53004 36/F Nil Nil 2 to 4  Nil Nil Nil 
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  URINE CULTURE BEFORE AND AFTER TREATMENT 
S.NO OPD 
NO 
AGE/
SEX 
BEFORE 
/AFTER 
TREATMENT 
 
ORGANISM COLONY 
COUNT(cfu/ml) 
1 J04255 35/F BT Escherichia coli 50,000 
AT No organism grown  
2 H86207 37/F BT Klebsiella spp. 1,00,000 
AT Klebsiella spp. 80,000 
3 J01022 36/F BT Escherichia coli More than 
100,000 
AT No organism grown  
4 I70491 45/M BT Escherichia coli 80,000 
AT No organism grown  
5 H02278 31/F BT Escherichia coli 1,30,000 
AT No organism grown  
6 J09324 43/F BT Escherichia coli More than 
1,00,000 
AT No organism grown  
7 I63314 40/F BT Escherichia coli 1,00,000 
AT No organism grown  
8 J07352 47/F BT Klebsiella spp. More than 2 lakh 
AT Klebsiella spp. More than 1 lakh 
9 J11800 41/F BT Escherichia coli 1,50,000 
AT No organism grown  
10 J08673 22/F BT Escherichia coli 50,000 
AT No organism grown  
 11 I87174 40/F BT  Escherichia coli 80,000 
AT No organism grown  
12 J16842 31/M BT Enterococcus spp. 50,000 
AT No organism grown  
13 J22865 52/F BT Proteus vulgaris 1,00,000 
AT Citrobactar koseri 1000 
14 J16540 34/F BT Escherichia coli More than 1 lakh 
AT Escherichia coli 10,000 
15 G87332 29/F BT Escherichia coli 30,000 
AT No organism grown  
16 J08665 52/F BT Escherichia coli 1,20,000 
AT Escherichia coli 30,000 
17 J39132 55/F BT Escherichia coli 1,00,000 
AT No organism grown  
18 H30798 43/F BT Escherichia coli More than 50,000 
AT No organism grown  
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19 J55501 42/F BT Escherichia coli More than 1 lakh 
AT No organism grown  
20 J45744 55/F BT Staphylococcus 
epidermis 
1,00,000 
AT Escherichia coli 60,000 
21 H99304 23/F BT Enterococcus spp. 60,000 
AT No organism grown  
22 J35640 54/M BT Staphylococcus 
aureus 
1,00,000 
AT Staphylococcus 
aureus 
60,000 
23 J78302 34/F BT Escherichia coli 50,000 
AT No organism grown  
24 J94334 40/F BT Escherichia coli 1,80,000 
AT No organism grown  
25 J09153 32/F BT Escherichia coli 1,00,000 
AT No organism  grown  
26 K09235 42/F BT Klebsiella spp. 1,00,000 
AT Pseudomonas spp 1000 
27 K05211 43/F BT Escherichia coli 80,000 
AT No organism grown  
28 K15624 42/M BT Escherichia coli 40,000 
AT No organism grown  
29 H06297 55/F BT Escherichia coli More than 1 lakh 
AT No organism grown  
30 H53004 36/F BT Escherichia coli 80,000 
AT No organism grown  
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                                                             DISCUSSION 
 Azhal neer churukku is one of the most common bacterial infection, particularly in 
females 20 -30% of women have recurrent infection at sometimes in their life. In men it is 
less common and primarily occur after 50 years of age. The signs and symptoms of azhal 
neer churukku are correlated with urinary tract infection in modern medicine. 
  The study drug was prepared in Gunapadam lab of National Institute of Siddha 
after the authentication of herbal raw drugs by botanist of NIS. The drug was prepared by 
standard operating procedure as mentioned in the protocol. 
 The biochemical (quantitative) analysis of the study drug was done at the 
biochemistry laboratory of NIS. It revealed the presence of mineral such as sodium, 
silicate, sulphide, borate, potassium, tannin. Physiochemical and phytochemical analysis 
were done at Tamilnadu Dr MGR Medical University, Guindy, Chennai.   
 In vitro study was done at Nobel research solution, Sathyabama University, 
Chennai. In vitro study revealed that the study drug Mallikai Choornam has anti-microbial 
activity, it acted well on Escherichia coli. 
 Pilot study had been conducted for fixing the duration of drug administration. 10 
patients were included based on inclusion and exclusion criteria. For 5 days trail drug was 
given and urine culture was taken. The duration at which urine culture became negative 
was fixed as a duration of drug administration. 
 The clinical study was conducted with a well-defined protocol and a proper 
proforma after getting the approval from the Institutional Ethical Committee (IEC NO: 
NIS/IEC/11-05/14-10-2016). 30 cases of Azhal neerchurukku were diagnosed based on 
clinical symptoms and urine culture. All the cases were treated in outpatient department of 
Ayothidoss pandithar hospital, NIS, Tambaram sanatorium, Chennai-47. 
 The various Siddha and Modern methods of examinations were carried out in 
patients and the data were recorded in the proforma. The patient were treated for a period 
of 15days with Mallikai choornam (Internal) at the dose of 6grams, twice a day after food 
with hot water as an adjuvant. 
Clinical assessment was done during each visit of patient once in 5days and the data 
were noted in the prescribed proforma. Urine culture were done in 0th day and 15th day of 
the study for all the enrolled patients. All the patients were put under observation for 1 
month to follow up period without the study drug treatment. 
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OBSERVATION: 
Gender distribution: 
 Among 30 cases 26 females and 4 males are affected. 
Inference; 
 According to anatomy female urethra shorter than male urethra. So urinary 
infection is common in females. 
Kaalam distribution (Age) 
 Among 30 cases 7cases were found to be in Vatha kaalam (1-33 years) and 23 cases 
were Pitha kaalam (34-66 years) 
Inference: 
 The peak incidence of urinary tract infection occurred between 35 to 55 years of 
age (Pitha kaalam 34 -66 years) 
Occupational reference: 
 Home maker accounts for highest number of occurrence ie. 20 cases (66.6%) 
Socio economic status: 
 Among 30 cases, 25 cases (83.3%) were middle class, 3 cases (10%) were poor 
class and 2case (6.7%) were upper class. So this disease was found mostly in middle class 
people. 
Dietary habit: 
  Among 30 cases, 25 (83.3%) cases were non vegetarians, 5 (16.7%) were 
vegetarians. Most of the cases were found in non-vegetarian category. In non-vegetarian 
people body heat is increased so it may be produce pitha disease. 
Paruvakalam: 
 Among 30 cases 13 cases (43.3%) were affected in Muthuvenil Kaalam (June 15- 
Aug 17), 8 cases (26.7%) were affected in Pinpani Kalam ( Feb13-April 13), 5cases 
(16.7%) were affected in Munpani kaalam ( Dec 17- Feb12) and 4 cases (13.3%) were 
affected in Ilavenil Kalam ( April 14-June14) 
 So this disease mainly occur in muthuvenil kalam. 
Thinai distribution: 
 63.3% (19) of the cases were coming from Neithal thinai and 36.7% (11) cases were 
coming from Marutha thinai. So maximum number of cases were from Neithal nilam. 
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Yakkai distribution: 
 Among 30 cases 11 cases (36.7%) were Vatha thegi 11 cases (36.7%) were Pitha 
thegi, 8cases (26.6%) were Kaba thegi. 
 Vatha and Pitha thegi were equally affected. In Azhal neerchurukku vatham and 
pitham is predominant. 
Gunam: 
 Among 30cases 20 cases (66.7%) possessed Rasogunam. 7 cases (23.3%) 
possessed Thamo gunam, 3 cases (10%) possessed Sathuva gunam. 
Distribution of cases by Envagai Thervugal (Eight fold examination) 
In Envagai thervugal, Naadi was affected in all the 30 cases (100%), Naa was 
affected ( coated,dryness) in 9 cases (30%), Niram was affected ( Hyperpigmentation, pale) 
in 3 cases (10%), Vizhi was affected ( pallor) in 1 case (3.3%), sparism was affected ( 
temperature) in 1 case (3.3%). 
 Moothiram was affected (Burning micturition, dysuria, hematuria) in 30 cases 
(100%), Malam was affected (Constipation) in 5 cases (16.7%). 
Distribution of cases by Udal kattukal: 
Among 30 patient Saaram was affected (indigestion, general tiredness) in 30 cases 
(100%), Seneer was affected (reduced Hb level) in 3case (10%), Kozhupu affected 
(hyperlipidemia) in 2 cases (6.7%), Enbu was affected (low back pain, knee joint pain) in 
11 cases (36.7%), Sukkilam and suronitham was affected (male infertility, PCOS) in 7 
cases (23.3%) 
Kosangal: 
Among 30 cases Annamaya kosam was affected (abdominal pain, anorexia), in 15 
cases (50%), Pranamaya kosam was affected (dyspnea, cough) in 9 cases (30%), 
manomaya kosam was affected (stress) in 1 case (3.3%), Ananthamaya kosam was affected 
(sleep disturbance) in 11 cases (36.7%), Vinyanamaya kosam normal in all. 
Derangement of Vatham: 
 Among 30 cases Pranan was affected (dyspnea, wheezing) in 8 cases (26.7%), 
Abanan was affected (burning miturition, dysuria) in 30 cases (100%), Samanan affected 
(derangement of other vayus), and Viyanan were affected (low back pain, abdominal pain) 
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in all 30 cases (100%), devathathan was affected (general tiredness) in all 30 cases (100%) 
at before treatment. 
 In after treatment, 5 cases was affected (16.7%) in pranan (dyspnea, wheezing), 13 
cases was affected (43.3%) in Abanan (burning micturition, dysuria), 20 cases (66.7%) 
were affected in Samanan, 24 cases (80%) were affected in Viyanan, 2 cases (6.7%) 
affected in Devathathan 
Derangement of Pitham: 
 Among 30 cases Analpitham was affected ( loss of appetite, abdominal pain ) in 7 
cases (23.3%),Ranjaga pitham ( low Hb ) was affected in 3 cases( 10%), Sathaga pitham ( 
inability to doing work) was affected in 28 cases ( 93.3%), Prasaka pitham ( 
hyperpigmentation) was affected in 2 cases ( 6.7%) at before treatment. 
 In after treatment, 5 cases (16.7%) were affected in Analpitham (loss of appetite, 
abdominal pain), 3 cases (10%) were affected in Ranjaga pitham (low Hb), 25 cases (83.3) 
were affected in Sathagapitham (inability to doing work), and 2 cases (6.7%) were affected 
in Prasaga pitham. 
Derangement of Kabam: 
 Avalambagam was affected (derangement of other type of kabam), in 15 cases 
(50%), Kilethagam was affected (loss of appetite) in 5 cases (26.7%), Santhigam affected 
(knee joint pain) was affected in 12 cases (40%) at before treatment. 
 In after treatment, 14 cases (46.7%) in Avalambagam (derangement of other type 
of kabam), 6 cases (20%) were affected in Kelethagam (loss of appetite), 12 cases (40%) 
were affected in Santhiga pitham. 
Distribution of cases by Neerkuri: 
Color: 
 In before treatment yellow color urine was observed in 26 cases (86.7%), red color 
urine was observed in 2 cases (6.7%), straw color urine was observed in 2 cases (6.7%). In 
after treatment yellow color urine was observed in 7 cases (23.3%), straw color urine was 
observed in 23 cases (76.7%). 
Manam – Foul smell was observed in 7 cases (23.3%) 
Nurai -   Froth was observed only in 2 cases (6.6%) 
Edai     - Affected in 12 cases (40%) 
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Enjal -    present in 30 cases (100%) 
Volume - The volume of urine was decreased in 22 cases (73.3%). 
Distribution cases by Neikuri: 
 Among 30 cases the Neikuri in 11 cases (36.6%) was observed as serpentine shape   
( Vatha neer), In 9 cases ( 30%) was observed as a ring shaped ( Pitha neer), in 7 cases ( 
23.3%) it was observed as pearl shaped ( Kaba neer ), in 1 case ( 3.3%) it observed in mixed 
shape ( Vatha pitham), in 2 cases was ( 6.7%) observed as irregular shape. 
Clinical features: 
 In clinical features 17 cases ( 56.7%) had frequency and urgency of micturition, 3 
cases    ( 10%) had supra pubic pain and tenderness, 4 cases ( 13. 3%) had hematuria, 5 
cases ( 16.7%) had cloudy and unpleasant odor urine, 11 cases ( 36.7%) had dysuria, 27 
cases (90%) had burning micturition, 5 cases (16.7%) had oliguria, 28 cases ( 93.3%) had 
low back pain, 26 cases (86.7%) had abdominal pain, 1 case (3.3%) had fever in before 
treatment. 
 In after treatment, 5 cases (16.7%) had frequency and urgency of micturition, 2 
cases (6.7%) had supra pubic pain and tenderness, 5 cases (16.7%) had dysuria, 6 cases 
(20%) had burning micturition, 1 case (3.3%) had oliguria, 18 cases (60%) had low back 
ache, 11 cases (36.7%) had abdominal pain, hematuria and urine may be appear cloudy and 
have an unpleasant odor negative. 
Statistical analysis: 
Statistical analysis showed significant difference between before and after 
treatment in the clinical symptoms and Total WBC count (p=<0.0001 and p value=0.0308) 
Outcome: 
Primary outcome observation: 
Result from urine culture after treatment: 
 Out of 30 cases, Good improvement in 22 cases (73.3%), Moderate improvement 
in 5 cases (10.7%), Poor improvement in 3 cases (10%). 
 Good – Urine culture negative (no organism) 
 Moderate – colony count slightly reduced 
 Poor – Additional organism found 
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Secondary outcome: 
Improvement in clinical features: 
 Among 30 cases 18 cases (60%) has clinically good improvement (symptoms 
completely relieved after treatment with test drug), 7 cases (23.3%) had moderately 
improved (symptoms slightly reduced), and 5 cases (16.6%) had poor improvement 
(symptoms persists). 
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SUMMARY 
 
 The aim of the study is to evaluate the therapeutic efficacy of the drug Mallikai 
choornam (Internal) in Azhal neer churukku.  
 Before initiating the clinical study, Institutional Ethical Committee 
(NIS/IEC/2016/11-05) approval got on 14.10.2016 for conducting the clinical 
study. 
 The clinical study was registered in Clinical Trail Registry of India 
(CTRI/2017/06/008760) 
 The raw drugs were authenticated by Botanist, Medicinal Botany Department of 
NIS.(No: NISMB 2732017), and the study drug was prepared by the investigator 
in the Gunapadam lab, National Institute of Siddha, as per the standard operating 
procedure mentioned in the protocol. 
 The Biochemical (qualitative) analysis were done at the Bio chemistry lab of 
National Institute of Siddha. The biochemical study revealed the presence of 
Sodium, Silicate, Sulphide, Borate, Potassium, and Tannin 
 Physico chemical and Phytochemical analysis of the study drug were done at 
Tamilnadu Dr MGR Medical University,Guindy, Chennai. The study drug revealed 
the presence of phytochemical such as Alkaloids, carbohydrates, Saponins, 
phenols, flavonoids, Protein and amino acids, Diterpenes. 
 In vitro study of anti-microbial and lithotriptic activity of Mallikai choornam were 
done (project ID: NRS/AS/0033/02/17) at Nobel Research Solution, Sathyabama 
university, Chennai. 
 Pilot study had been conducted using laboratory parameter (Urine culture), in 
which 35 patient had been screened based on inclusion and exclusion criteria, 10 
patients had been included in the trial for fixing the duration of the trial drug. 
 For clinical study 75 patients were screened based on inclusion and exclusion 
criteria at the outpatient department of Maruthuvam, National Institute of Siddha. 
Out of 75 cases 30 cases were recruited for the clinical study. Clinical diagnosis of 
Azhal naeerchurukku (UTI) was arrived by both siddha and modern methodologies. 
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 Required laboratory investigations were carried out before and after treatment and 
the concerned data were recorded in proforma. Before initiating the study, informed 
consent was obtained from the patients. 
 A day before starting the study drug treatment, oil bath was given (Seeraga thylam) 
to the patients corrected the elevated azhal kutram. 
 The patient were treated for a period of 15 days with the study medicine selected 
Mallikai choornam at the dose of 6 gram (1/2 thola) twice a day with adjuvant of 
Hot water, before food. (Ref; Chikicha rathina deepam, pg no 122). 
 Clinical assessment was done during each visit once in 5 days and the data were 
noted in the prescribed proforma. During the study period there was no events of 
any adverse reaction owing to the drug was reported. 
 In vitro study revealed that the study drug Mallikai choornam has Antimicrobial 
and Lithotriptic activity, it acted well in Escherichia coli and staphylococcus aures. 
 Statistical analysis showed significant difference between before and after 
treatment in the clinical symptoms and Total WBC count (p=<0.0001 and p 
value=0.0308) 
 Clinically out of 30 cases, 18 cases (60%) has clinically good improvement 
(symptoms completely relieved after treatment with test drug), 7 cases (23.3%) had 
moderately improved (symptoms slightly reduced), 5 cases (16.6%) had poor 
improvement (symptoms persists). 
 All 30 cases were taken urine culture before and after the completion of the trial 
drug treatment. 
 Based on urine culture out of 30 cases, Good improvement in 22 cases (73.3%),  
Moderate improvement in 5 cases (10.7%), Poor improvement in 3 cases (10%). 
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CONCLUSION 
 
 The aim of the study was to evaluate the therapeutic efficacy of the study drug 
Mallikai choornam (Internal) in Azhal neerchurukku. 
 The clinical study revealed the therapeutic efficacy of the study drug was read from 
urine culture. Good improvement in 22 cases (73.3%), Moderate improvement in 5 cases 
(10.7%), Poor improvement in 3 cases (10%). 
 After treatment out of 30 cases, 18 cases (60%) has clinically good improvement 
(symptoms completely relieved after treatment with test drug), 7 cases (23.3%) had 
moderately improved ( symptoms slightly reduced), 5 cases ( 16.6%) had poor 
improvement ( symptoms persists). There were no adverse reaction complaint received 
during the study. 
 The pharmacological study revealed the trial drug had anti-microbial and 
lithotriptic activity. 
 Physicochemical and phytochemical analysis showed phytoconstituents which is 
responsible for therapeutic action. 
 There were no recurrences of urinary infection during the followup period of one 
month. Statistical analysis showed significant difference between before and after 
treatment in the clinical symptoms and Total WBC count (p=<0.0001 and p=0.0308). 
Because of encouraging clinical and laboratory results, the study may be extended with the 
same drug in more number of cases in treating Azhal neerchurukku successfully. 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSSPANDITHARHOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
 
  Clinical Evaluation of Siddha herbal formulation “MALLIKAI CHOORNAM” 
(Internal) in the treatment of “AZHAL NEERCHURUKKU” (Urinary Tract 
Infection) 
                                            FORM l - SCREENING AND SELECTION PROFORMA 
OP NO:                        NAME: ……………………                         AGE: ……GENDER: …  
OCCUPATION: ……………………………   
 ADDRESS: 
CONTACT NO:              
INCLUSION CRITERIA 
             Patients who will fulfill any of the  following criteria will be included in the study:
  
 Age:19-59yrs                                                                                                                
 Sex:Both                                                                         
 Patient having any 3 symptoms such as burning micturition,dysuria                                              
Abdominal pain, lowback ache, frequent urination, oliguria                              
  Patient willing to go for urine culture                
 Patient willing to undergo routine blood investigation                    
 Patient with urine culture significant for bacteria and fungus (eg: Escherichia coli, 
klebsiella, enterococci, S.saprophyticus...)                                                              
 Patient  willing to participate in trial and signing in consent form                   
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EXCLUSION CRITERIA:  
 History of Diabetes mellitus          
Yes / No 
 History of STD (Syphilis,HIV,gonorrhoea)                                            
Yes / No 
 Pregnancy and lactation                                   
Yes / No                                                                                 
 History of Malignancy                                                                                               
Yes / No 
 
ADMITTED TO TRIAL  
              YES           NO  
 
Date:        
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD:   
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 NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
 AYOTHIDOSS PANDITHAR HOSPITAL 
                                          DEPARTMENT OF MARUTHUVAM 
 
 Clinical evaluation of Siddha herbal formulation“MALLIKAI 
CHOORANAM” (Internal) in the treatment of “AZHAL NEERCHURUKKU” 
(Urinary tract infection) 
 
  FORM II- CASE RECORD FORM 
 
1. STUDY NO -----------                              2. OP/IP NO ------------------            
3.  NAME ---------------------------                4. . Age (years): ________                         Height: 
____cms Weight: ______ Kg   BMI------------    
5. Educational Status: 
1) Literate        2) Illiterate  
6. Occupation:                                           
7. Marital Status:   1.Married             2 .Unmarried 
 
 Complaints and Duration:   
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________      
                                            
 History of present illness: 
________________________________________________________________________
_ 
________________________________________________________________________
_ 
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Past History: 
________________________________________________________________________
_ 
________________________________________________________________________
_ 
________________________________________________________________________
_ 
________________________________________________________________________
_ 
 
 Socio economic status: 
Income group  1.lower   2.middle   3.higher 
 
FAMILY HISTORY 
              Whether this problem runs in family?     1. Yes                2.No            
              If yes, mention the relationship of affected person(s) 
1._________________ 
 2._________________ 
 3._________________ 
 
DIETARY STYLE     
  1.Pure vegetarian                                 2.Non-vegetarian               
 
BOWEL HABITS & MICTURITION: 
             
            History of habitual constipation             1.Yes               2.No                                                       
            History of frequent diarrhea                  1.Yes              2.No                                                         
           History of frequent dysuria                      1.Yes              2.No                        
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7. THEGI: [TYPE OF BODY CONSTITUTION] 
Vatham predominant  Kabam predominant  
Pitham predominant  Thondha udal  
 
8. NILAM: [LAND WHERE PATIENT LIVED MOST] 
Kurinji             Mullai                Marutham            Neithal             Palai 
 (Hillyterrain)   (Forest)                     (Plains)         (Coastalbelt)         (Aridregions)     
9.KAALAM:[SEASON] 
 Kaarkalam-    -                             Pinpanikalam            
(Aug 18-Oct17)                           (Feb 13-Apr 13) 
Koothirkalam-                            Ilavenil                                     
(Oct 18- Dec16)                          (Apr 14- June14) 
Munpanikalam -                         Muthuvenil                               
(Dec 17-Feb-12)                       (Jun 15- Aug-17) 
10. GUNAM:[CHARACTER] 
 
Sathuvam                        Rasatham                       Thamasam    
 
SIDDHA SYSTEM OF EXAMINATION: 
1. ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
I.NAADI: [PULSE PERCEPTION] 
  0th day 5th day 10th day 15th day 
 DATE     
KALAM VATHAM     
 PITHAM     
 KABAM     
MATHIRAI VATHAM     
 PITHAM     
 KABAM     
NAADI      
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II.NAA:[TONGUE] 
 0th day 5th day 10th day 15th day 
Date     
Colour normal/Red 
pale/yellow 
normal/Red 
pale/yellow 
normal/Red 
pale/yellow 
normal/Red 
pale/yellow 
Taste Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Coatin
g 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Fissure Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Saliva Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Drynes
s 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Glossiti
s 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Baldne
ss 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
III.NIRAM: [COMPLEXION]    
 0th day 5th day 10th  day 15th day 
Date     
 Dark/pale/ 
Yellow 
tinted/ 
whitish 
brown 
Dark/pale/ 
Yellow 
tinted/ 
whitish 
brown 
Dark/pale/ 
Yellow 
tinted/ 
whitish 
brown 
Dark/pale/ 
Yellow 
tinted/ 
whitish 
brown 
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IV.MOZHI: [VOICE] 
 0th day 5th day 10th day 15th day 
Date     
 Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
 
V.VIZHI: [EYES] (Lower palpebral conjunctiva)     
 0th day 5th day 10th day 15th  day 
Date     
 Normal/Red 
pale/yellow 
Normal/ 
Red 
pale/yellow 
Normal/ 
Red 
pale/yellow 
Normal/ 
Red 
pale/yellow 
   
VI. MALAM:[BOWEL HABITS / STOOLS] 
 0th day 5th day 10th day 15th day 
Date     
Colour Dark/pale
/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Consisten
cy 
Solid/ 
Semisolid
/Watery 
Solid/ 
Semisolid/Wa
tery 
Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/W
atery 
stool  bulk                          Normal/
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipat
ion   
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diaarhoe
a 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
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Neikuri: 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Fs- Fast spread, Ss-slow spread,, Ns- No spread 
VIII. SPARISAM: [PALPATORY PERCEPTION] 
0th day 5th day 10th day 15th day 
Date    
Warmth/H
ot/ 
cold/ 
Sweat 
Warmth/H
ot/cold/ 
Sweat 
Warmth/Ho
t/ 
cold/ Sweat 
Warmth/Ho
t/ 
cold/ Sweat 
 
2. IYMPORIGAL:[SENSORY ORGANS] 
 0th day 5th day 10th day 15th day 
Date     
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Mei 
[Skin] 
    
Neikkuri 0th day 5th day 10th day 15th day 
Date     
Serpentine 
fashion 
at___mint 
Fs/Ss/Ns 
at___ min 
Fs/Ss/Ns 
at___ min 
Fs/Ss/Ns 
at___min 
Fs/Ss/Ns 
Annular/Rin
ged fashion 
at___min 
Fs/Ss/Ns 
at___ min 
Fs/Ss/Ns 
at___ min 
Fs/Ss/Ns 
at___mint 
Fs/Ss/Ns 
Pearl beaded 
fashion  
at___mint 
Fs/Ss/Ns 
at___ min 
Fs/Ss/Ns 
at___ min 
Fs/Ss/Ns 
at___mint 
Fs/Ss/Ns 
Mixed 
fashion 
at___mint 
Fs/Ss/Ns 
at___min 
Fs/Ss/Ns 
at___mint 
Fs/Ss/Ns 
at___mint 
Fs/Ss/Ns 
Other 
fashion 
at___mint 
Fs/Ss/Ns 
at___min 
Fs/Ss/Ns 
at___mint 
Fs/Ss/Ns 
at___mint 
Fs/Ss/Ns 
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Vaai[Buc
cal cavity]
  
    
Kan 
[Eyes] 
    
Mooku[N
ose] 
    
Sevi [ear]     
 
3. IYMPULANGAL: [MOTOR ORGANS] 
 0th day 5th day 10th day 15th day 
Date     
 Normal/  
Affected      
Normal/  
Affected   
Normal/  
Affected      
Normal/  
Affected      
Kai 
[upperlim
b] 
     
Kal 
[lowerlim
b] 
   
 
 
Vai[Bucc
al cavity] 
    
Eruvai  
[excretory 
organ] 
    
Karuvai[
Reporduc
-tive 
organ] 
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4. KOSAM: [SHEATHS] 
  
 
0th day 5th day 10th day 15th day 
Date     
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Annamaya 
kosam 
(Digestive 
system) 
 
    
Pranamaya 
Kosam 
Respiratory 
System 
    
Manonmayak
osam 
(Cardio 
vascular 
system) 
 
    
Vingyanamay
akosam 
(Central 
nervous 
system) 
    
Anandhamay
akosam 
(Reproductive 
system) 
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5. MUKKUTRAM: (AFFECTION OF THREE HUMORS) 
 
A) VATHAM:    
 0th day 5th day 10th day 15th day 
Date     
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Praanan     
Abaanan      
Samaanan     
Udhaanan     
Viyaanan     
Naahan     
Koorman     
Kirukaran     
Devathathan     
Dhananjeyan     
 
B) PITHAM: 
 0th day 5th day 10th day 15th day 
Date Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Analapitham      
Prasakam                  
Ranjakam     
Aalosakam     
Saathakam     
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A) KABAM: 
 0th day 5th day 10th day 15th day 
Date     
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Avalambaga
m 
    
Kilethagam     
Pothagam     
Tharpagam     
Santhigam     
 
6. SEVEN DHATHUS: [SEVEN SOMATIC COMPONENTS]  
 0th day 5th day 10th day 15th day 
Date     
 Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Normal/  
Affected       
Saaram[chyme]     
Senneer[Blood]     
Oon[Muscle]     
Kozhuppu[Fat]     
Enbu[Bones]     
Moolai[Bone 
marrow] 
    
Sukkilam/Suroni
tham 
[Genital 
discharges] 
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7. SYSTEMIC EXAMINATION: 
 0th day 5th day 10th day 15th day 
GENITO URINARY SYSTEM     
LOCOMOTOR SYSTEM     
CARDIO VASCULAR  SYSTEM     
RESPIRATORY SYSTEM          
GASTRO INTESTINAL SYSTEM        
CENTRAL NERVOUS  SYSTEM            
ENDOCRINE  SYSTEM     
 
8. GENERAL EXAMINATION: 
 
 0th day 5th day 10th day 15th day 
Date     
Height (cms)     
Weight (kg)     
Temperature(°F)     
Pulse rate  
(per/ min) 
    
Heart rate 
 (per/min) 
    
Respiratory 
rate(per min) 
    
Blood pressure 
(mm/Hg) 
    
Pallor     
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9. CLINICAL SYMPTOMS: 
 0th day 5th day 10th day 15th day 
Date     
Frequency and 
urgency of 
micturition 
    
Suprapubic pain, 
and tenderness 
    
Haematuria     
Urine that may 
appear cloudy and 
have an unpleasant 
odour 
 
    
Dysuria  (Painful 
voiding) 
    
Burning micturition     
Oliguria     
Low back ache     
Abdominal pain     
               Fever     
 
Date: 
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                    signature of the HOD                                     
Jaundice     
Cyanosis     
Lymphadenopathy     
Pedal edema     
Clubbing     
Jugular vein 
pulsation 
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                      NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSSPANDITHARHOSPITAL 
DEPARTMENT OF MARUTHUVAM 
Clinical Evaluation of Siddha herbal formulation “MALLIKAI 
CHOORNAM”(Internal) in the treatment of“AZHAL NEERCHURUKKU” 
(Urinary tract infection) 
 
FORM III   LABORATORY INVESTIGATION FORM 
 
 
1. OP/IP No: ________                          2 .S. No:                                  3. LabReg no:  
 
  
BLOOD INVESTIGATION 
Before 
treatment 
Date: 
After 
treatment 
Date: 
NORMAL 
VALUES 
HB (gms %)   11-16 
T.RBC(milli/cu.mm)   3.8-5.5 
ESR (mm) 
½ hr.    
1 hr.   1-20 
T.WBC (cu.mm) 
 
   
4000-11,000 
 
 
DIFFERENTIAL 
COUNT (%) 
Polymorphs   40-75 
Lymphocytes   20-40 
Monocytes   2-10 
Eosinophils   1-6 
Basophils   0-1 
Blood glucose 
(mg/dl) 
Fasting   70-110 
PP   80-140 
Random   80-160 
Lipid profile (mg/dl) 
Serum 
cholesterol 
  150-225 
HDL   30-63 
LDL   Upto 130 
VLDL   Up to 40 
TGL   Upto 160 
RFT (mg/dl) 
Blood urea   16-50 
Serum 
creatinine 
  0.6-1.2 
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Serum Uric 
acid 
  2.5-7.5 
LFT (mg/dl) 
Total bilirubin   0.2-1.2 
Direct bilirubin   0.1-1.4 
Indirect 
bilirubin 
  0.2-0.7 
Serum total 
protein 
  6-8 
Serum 
Albumin 
  3.5-5 
Serum globulin   2.3-3.5 
Serum 
fibrinogen 
   
Serum calcium   8.5-10.5 
Serum 
phosphorous 
  3-4.5 
SGOT   IU/L   0-40 
SGPT  IU/L   0-35 
Alkaline 
phosphatase  
IU/L 
  80-290 
  
 
URINE INVESTIGATION 
Urine investigation Before TMT(with Date) After TMT (With Date) 
Albumin   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salts   
Bile pigments   
Urobilinogen   
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MICROBIOLOGY 
 
         SEROLOGY 
 
Before treatment 
Date: 
After treatment 
 Date: 
 
          VDRL  
 
 
 
 
 
SPECIFIC INVESTIGATION 
 
 
URINE CULTURE-
for Bacterial/Fungal 
infection 
0th Day 
Date : 
5th Day 
Date : 
 
10th Day  
Date : 
15th Day 
Date : 
20th Day 
Date : 
  
 
 
 
 
 
 
  
 
 
 
Date: 
Station: 
 
 
Signature of the Investigator: 
Signature of the Lecturer:                                                                   Signature of the HOD 
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                            NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47, 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
Clinical Evaluation of Siddha herbal formulation“MALLIKAI CHOORNAM” 
(Internal) in the Treatment of“AZHAL NEERCHURUKKU” 
FORM IV -DRUG COMPLIANCE FORM 
S. NO: ---------   OPD/IPD NO: --------------- NAME: -----------------------       REG NO:  
Name Of The Drug: MALLIKAI CHOORNAM-6grams/bid/before food with hot water 
 
DAY DATE MORNING 
Time 
EVENING 
Time 
 
DAY1    
DAY2    
DAY3    
DAY4    
DAY5    
DAY6    
DAY7    
DAY8    
DAY9    
DAY10    
DAY11    
DAY12    
DAY13    
DAY14    
DAY15    
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
 AYOTHIDASSPANDITHARHOSPITAL  
                                     DEPARTMENT OF   MARUTHUVAM 
  Clinical evaluation of siddha herbal formulation“MALLIKAI CHOORANAM” 
(Internal) in the treatment of “AZHAL NEERCHURUKKU”(Urinary tract 
infection) 
                                             FORM V- PATIENT INFORMATION SHEET 
Name of the Principal Investigator: Dr.G.Rathiga (PG Student)                                                 
Name of the Institution                   :  National Institute of Siddha 
                                                            Tambaram,Sanatorium   Chennai-47. 
I Dr.G.Rathiga studying M.D (Siddha) in National Institute of Siddha, Chennai. I 
am doing a clinical trial on the study of AZHALNEERCHURUKKU( Urinary Tract 
infection), which has the symptos like Yellowish discolouration of urine,Cloudy urine,Pain 
& tenderness in genitals, Fever followed by dryness of mouth, Bloating of abdomen, 
Tiredness .This condition is being treated in NIS with many siddha formulation. As a part 
of M.D(S) research programme and developing new efficacious medicine, I have proposed 
to study the drug MALLIKAI CHOORANAM for treating this condition. This formulation 
has been mentioned in siddha literature and empirical evidence with contemporary tools is 
required for documentation. You can receive medicines free of cost. The duration of 
treatment period is maximum 15 days. You have to visit NIS 5 days once and collect drugs 
for 5days. The diagnosis tests will be carried out free of cost. The lab investigation will be 
taken on the first day and after end of the trial. We will assess the effect of treatment after 
completion of 15days of treatment using clinical and lab parameter. 
 In this regard, I need to ask you few questions. I will maintain confidentiality of 
your comments and data obtained from you. There will be no risk of disclosing your 
identity and no physical, psychological or professional risk is involved by taking part in 
this study. 
 Taking part in this study is voluntary. No compensation will be paid to you for 
taking part in this study. You can choose not to answer any specific question. There is no 
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specific benefit for you if you take part in the study, but you will be under our clinical 
monitoring and specific attention will be given for your health. Taking part in the study 
may be of benefit to the community, as it may help us to develop medicine for Azhal 
neerchurukku. In case of any adverse symptoms like severe low back pain, Burning 
micturition and fever during the treatment shall be reported to me and care will be taken in 
NIS for relief. You can withdraw from the study at the midst of treatment period, if you 
are not interested to continue and you will receive our usual treatment without condition. 
 
 The information collected in this study, will remain between you and me as a 
principal investigator.  I will not write your name on different forms which sent to different 
investigating/analysis sections and I will use a code instead given by the principal 
investigator. Only the principal investigator will know the key to this code which will be 
kept in safe custody. If you agree to be a participant in this study, you will be screened as 
per the study protocol.  
 
 If you wish to find out more about this study before taking part, you can ask me all 
the questions you want or contact Dr,G.Rathiga, PG student cum principal investigator of 
this study, attached to the National Institute of Siddha, Chennai (Mobile phone 
no:9943119317). You can also contact the Chairman/Member-secretary of Ethics 
committee, National Institute of Siddha, Chennai – 600047, Tel no: 91-44-22411611, for 
rights and participation in the study. 
 
 
 
 
 
 
 
 
 
 
 
219 
 
 Njrpa rpj;j kUj;Jt epWtdk; 
         mNahj;jpjh]u; gz;bju; kUj;Jtkid nrd;id- 47 
moy; ePu;r;RUf;F vd;Dk; Neha;f;fhd ky;ypif #uzk; (cs;kUe;J) rpj;j kUe;jpd; 
gupfupg;G jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;fhd jfty; gbtk; 
Kjd;ik Muha;r;rpahsu; ngau;:  
epWtdj;jpd; ngau;:   Njrpa rpj;j kUj;Jt epWtd;k; 
       jhk;guk; rhdl;Nlhupak; 
       nrd;id-47. 
Njrpa rpj;j kUj;Jt epWtdj;jpy; gl;l Nkw;gbg;G gapd;W tUk; 
ehd;(kUj;Jtu;.f.uhjpfh)> moy; ePu;r;RUf;F vd;Dk; Nehapy; kUj;Jt Muha;rpapy; 
<Lgl;LNsd;.; moy; ePu;r;RUf;F vd;Dk; NehahdJ rpWePh; kQ;rspj;J rpte;jpUf;Fk; 
ePH fopj;j gpwF jhq;f Kbahj typ kw;Wk; vhpr;riy Vw;gLj;jy; if, fhy; mrjp 
Ruk; tha; twl;rp cz;lhjy; Mfpa FwpFzq;fis cz;lhf;Fk;  
,e;j Muha;r;rp rk;ge;jkhf rpy Nfs;tpfis Nfl;fTk;> Njitahd Ma;tf 
guppNrhjidf;F jq;fis cl;gLj;jTk; cs;Nsd;. Njitahd Ma;tf guppNrhjid 
kUj;Jt Ma;Tf;F Kd;Dk; kUj;Jt Ma;tpd; KbT ehshd 15k; ehSk; 
Nkw;nfhs;sg;gLk;. ,J rk;ge;jkhf jq;fsJ midj;J tptuq;fSk; ufrpakhf 
itf;fg;gLk; vd cWjpaspf;fpNwd;. 
,jpy; gazg;gb Kjypa ve;j cjtpj; njhifAk; toq;fg;glkhl;lhJ. 
,e;j Muha;r;rpapd; NghJ clYf;F NtW ghjpg;G Vw;gLk; gl;rj;jpy; Njrpa rpj;j 
kUj;Jtkidapy; jf;f rpfpr;ir mspf;fgLk;. 
,e;j Muha;rpf;F jhq;fs; tpUg;gj;jpd; Nghpy; cl;gLk; gl;rj;jpy; cs;kUe;jhf 
ky;ypif #uzk; toq;fg;gLk;.5 ehisf;F xU Kiw; kUj;Jtkidf;F tuNtz;Lk;. 
,e;j Muha;r;rpapy; Nehapduhf Nru;e;j gpwF cq;fSf;F tpUg;gk; 
,y;iynadpy; vg;NghJ Ntz;LkhdhYk; tpyfp nfhs;syhk;. 
,e;j Muha;r;rp rk;ge;jkhf kw;w tpguq;fSf;Fk; Nehapd; jd;ik gw;wpAk; 
Kjd;ik Muha;r;rpahsuhd kUj;Jtu; uhjpfh (gl;l Nkw;gbg;ghsu; nghJ kUj;Jt 
Jiw) mZfTk;. ifg;Ngrp vz; 9943119317.  
NkYk; ,e;j Muha;r;rpf;F Iaprp rhd;W ngwg;gl;Ls;sJ. ,e;j kUe;J rpwg;ghf moy; 
ePu;r;RUf;F Neha;f;fhf kUj;Jt ghlE}ypy; $wg;gl;LsJ 
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                         NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
                                    AYOTHIDOSS PANDITHAR HOSPITAL 
   DEPARTMENT OF   MARUTHUVAM 
 Clinical evaluation of siddha herbal formulation“MALLIKAI CHOORANAM” 
(Internal) in the treatment of“AZHAL NEERCHURUKKU”( Urinary tract 
infection) 
                                         FORM VI –INFORMED CONSENT FORM 
 “I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered 
to my satisfaction.  
            I   consent voluntarily to participate in this study and understand that I have the 
right to withdraw from the study at any time without in any way it affecting my further 
medical care”. 
           "I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that 
the individual has given consent freely.”                                                   
 
Date: 
 
Signature of a witness                                            Left thumb Impression of the Participant     
(Selected by the participant bearing no connection with the survey team)      
 
 Date:    
Station:                                                                                  
Signature of participant:                                                 
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Signature of the Investigator: 
Signature of the Lecturer:                                                          Signature of the HOD 
 
moy; ePu;r;RUf;F vd;Dk; Neha;f;fhd ky;ypif #uzk; (cs;kUe;J) rpj;j kUe;jpd; 
gupfupg;G jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;fhd;  
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
 AYOTHIDOSSPANDITHARHOSPITAL  
DEPARTMENT OF   MARUTHUVAM 
 
                    Clinical Evaluation of Siddha herbal formulation “MALLIKAI 
CHOORNAM”(Internal) in the treatment of “AZHAL NEERCHURUKKU”(Urinary 
tract infection) 
                                                      FORM VII-WITHDRAWAL FORM 
1. SERIAL NO OF THE CASE: …………………   
2. OP / IP NO: ......................................   
3. NAME: ……………………………    4.AGE: …………    5.GENDER: .................                           
6. DATE OF TRIAL COMMENCEMENT: ………………... 
7. DATE OF WITHDRAWAL FROM TRIAL: …………….. 
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:              Yes/ No 
Irregular treatment:                          Yes/ No 
Shift of locality:                                    Yes/No 
Increase in severity of symptoms:    Yes/No 
Development of severe adverse drug reactions:  Yes/No 
Date:          
Station: 
 
Signature of the Investigator: 
Signature of the Lecturer:                                                 Signature of the HOD: 
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NATIONAL PHARMACOVIGILANCE PROGRAMME FOR 
SIDDHA DRUGS 
 
 
 
 
Please note:  i. all consumers / patients and reporters information will remain confidential. 
 ii. It is requested to report all suspected reactions to the concerned, even if it does not have 
complete data, as soon as possible. 
PeripheralCenter code:     State:  
 
1. Patient / consumer identification (please complete or tick boxes below as 
appropriate) 
 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / Female  
Weight : 
Degum: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 
 Geographical area: 
 
3. List of all medicines / Formulations including drugs of other systems used by the 
patient during the reporting period: 
 
Medicine Dail
y 
dose 
Route of 
administration 
& Vehicle - 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  
Starting Stopped 
Siddha 
 
 
 
 
     
Any other system 
of medicines 
 
 
     
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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4. Brief details of the Siddha Medicine which seems to be toxic: 
 
Details Drug – 1 Drug – 2 Drug – 3 
a) Name of the medicine    
b) Manufacturing unit and 
batch No. and date 
   
c) Expiry date    
d) Purchased and obtained 
from 
   
e) Composition of the 
formulation / Part of the drug 
used 
   
 
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under institutionally qualified medical supervision or 
used as self medication.  
d) Any other relevant information. 
 
5. Treatment provided for adverse reaction: 
 
6. The result of the adverse reaction / side effect / untoward effects (please complete 
the boxes below) 
 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If 
yes, give name and address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition  
 
Any Others  
 
9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
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11. Identification of the reporter: 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
Signature of the reporter:       Date: 
 
Please send the completed form to:  
    The Director 
            National Institute of Siddha, 
(Pharmacovigilance Regional Centre For Siddha Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
 (O) 044-22381314  Fax : 044 – 22381314 
        Website : www.nischennai.org 
Email: nischennaisiddha@yahoo.co.in 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
This filled-in ADR report may be sent within one month of observation /occurrence 
of ADR   
 
 
 
Date:                                                                              
Station:  
 
 
 
Signature of the Investigator: 
Signature of the Lecturer:                                                             
 
Date:      
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                       Signature of the HOD 
 
 
Who Can Report?     
 Any Health care professionals like Siddha Doctors / Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence and protected to the 
fullest extent.  
 Submission of report will be taken up for remedial measures only not for legal 
claim  
Name & address of the RRC-
ASU / PPC-ASU 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASSPANDITHARHOSPITAL 
DEPARTMENT OF MARUTHUVAM 
Clinical evaluation of siddha herbal formulation“MALLIKAI CHOORANAM” 
(Internal) in the treatment of “AZHAL NEERCHURUKKU”( Urinary tract 
infection) 
 
FORM VIII- DIETARY ADVICE FORM 
 
The following diet to be taken: 
  Drink adequate water 
 Leafy greens& vegetables 
 Lady’s finger 
 Small Onion 
 Ginger 
 Steamed vegetables & vegetable salads 
  Bananas 
 Lemon or orange juice 
 Apple 
 Pears 
 Gooseberry 
 Dates 
 Fig fruit 
 Pomegranate 
 Grapes 
 Guava 
 Whole wheat 
 Brown rice 
 Milk 
 Butter milk 
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 Ghee 
 Fenugreek 
 Coriander seeds 
 Cumin seeds 
The following food should be avoided ;( ITCHA PATHIYAM) 
 Tamarind 
 Bitter gourd                                                         
 Mango 
 Brinjal 
 Cluster been 
 White pumpkin 
 Sesbanian leaves 
 Mustard 
 Sesame   
 Mushrooms 
 Tea 
 Coffee 
 Preserved cool drinks 
 Oily & fried foods 
 Sour foods 
  Foods which causes indigestion 
AVOID 
 Excessive lust 
 Alcohol 
 Tobacco   
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moy; ePu;r;RUf;F vd;Dk; Neha;f;fhd ky;ypif #uzk; (cs;kUe;J) rpj;j kUe;jpd; 
gupfupg;G jpwidf; fz;lwpAk; kUj;Jt Ma;T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
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 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
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FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of 
Trial 
CTRI No 
CTRI/2017/06/008760 [Registered on: 05/06/2017] Trial 
Registered Prospectively 
Acknowledgement 
Number  
REF/2017/05/014430  
Last Modified On: 05/06/2017 
Post Graduate 
Thesis  
Yes  
Type of Trial  Interventional  
Type of Study   Drug  
Study Design  Single Arm Trial  
Public Title of 
Study  
Clarification(s) with 
Reply  
Modification(s)   
Clinical study of siddha medicine Mallikai choornam in the treatment 
of Neer erichal(Urinary tract infection)  
Scientific Title of 
Study  
Clarification(s) with 
Reply  
Modification(s)   
Clinical evaluation of siddha herbal formulation“Mallikai chooranam” 
(Internal) in the treatment of “Azhal neerchurukku” ( Urinary Tract 
infection)  
Trial Acronym    
Secondary IDs if 
Any   
Secondary ID  Identifier  
NIL  NIL  
  
Details of 
Principal 
Investigator or 
overall Trial 
Coordinator 
(multi-center 
study)   
Name  Dr G Rathiga  
Designation  PG scholar  
Affliation  National institute of Siddha   
Address  
Department of Maruthuvam National Institute of 
Siddha Tambaram Sanatorium  
 
Kancheepuram 
TAMIL NADU 
600 047 
India  
Phone  9943119317   
Fax  04422381314   
Email  grathiga90@gmail.com   
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Details Contact 
Person 
Scientific Query   
Name  Dr T Lakshmikantham  
Designation  Lecturer  
Affliation  National institute of Siddha   
Address  
Department of Maruthuvam National Institute 
of Siddha Tambaram Sanatorium  
 
Kancheepuram 
TAMIL NADU 
600 047 
India  
Phone  9444466880   
Fax  04422381314   
Email  drlakshmiramaswamy@gmail.com   
  
Details Contact 
Person 
Public Query   
Name  Dr G Rathiga  
Designation  
Department of Maruthuvam National Institute 
of Siddha  
Affliation  National institute of Siddha  
Address  
Department of Maruthuvam National Institute 
of Siddha Tambaram Sanatorium 
 
Kancheepuram 
TAMIL NADU 
600 047 
India  
Phone  4422381314   
Fax  04422381314   
Email  grathiga90@gmail.com   
  
Source of 
Monetary or 
Material Support  
Clarification(s) 
with Reply  
Modification(s)   
National institute of Siddha Tambaram Sanatorium chennai 47  
  
Primary Sponsor  
Clarification(s) 
with Reply  
Modification(s)   
Name  Ayothidoss pandithar hospital  
Address  
National Institute of Siddha Tambaram 
sanatorium chennai 600047  
Type of 
Sponsor  
Research institution and hospital  
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Details of 
Secondary 
Sponsor   
Name  Address  
NIL  NIL  
  
Countries of 
Recruitment   
  India   
Sites of Study   
No of Sites = 1   
Name of 
Principal 
Investigato
r  
Name of 
Site  
Site 
Address  
Phone/Fax/Email  
Dr G Rathiga  
Ayothidos
s 
Pandithar 
Hospital  
Room no 1 
Department 
of 
Maruthuvam 
National 
Institute Of 
Siddha 
Tambaram 
sanatorium 
Kancheepura
m 
TAMIL NADU  
9943119317 
04422381314 
grathiga90@gmail.co
m  
  
Details of Ethics 
Committee   
No of Ethics Committees= 1   
Name of 
Committee  
Approval 
Status  
Date of 
Approval  
Approval 
Document  
Is 
IEC?  
Institutional 
ethics 
committee  
Approved  14/10/2016  Approval File  No  
  
Regulatory 
Clearance Status 
from DCGI   
Status  Date  Aproval Document  
Not Applicable  No Date Specified  No File Uploaded  
  
Health Condition 
/ Problems 
Studied  
Health Type  Condition  
Patients  Azhal neerchurukku (urinary tract infection)  
  
Intervention / 
Comparator 
Agent  
Type  Name  Details  
Intervention  
Mallikai 
choornam  
6 grams of malligai choornam will 
be orally twice a day along with 
hot water for a period of 15 days  
Comparator 
Agent  
Nil  Nil  
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Inclusion 
Criteria  
Age 
From  
19.00 Year(s) 
Age To  59.00 Year(s) 
Gender  Both  
Details  
1 Patient having any of three symptoms such as 
burning micturation oliguria, dysuria,abdominal 
pain,low backache 
2 Patient whois willing to go for urine 
culture&undergo routine blood investigation. 
3 Patients with Urine culture significant for bacteria 
or fungus (eg.E.coli,klebsiella,enterococci,gram-
verods,proteusmirablis.....) 
  
  
Exclusion 
Criteria  
Details  
1 Pregnant 
2 H/O Diabetes mellitus 
3 H/O Sexually transmitted disease  
4 H/O Malignancy 
  
  
Method of 
Generating 
Random 
Sequence  
Not Applicable  
Method of 
Concealment   
Case Record Numbers  
Blinding/Maskin
g  
Open Label  
Primary 
Outcome  
Outcome  TimePoints  
It is assessed by the Urine culture when the 
bacterial or fungal infection becomes negative 
after treatment and Absence of clinical signs and 
symptoms.  
15 days  
  
Secondary 
Outcome   
Outcome  TimePoints  
Socio economic status , Age related to the 
disease will be assessed  
15 days  
  
Target Sample 
Size   
Total Sample Size="30" 
Sample Size from India="30"  
Final Enrollment numbers achieved (Total)= "Applicable 
only for Completed/Terminated trials"  
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Final Enrollment numbers achieved (India)="Applicable 
only for Completed/Terminated trials"  
Phase of Trial   Phase 2  
Date of First 
Enrollment 
(India)   
15/06/2017  
Date of Study 
Completion 
(India) 
Applicable only for Completed/Terminated trials  
Date of First 
Enrollment 
(Global)  
No Date Specified  
Date of Study 
Completion 
(Global) 
Applicable only for Completed/Terminated trials  
Estimated 
Duration of 
Trial   
Years="1" 
Months="0" 
Days="0"  
Recruitment 
Status of Trial 
(Global)   
Not Applicable  
Recruitment 
Status of Trial 
(India)  
Not Yet Recruiting  
Publication 
Details   
Non yet  
Brief Summary   
it is a single,non -randamized open -label trial to determine the 
efficacy and safety of MALLIKAI CHOORNAM  in patients with 
AZHAL NEERCHURUKKU(URINARY TRACT INFECTION). In this 
trail 30 urinary tract infections patients will be recruited and the 
trial drug will be administered 6 gram twice a day along with hot 
water for a period of 15 days  during the study period all the 
study related data will be recorded and documented in a 
separate trail master file for each patients. During the trial 
period if any adverse effect will be noticed and referred to 
pharmacovigilance dept.in NIS  and further management will 
also be given in NIS OPD and IPD. The entire trail will be 
monitored by the research monitoring committee of NIS. During 
this trail all the safety and efficacy parameters will be recorded 
in the CRF. After completion of the trail all the study related data 
will be analysed statistically the outcome of this trail will be 
published in Indian Journal of Medical Research.  
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